


# GLOBAL JOURNAL

OF MEDICAL RESEARCH: A

## Neurology & Nervous System



Strokes in Black Africa

Pilot Study Revealed Association

Highlights

Impact of Gender on Dementia

Healing of Neurological Disorders

Discovering Thoughts, Inventing Future

VOLUME 16 ISSUE 2 VERSION 1.0



GLOBAL JOURNAL OF MEDICAL RESEARCH: A  
NEUROLOGY AND NERVOUS SYSTEM

---



GLOBAL JOURNAL OF MEDICAL RESEARCH: A  
NEUROLOGY AND NERVOUS SYSTEM

---

VOLUME 16 ISSUE 2 (VER. 1.0)

OPEN ASSOCIATION OF RESEARCH SOCIETY

© Global Journal of Medical Research. 2016.

All rights reserved.

This is a special issue published in version 1.0 of "Global Journal of Medical Research." By Global Journals Inc.

All articles are open access articles distributed under "Global Journal of Medical Research"

Reading License, which permits restricted use. Entire contents are copyright by of "Global Journal of Medical Research" unless otherwise noted on specific articles.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission.

The opinions and statements made in this book are those of the authors concerned. Ultraculture has not verified and neither confirms nor denies any of the foregoing and no warranty or fitness is implied.

Engage with the contents herein at your own risk.

The use of this journal, and the terms and conditions for our providing information, is governed by our Disclaimer, Terms and Conditions and Privacy Policy given on our website <http://globaljournals.us/terms-and-condition/menu-id-1463/>

By referring / using / reading / any type of association / referencing this journal, this signifies and you acknowledge that you have read them and that you accept and will be bound by the terms thereof.

All information, journals, this journal, activities undertaken, materials, services and our website, terms and conditions, privacy policy, and this journal is subject to change anytime without any prior notice.

Incorporation No.: 0423089  
License No.: 42125/022010/1186  
Registration No.: 430374  
Import-Export Code: 1109007027  
Employer Identification Number (EIN):  
USA Tax ID: 98-0673427

## Global Journals Inc.

(A Delaware USA Incorporation with "Good Standing"; Reg. Number: 0423089)

Sponsors: *Open Association of Research Society*  
*Open Scientific Standards*

### *Publisher's Headquarters office*

Global Journals® Headquarters  
945th Concord Streets,  
Framingham Massachusetts Pin: 01701,  
United States of America  
USA Toll Free: +001-888-839-7392  
USA Toll Free Fax: +001-888-839-7392

### *Offset Typesetting*

Global Journals Incorporated  
2nd, Lansdowne, Lansdowne Rd., Croydon-Surrey,  
Pin: CR9 2ER, United Kingdom

### *Packaging & Continental Dispatching*

Global Journals  
E-3130 Sudama Nagar, Near Gopur Square,  
Indore, M.P., Pin: 452009, India

### *Find a correspondence nodal officer near you*

To find nodal officer of your country, please  
email us at [local@globaljournals.org](mailto:local@globaljournals.org)

### *eContacts*

Press Inquiries: [press@globaljournals.org](mailto:press@globaljournals.org)  
Investor Inquiries: [investors@globaljournals.org](mailto:investors@globaljournals.org)  
Technical Support: [technology@globaljournals.org](mailto:technology@globaljournals.org)  
Media & Releases: [media@globaljournals.org](mailto:media@globaljournals.org)

### *Pricing (Including by Air Parcel Charges):*

#### *For Authors:*

22 USD (B/W) & 50 USD (Color)  
Yearly Subscription (Personal & Institutional):  
200 USD (B/W) & 250 USD (Color)

# GLOBAL JOURNALS CONSTITUTIONAL EDITORIAL BOARD

~INTEGRATED~

## *Dr. Shaoping Xiao*

BS, MS, Ph.D Mechanical Engineering,  
Northwestern University  
The University of Iowa  
Department of Mechanical and Industrial Engineering  
Center for Computer-Aided Design

## *Dr. A. Heidari*

Ph.D, D.Sc, Faculty of Chemistry  
California South University (CSU),  
United States

## *Dr. Maria Gullo*

Ph.D, Food Science and Technology  
University of Catania  
Department of Agricultural and Food Sciences  
University of Modena and Reggio Emilia, Italy

## *Dr. Bingyun Li*

Ph.D Fellow, IAES  
Guest Researcher, NIOSH, CDC, Morgantown, WV  
Institute of Nano and Biotechnologies  
West Virginia University, US

## *Dr. Lucian Baia*

Ph.D Julius-Maximilians University Würzburg, Germany  
Associate professor  
Department of Condensed Matter Physics and  
Advanced Technologies, Babes-Bolyai University,  
Romania

## *Dr. Houfa Shen*

Ph.D Manufacturing Engineering,  
Mechanical Engineering, Structural Engineering  
Department of Mechanical Engineering  
Tsinghua University, China

## *Dr. Osman Balci, Professor*

Department of Computer Science  
Virginia Tech, Virginia University  
Ph.D. and M.S. Syracuse University, Syracuse, New York  
M.S. and B.S. Bogazici University, Istanbul, Turkey  
Web: [manta.cs.vt.edu/balci](http://manta.cs.vt.edu/balci)

## *Dr. Miklas Scholz*

B.Eng. (equiv), PgC, MSc, Ph.D, CWEM, C.Env., CSci,  
C.Eng.  
Nigeria Health, Wellness and Fitness  
University of Lund

## *Dr. Qiang Wu*

Ph.D University of Technology, Sydney  
Department of Mathematics,  
Physics and Electrical Engineering  
Northumbria University

## *Dr. Audeh Ahmad Ahmad*

Amman Arab University For Higher Education  
Ph.D, Accounting-Ais  
Faculty of Business Administration  
Alalbyt University, Jordan, Amman

## *Dr. Sahraoui Chaieb*

PhD Physics and Chemical Physics  
M.S. Theoretical Physics  
B.S. Physics, École Normale Supérieure, Paris  
Associate Professor, Bioscience  
King Abdullah University of Science and Technology

## *Dr. Arshak Poghossian*

Ph.D Solid-State Physics  
Leningrad Electrotechnic Institute, Russia  
Institute of Nano and Biotechnologies  
Aachen University of Applied Sciences, Germany

*Dr. A. Stegou-Sagia*

Ph.D Mechanical Engineering, Environmental  
Engineering School of Mechanical Engineering  
National Technical University of Athens

*Giuseppe A Provenzano*

Irrigation and Water Management, Soil Science,  
Water Science Hydraulic Engineering  
Dept. of Agricultural and Forest Sciences  
Universita di Palermo, Italy

*Dr. Ciprian LĂPUȘAN*

Ph. D in Mechanical Engineering  
Technical University of Cluj-Napoca  
Cluj-Napoca (Romania)

*Dr. Haijian Shi*

Ph.D Civil Engineering Structural Engineering  
Oakland, CA, United States

*Dr. Yogita Bajpai*

Ph.D Senior Aerospace/Mechanical/  
Aeronautical Engineering professional  
M.Sc. Mechanical Engineering  
M.Sc. Aeronautical Engineering  
B.Sc. Vehicle Engineering  
Orange County, California, USA

*Dr. Abdurrahman Arslanyilmaz*

Computer Science & Information Systems Department  
Youngstown State University  
Ph.D., Texas A&M University  
University of Missouri, Columbia  
Gazi University, Turkey  
Web:[cis.yzu.edu/~aarslanyilmaz/professional\\_web](http://cis.yzu.edu/~aarslanyilmaz/professional_web)

*Dr. Chao Wang*

Ph.D. in Computational Mechanics  
Rosharon, TX, USA

*Dr. Adel Al Jumaily*

Ph.D Electrical Engineering (AI)  
Faculty of Engineering and IT  
University of Technology, Sydney

*Kitipong Jaoruek*

B. Eng, M. Eng D. Eng (Energy Technology, Asian  
Institute of Technology).  
Kasetsart University Kamphaeng Saen (KPS) Campus  
Energy Research Laboratory of Mechanical Engineering

*Dr. Mauro Lenzi*

Ph.D, Biological Science, Pisa University, Italy  
Lagoon Ecology and Aquaculture Laboratory  
Orbetello Pesca Lagunare Company

*Dr. Omid Gohardani*

M.Sc. (Computer Science), FICCT, U.S.A.  
Email: [yogita@computerresearch.org](mailto:yogita@computerresearch.org)

*Dr. Yap Yee Jiun*

B.Sc.(Manchester), Ph.D.(Brunel), M.Inst.P.(UK)  
Institute of Mathematical Sciences,  
University of Malaya,  
Kuala Lumpur, Malaysia

*Dr. Thomas Wischgoll*

Computer Science and Engineering,  
Wright State University, Dayton, Ohio  
B.S., M.S., Ph.D.  
(University of Kaiserslautern)  
Web:[avida.cs.wright.edu/personal/wischgol/index\\_eng.html](http://avida.cs.wright.edu/personal/wischgol/index_eng.html)

*Dr. Baziotis Ioannis*

Ph.D. in Petrology-Geochemistry-Mineralogy  
Lipson, Athens, Greece

*Dr. Xiaohong He*

Professor of International Business  
University of Quinnipiac  
BS, Jilin Institute of Technology; MA, MS, Ph.D,  
(University of Texas-Dallas)  
Web: [quinnipiac.edu/x1606.xml](http://quinnipiac.edu/x1606.xml)

*Dr. Burcin Becerik-Gerber*

University of Southern Californi  
Ph.D in Civil Engineering  
DDes from Harvard University  
M.S. from University of California, Berkeley  
M.S. from Istanbul Technical University  
Web: [i-lab.usc.edu](http://i-lab.usc.edu)

*Dr. Söhnke M. Bartram*

Department of Accounting and Finance  
Lancaster University Management School  
Ph.D. (WHU Koblenz)  
MBA/BBA (University of Saarbrücken)  
Web: [lancs.ac.uk/staff/bartras1/](http://lancs.ac.uk/staff/bartras1/)

*Dr. Söhnke M. Bartram*

Ph.D, (IT) in Faculty of Engg. & Tech.  
Professor & Head,  
Dept. of ISE at NMAM Institute of Technology

*Dr. Balasubramani R*

Department of Accounting and Finance  
Lancaster University Management School  
Ph.D. (WHU Koblenz)  
MBA/BBA (University of Saarbrücken)  
Web: [lancs.ac.uk/staff/bartras1/](http://lancs.ac.uk/staff/bartras1/)

*M. Meguellati*

Department of Electronics,  
University of Batna, Batna 05000, Algeria

*Dr. T. David A. Forbes*

Associate Professor and Range Nutritionist  
Ph.D Edinburgh University - Animal Nutrition  
M.S. Aberdeen University - Animal Nutrition  
B.A. University of Dublin- Zoology.  
Web: [essm.tamu.edu/people-info/faculty/forbes-david](http://essm.tamu.edu/people-info/faculty/forbes-david)

*Dr. Bassey Benjamin Esu*

B.Sc. Marketing; MBA Marketing; Ph.D Marketing  
Lecturer, Department of Marketing, University of Calabar  
Tourism Consultant, Cross River State Tourism  
Development Department  
Co-rdinator , Sustainable Tourism Initiative, Calabar,  
Nigeria

*Dr. Maciej Gućma*

Asistant Professor,  
Maritime University of Szczecin Szczecin, Poland  
Ph.D. Eng. Master Mariner  
Web: [www.mendeley.com/profiles/maciej-gucma/](http://www.mendeley.com/profiles/maciej-gucma/)

*Dr. Maciej Gućma*

Asistant Professor ,  
Maritime Univeristy of Szczecin Szczecin, Poland  
PhD. Eng. Master Mariner  
Web: [www.mendeley.com/profiles/maciej-gucma/](http://www.mendeley.com/profiles/maciej-gucma/)

*Dr. Fotini Labropulu*

Mathematics - Luther College, University of Regina  
Ph.D, M.Sc. in Mathematics  
B.A. (Honours) in Mathematics, University of Windsor  
Web: [luthercollege.edu/Default.aspx](http://luthercollege.edu/Default.aspx)

*Dr. Vesna Stanković Pejnović*

Ph. D. Philosphy , Zagreb, Croatia  
Rusveltova, Skopje, Macedonia

*Dr. Miguel Angel Ariño*

Professor of Decision Sciences  
IESE Business School  
Barcelona, Spain (Universidad de Navarra)  
CEIBS (China Europe International Business School).  
Beijing, Shanghai and Shenzhen  
Ph.D. in Mathematics, University of Barcelona  
BA in Mathematics (Licenciatura)  
University of Barcelona  
Web: [web.iese.edu/MAArino/overview.axd](http://web.iese.edu/MAArino/overview.axd)

*Dr. Philip G. Moscoso*

Technology and Operations Management  
IESE Business School, University of Navarra  
Ph.D in Industrial Engineering and Management,  
ETH Zurich , M.Sc. in Chemical Engineering,  
ETH Zurich Link: Philip G. Moscoso personal webpage

*Dr. Mihaly Mezei*

Associate Professor  
Department of Structural and Chemical Biology  
Mount Sinai School of Medical Center  
Ph.D., Etsv Lornd University, Postdoctoral Training,  
New York University, MSSM home:  
<https://www.mountsinai.org/Find%20A%20Faculty/profile.do?id=0000072500001497192632>  
Lab home - software,  
publications: <https://inka.mssm.edu/~mezei>  
Department: <https://atlas.physbio.mssm.edu>

*Dr. Vivek Dubey (HON.)*

MS (Industrial Engineering),  
MS (Mechanical Engineering)  
University of Wisconsin  
FICCT  
Editor-in-Chief, USA  
[editorusa@globaljournals.org](mailto:editorusa@globaljournals.org)

*Dr. Carlos García Pont*

Associate Professor of Marketing  
IESE Business School, University of Navarra  
Doctor of Philosophy (Management),  
Massachusetts Institute of Technology (MIT)  
Master in Business Administration, IESE,  
University of Navarra  
Degree in Industrial Engineering,  
Universitat Politècnica de Catalunya  
Web: [iese.edu/aplicaciones/faculty/facultyDetail.asp](http://iese.edu/aplicaciones/faculty/facultyDetail.asp)

*Dr. Sanjay Dixit, M.D.*

Director, EP Laboratories, Philadelphia VA Medical Center  
Cardiovascular Medicine - Cardiac Arrhythmia  
University of Penn School of Medicine  
Web: [pennmedicine.org/wagform/MainPage.aspx?](http://pennmedicine.org/wagform/MainPage.aspx?)

*Dr. Pina C. Sanelli*

Associate Professor of Radiology  
Associate Professor of Public Health  
Weill Cornell Medical College  
Associate Attending Radiologist  
NewYork-Presbyterian Hospital  
MRI, MRA, CT, and CTA  
Neuroradiology and Diagnostic Radiology  
M.D., State University of New York at Buffalo,  
School of Medicine and Biomedical Sciences  
Web: [weillcornell.org/pinasanelli/](http://weillcornell.org/pinasanelli/)

*Er. Suyog Dixit*

(M.Tech), BE (HONS. in CSE), FICCT  
SAP Certified Consultant  
CEO at IOSRD, GAOR OSS  
Technical Dean, Global Journals Inc.(US)  
Website: [www.suyogdixit.com](http://www.suyogdixit.com)  
Email: [suyog@suyogdixit.com](mailto:suyog@suyogdixit.com),  
[deanind@globaljournals.org](mailto:deanind@globaljournals.org)



*Er. Pritesh Rajvaidya*

Computer Science Department  
California State University  
BE (Computer Science), FICCT  
Technical Dean, USA  
Email: [pritesh@computerresearch.org](mailto:pritesh@computerresearch.org),  
[deanusa@globaljournals.org](mailto:deanusa@globaljournals.org)

*Dr. Apostolos Ch. Zarros*

DM, Degree (Ptychio) holder in Medicine,  
National and Kapodistrian University of Athens  
MRes, Master of Research in Molecular Functions in  
Disease,  
University of Glasgow  
FRNS, Fellow, Royal Numismatic Society  
Member, European Society for Neurochemistry  
Member, Royal Institute of Philosophy  
Scotland, United Kingdom

*Dr. Han-Xiang Deng*

MD., Ph.D  
Associate Professor and Research Department  
Division of Neuromuscular Medicine  
Davee Department of Neurology and Clinical  
Neurosciences  
Northwestern University Feinberg School of Medicine  
Web: [neurology.northwestern.edu/faculty/deng.html](http://neurology.northwestern.edu/faculty/deng.html)

*Dr. Roberto Sanchez*

Associate Professor  
Department of Structural and Chemical Biology  
Mount Sinai School of Medicine  
Ph.D., The Rockefeller University  
Web: [mountsinai.org/](http://mountsinai.org/)

*Jixin Zhong*

Department of Medicine,  
Affiliated Hospital of Guangdong Medical College,  
Zhanjiang, China Davis Heart and Lung Research Institute,  
The Ohio State University, Columbus, OH 43210, USA

*Dr. Wen-Yih Sun*

Professor of Earth and Atmospheric Sciences  
Purdue University, Director  
National Center for Typhoon and Flooding Research,  
Taiwan  
University Chair Professor  
Department of Atmospheric Sciences,  
National Central University, Chung-Li, Taiwan  
University Chair Professor  
Institute of Environmental Engineering,  
National Chiao Tung University, Hsin-chu, Taiwan.  
Ph.D., MS The University of Chicago, Geophysical Sciences  
BS National Taiwan University, Atmospheric Sciences  
Web: [event.nchc.org.tw/2009](http://event.nchc.org.tw/2009)

*Dr. Michael R. Rudnick*

M.D., FACP  
Associate Professor of Medicine  
Chief, Renal Electrolyte and Hypertension Division (PMC)  
Penn Medicine, University of Pennsylvania  
Presbyterian Medical Center, Philadelphia  
Nephrology and Internal Medicine  
Certified by the American Board of Internal Medicine  
Web: [uups.upenn.edu/](http://uups.upenn.edu/)

*Dr. Aziz M. Barbar, Ph.D.*

IEEE Senior Member  
Chairperson, Department of Computer Science  
AUST - American University of Science & Technology  
Alfred Naccash Avenue - Ashrafieh

*Dr. Minghua He*

Department of Civil Engineering  
Tsinghua University  
Beijing, 100084, China

*Anis Bey*

Dept. of Comput. Sci.,  
Badji Mokhtar-Annaba Univ.,  
Annaba, Algeria

*Chutisant Kerdvibulvech*

Dept. of Inf.& Commun. Technol.,  
Rangsit University, Pathum Thani, Thailand  
Chulalongkorn University, Thailand  
Keio University, Tokyo, Japan

*Dr. Wael Abdullah*

Elhelece Lecturer of Chemistry,  
Faculty of science, Gazan Univeristy,  
KSA. Ph. D. in Inorganic Chemistry,  
Faculty of Science, Tanta University, Egypt

*Yaping Ren*

School of Statistics and Mathematics  
Yunnan University of Finance and Economics  
Kunming 650221, China

*Ye Tian*

The Pennsylvania State University  
121 Electrical Engineering East  
University Park, PA 16802, USA

*Dr. Diego González-Aguilera*

Ph.D. Dep. Cartographic and Land Engineering,  
University of Salamanca, Ávila, Spain

*Dr. Maciej Gućma*

PhD. Eng. Master Mariner  
Warsaw University of Technology  
Maritime University of Szczecin  
Waly Chrobrego 1/2 70-500 Szczecin, Poland

*Dr. Tao Yang*

Ph.D, Ohio State University  
M.S. Kansas State University  
B.E. Zhejiang University

*Dr. Feng Feng*

Boston University  
Microbiology, 72 East Concord Street R702  
Duke University  
United States of America

*Shengbing Deng*

Departamento de Ingeniería Matemática,  
Universidad de Chile.  
Facultad de Ciencias Físicas y Matemáticas.  
Blanco Encalada 2120, piso 4.  
Casilla 170-3. Correo 3. - Santiago, Chile

*Claudio Cuevas*

Department of Mathematics  
Universidade Federal de Pernambuco  
Recife PE Brazil

*Dr. Alis Puteh*

Ph.D. (Edu.Policy) UUM  
Sintok, Kedah, Malaysia  
M.Ed (Curr. & Inst.), University of Houston, USA

*Dr. R.K. Dixit(HON.)*

M.Sc., Ph.D., FICCT Chief Author, India  
Email: [authorind@globaljournals.org](mailto:authorind@globaljournals.org)

*Dr. Dodi Irawanto*

PhD, M.Com, B.Econ Hons.  
Department of Management,  
Faculty of Economics and Business, Brawijaya University  
Malang, Indonesia

*Ivona Vrdoljak Raguz*

University of Dubrovnik, Head,  
Department of Economics and Business Economics,  
Croatia

*Dr. Prof Adrian Armstrong*

BSc Geography, LSE, 1970  
PhD Geography (Geomorphology)  
Kings College London 1980  
Ordained Priest, Church of England 1988  
Taunton, Somerset, United Kingdom

*Thierry FEUILLET*

Géolittomer – LETG UMR 6554 CNRS  
(Université de Nantes)  
Institut de Géographie et d'Aménagement  
Régional de l'Université de Nantes.  
Chemin de la Censive du Tertre – BP, Rodez

*Dr. Yongbing Jiao*

Ph.D. of Marketing  
School of Economics & Management  
Ningbo University of Technology  
Zhejiang Province, P. R. China

*Cosimo Magazzino*

Roma Tre University  
Rome, 00145, Italy

*Dr. Christos Kalialakis*

Ph.D., Electrical and Electronic Engineering,  
University of Birmingham,  
UKM.Sc., Telecommunications, Greece B.Sc, Physics,  
Aristotle University of Thessaloniki, Greece

*Dr. Alex W. Dawotola*

Hydraulic Engineering Section,  
Delft University of Technology,  
Stevinweg, Delft, Netherlands

*Dr. Luisa dall'Acqua*

PhD in Sociology (Decisional Risk sector),  
Master MU2, College Teacher in Philosophy (Italy),  
Edu-Research Group, Zürich/Lugano

*Xianghong Qi*

University of Tennessee  
Oak Ridge National Laboratory  
Center for Molecular Biophysics  
Oak Ridge National Laboratory  
Knoxville, TN 37922, United States

*Gerard G. Dumancas*

Postdoctoral Research Fellow,  
Arthritis and Clinical Immunology Research Program,  
Oklahoma Medical Research Foundation  
Oklahoma City, OK  
United States

*Vladimir Burtman*

Research Scientist  
The University of Utah, Geophysics  
Frederick Albert Sutton Building, 115 S 1460 E Room 383  
Salt Lake City, UT 84112, USA

*Jalal Kafashan*

Mechanical Engineering, Division of Mechatronics  
KU Leuven, BELGIUM

*Zhibin Lin*

Center for Infrastructure Engineering Studies  
Missouri University of Science and Technology  
ERL, 500 W. 16th St. Rolla,  
Missouri 65409, USA

*Dr. Lzzet Yavuz*

MSc, PhD, D Ped Dent.  
Associate Professor,  
Pediatric Dentistry Faculty of Dentistry,  
University of Dicle, Diyarbakir, Turkey

*Prof. Dr. Eman M. Gouda*

Biochemistry Department,  
Faculty of Veterinary Medicine, Cairo University,  
Giza, Egypt

*Della Ata*

BS in Biological Sciences  
MA in Regional Economics  
Hospital Pharmacy  
Pharmacy Technician Educator

*Dr. Muhammad Hassan Raza, PhD*

Engineering Mathematics  
Internetworking Engineering, Dalhousie University,  
Canada

*Dr. Charles A. Rarick*

Ph.D.  
Professor of International Business  
College of Business  
Purdue University Northwest  
Hammond, Indiana USA

*Dr. Asunción López-Varela*

BA, MA (Hons), Ph.D (Hons)  
Facultad de Filología.  
Universidad Complutense Madrid  
29040 Madrid, Spain

*Dr. Bondage Devanand Dhondiram*

Ph.D  
No. 8, Alley 2, Lane 9, Hongdao station,  
Xizhi district, New Taipei city 221, Taiwan (ROC)

*Dr. Latifa Oubedda*

National School of Applied Sciences,  
University Ibn Zohr, Agadir, Morocco  
Lotissement Elkhier N°66  
Bettana Salé Maroc

*Dr. Hai-Linh Tran*

PhD in Biological Engineering  
Department of Biological Engineering  
College of Engineering Inha University, Incheon, Korea

*Dr. Shun-Chung Lee*

Department of Resources Engineering,  
National Cheng Kung University, Taiwan

## CONTENTS OF THE ISSUE

---

- i. Copyright Notice
- ii. Editorial Board Members
- iii. Chief Author and Dean
- iv. Contents of the Issue
  1. Healing of Neurological Disorders with Bio Electron's Photons. *1-5*
  2. Strokes in Black Africa. *7-7*
  3. Pilot Study Revealed Association of DRD4 Promoter Variants with ADHD Associated Functional Deficit in Indian Probands. *9-20*
  4. Recurring Ischemic Infarcts Showing Biermer's Disease Associated with Protein S Deficiency. *21-21*
  5. Size of Hemorrhage on CT Scan and GC Scale use to Determine the Outcome of Hemorrhagic Stroke in Hypertensive Patients. *23-27*
  6. Impact of Gender on Dementia in Elderly Urban Population. *29-31*
  7. Early Diagnosis of Neuron Mitochondrial Dysfunction May Reverse Global Metabolic and Neurodegenerative Disease. *33-40*
- v. Fellows
- vi. Auxiliary Memberships
- vii. Process of Submission of Research Paper
- viii. Preferred Author Guidelines
- ix. Index



GLOBAL JOURNAL OF MEDICAL RESEARCH: A  
NEUROLOGY AND NERVOUS SYSTEM  
Volume 16 Issue 2 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Healing of Neurological Disorders with Bio Electron's Photons

By Nick Kostovic

*Kostovic Acupuncture by Bio Electrons Laser, United States*

**Introduction-** Before I begin the cases below, let me explain what and how this Kostovic Biotechnological Energetic Medical Laser Device, K-BTE works. The K-BTE Device is created in a proprietary method, we've assembled in a special circuitry 120volts of Dc/Ac/ Reverse(canceling the magnetic from the electric) which then is transferred through water. After deleting the magnetic aspect we extract the bio electrons from this water (electric fluid), controlling their direction and strength(micro and nano amperes frequency). Lastly we add in extracted electrons enriched with a number of natural acids. We incorporate these natural acids into our Biological Agents Device.

Knowing the human body's resistance to the ground is 1,000 Ohms (dry) yet using 120 voltages of AC we very safely produce the gentle effect of 12-15 Micro Amperes (DC). By utilizing this newly discovered Reverse Current and separating electro from magnetic we easily prevent electromagnetic shock. Our K-BTE device utilizing these gentle Micro Amperes frequencies can effectively burn and disperse oxidized proteins from the body. This frequency is 10,000 times less in strength than today's developed laser technology. These energetic acupuncture type penetrations on the surface of the skin are soft, not at all an electric shock.

*GJMR- A Classification: NLMC Code: WM 475*



*Strictly as per the compliance and regulations of:*



© 2016. Nick Kostovic. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

# Healing of Neurological Disorders with Bio Electron's Photons

Nick Kostovic

## I. INTRODUCTION

Before I begin the cases below, let me explain what and how this Kostovic Biotechnological Energetic Medical Laser Device, K-BTE works. The K-BTE Device is created in a proprietary method, we've assembled in a special circuitry 120volts of Dc/Ac/Reverse(canceling the magnetic from the electric) which then is transferred through water. After deleting the magnetic aspect we extract the bio electrons from this water (electric fluid), controlling their direction and strength(micro and nano amperes frequency). Lastly we add in extracted electrons enriched with a number of natural acids. We incorporate these natural acids into our Biological Agents Device.

Knowing the human body's resistance to the ground is 1,000 Ohms (dry) yet using 120 voltages of AC we very safely produce the gentle effect of 12-15 Micro Amperes (DC). By utilizing this newly discovered Reverse Current and separating electro from magnetic we easily prevent electromagnetic shock. Our K-BTE device utilizing these gentle Micro Amperes frequencies can effectively burn and disperse oxidized proteins from the body. This frequency is 10,000 times less in strength than today's developed laser technology. These energetic acupuncture type penetrations on the surface of the skin are soft, not at all an electric shock. It doesn't matter the human body's resistance to the ground is 1,000, or 100,000 or 1,000,000, wet or dry, it just doesn't matter anymore because we can produce such a low frequency of Micro Amperes and we have eliminated the magnetic from the equation. We can even bring it down further to the Nano Amperes frequency which is 1 billionth of the amplitude.

The new invented laser medical device Kostovic Biotechnological Energizer, called K-BTE correlates to the energetic fields that already exist in nature, but in more effective form. The mineral granite fields surrounded by ice, caused by low temperature in nature, radiate strong elementary energy. The irradiated elementary energy from mineral fields interacts with complex elementary biochemical energy charges from the sun's rays. It is well known that these fields exist in the far regions of Earth.

For example, some of these extraordinary energy fields are found on the slopes of Himalayas. These areas attract extremely powerful, complex and rich sun's ray elementary biochemical energy charges from nature and can contribute to a longer lasting and healthier life. For this reason, some people in these areas live extended lives, up to one hundred years or more and are not prone to most degenerative diseases.

Kostovic -Biotechnological Energizer, K-BTE medical laser device creates a powerful energetic vibration through its field that is capable to attract these elementary biochemical charges and the electron neutrinos, which are more effective, form than extraordinary fields on the Earth, as the slopes of Himalayas.

The durability of rudiment of cellular components is directly dependent on the attracted new elementary biochemical charges and electron neutrinos. Released elementary biochemical charges and electron neutrinos are the only ones in the form of the elemental energetic values. These are capable of nourishing and rebuilding the cellular components into central nervous system. Enzyme proteins are enriched, and the oxidized proteins are unmistakably "burned off". The rudiment of cellular components is consist of DNA, proteins and lipids as chemical element. Its recovery depends exclusively on attracted elemental biochemical energetic values.

The Center has further continued research and development of the transfer of the different elementary energy values from nature through hairs and skin (hairs are the offshoot of central nervous system), directly into the cellular components of the brain. Due to the stimulation of the pineal gland in the brain, this process is visible with the closed eyes.

On a daily basis our cells are always being born and dying. When we are young our bodies can disperse and get rid of all the dead cells. We have cells that eat these dead oxidized proteins. But with aging the dead cells are produced faster than the aging body can get rid of. When the oxygen and protein rich blood supply is prevented from reaching and feeding the muscle fibers due to this build up of dead cells, then the nourishing proteins become oxidized proteins.

These oxidized proteins become our number 1 enemy, as they attract parasites, microbes and bacterias etc. So now the human body not only has dying fiber tissue, the building blocks of muscle tissue

but we also have diseases developing. If we are not able to clean this declining fiber tissue from the dead cells and oxidized proteins, then the tissue will die, creating a domino like effect killing more and more fiber tissues, the building blocks of the organs.

For the first time in history our discovery enables us to maintain the physical organs. We do this by first cleansing the fiber tissues, burning away the dead cells and oxidized proteins with our wireless acupuncture therapy. After we have burned away the dead cells and oxidized proteins making space for the healthy blood supply to finally reach the fiber tissues, then body can rebuild healthy fiber tissue.

The K-BTE Medical Laser Device is always preformed in three phases which is why it is so highly efficient in improving and healing the different types of neurological and physical disorders. As I have stated first we wirelessly send biochemical electrical impulses into the diseased fiber tissue of injured areas to "burn off" the oxidized proteins, unhealthy and malignant cells from the healthy cells, enabling the body to easily excrete them.

While wirelessly sending these photons of bio electrons through the patient's skin to burn away the diseased areas, we are also burning away any plaque within the vascular system that is supplying this area. Thereby eliminating clots in vascular system, enabling the injured and healthy cells to fully receive the healthy blood supply of oxygen and proteins.

After we have cleansed the area with the bio electrical electricity, the second process is using the Biological Agent Device. This Biological Agent Device releases sheaves of elementary laser beams of biological electricity with enriched electrons. We enrich the electrons with biological and mineral agents such as gold, silver and pyrite-Fe<sub>2</sub> and converted amino acids. We use various natural acid liquids such as virgin olive oil, fig acid, and lemon, etc., ("values of different energetic conductors") into an energetic form of enriched electrons. The virgin olive oil contains natural acids, Oleic and Linoleic which are considered antioxidants, not saturated fats, like polyphenol.

These ingredients are very important in the *protection of healthy cells from destructible free radicals*. We biochemically charge these natural acids converting them into a *light* wrapping which surrounds the electrons. Extracted from the H<sub>2</sub>O electric fluid and coated with the converted natural acids (light charged), these electrons become bio electron photons which we are capable to absolutely control and direct into the patient's tissue, nourishing and invigorating the healthy cells.

The final segment of this therapy, is very intricate. I have many documents on my website that delve into greater detail. This Center has continued in-depth research and development of the laser's transfer of the different elementary energy values from nature

through the hair and skin pores (hairs are the offshoots of the central nervous system), directly into the cellular components of the brain. In this final segment the therapist touches the client's forehead with his/her index fingers which stimulates the pineal gland in the brain, this laser process is easily visible with the patients closed eyes.

The therapist transfers the biological electricity in the form of different energetic vibrations by pressing his/her fingers on the patient's forehead, scalp and skin releasing this bio electric vibration which supplies throughout the recently cleansed brain with more of the finest/slightest bio photon elemental energy.

This finest bio photon elemental energy interacts with the brain enabling/reflecting surplus weaker elemental energy to irradiate out from the brain creating an aura of elemental energy. This aura around the outside of the calvarium/skull becomes the catalyst for attracting more elemental biophoton particles of sunlight directly into the brain. These elemental bio photon sunlight particles (which can't be seen with the naked eye) surrounds us in nature and now for the first time in history we can attract and direct them. This surplus of weaker elemental brain irradiation now circulating in an aura outside of the skull appears to the patient's open eyes as a wavy blurry view. Our ability to attract these bio photon sunlight particles directly into the brain provokes/awakens passive, dormant, hibernating brain nerve cells. As we awaken the passive/hibernating brain nerve cells we are simultaneously nourishing and feeding any damaged and weaken areas thereby regenerating these harmed and injured areas in the brain.

The healing process to the brain's nerve cells gradually become visible to the patient by this special way of attracting elementary biochemical bio photon charges. With closed eyes the patient sees circles of many colors including white, black, blue, green, red, rose, yellow, turquoise, purple, orange and gold as the body absorbs the elementary biochemical bio photon charges awakening billions of hibernating passive brain nerve cells converting them into newly activated brain nerve cells.

When dormant, passive brain nerve cells now become newly activated brain nerve cells, the brain can then successfully combat the causes of most neurological disorders and traumatic brain injuries. Simultaneously, while the newly activated brain nerve cells (the former passive, dormant brain nerve cells) are being strengthened and invigorated they are now creating improvement in the neuronal functioning plus increasing neuronal production and improving the various nerve impulses throughout the body.

The mobility and movements of the arms, legs, spine etc, reacquire their normal function, since the neuronal activity has been repaired, the body is restored. The results are notable, the mitigation of



immobility displays the improvement for the patients suffering from this horrible disease. In their dormant form these passive brain nerve cells are resistant and indestructible to all neurological illnesses. The passive brain nerve cells are slight and very sensitive and contain faint energy charges which can only be stimulated/awakened by attracting to them the finest elementary biochemical energy charges through this very slight form of energetic vibrations.

## II. ALS TREATMENT

ALS (Aumyotropic Lateral Sclerosis) is a disorder of the motor neurons which are responsible for contracting skeletal muscles. The body's organ muscles start to atrophy, losing functionality and with some paralysis begins. The varying degrees of this illness affect gradually two groups of motor neurons. One group of motor neurons results in the immobility of the extremities and other in the form of paralysis in some organs. The characteristic symptoms of ALS eventually appear as a weakened neuronal structure. ALS is most likely well established by the time the patient first notices muscles weakness, shortness of breath, reduced ability to swallow, decreased mobility etc. As we perform our Bio-electric surgery and therapy on ALS sufferers, releasing bio electron's photons enriched with natural acids into the brain,. The damaged areas are easily revealed due to the fact that the infected areas in the brain are quite painful when touched with our bio energetic acupuncture technique. Using two agents, one from minerals such as gold, silver, or pyrite and the other from biological agents such as lemons, fig acids and fish bones we simultaneously send the bio electron's photons enriched with these natural acids into the brain. As they penetrate throughout the brain the unhealthy cells from the damaged areas begin a "burning off" process enabling them now to be easily excreted from the body. The ALS damaged areas in the brain are a source of aggressive "dying off" of active brain nerve cells. We are able to prevent this condition from further neuronal deterioration and non functioning of motor impulses. Our results are a notable process due to the mitigation of further immobility as well as paralysis. For some clients we can completely bring back the body's normal functioning again.

Treatment plans for ALS patients are a minimum of one year with daily sessions of 50 minutes at least 6 days a week. Daily sessions could consist of more than one 50 minute treatment per day. Treatment plans are determined by the severity of their condition. After the treatment plan has been completed it is necessary to have a yearly follow up of at least one month. It is strongly recommended to have this yearly clean-up to refresh those formerly affected weakened areas of the ALS. These patients who have had the bio-electric therapy benefit greatly especially since it is also

preventive to paralysis. The duration of recovery and improvement is long lasting but follow-ups are imperative to keep those dead cells from piling up again. Though the enriched bio electron's photons released has the capability of regaining neuronal motor impulses many wheelchair bound patients still need to get physical therapy to rebuild those atrophied muscles so they can finally get out of the wheelchair.

## III. ALS BERBERY TYPE CASE

The patient A. was diagnosed with ALS Berbery type in June 2001. He was seen by the top ALS expert at UCLA in August 2001. The doctors informed the patient that his CO<sub>2</sub> would measure 45 points within 6 months which would cause suffocation. The doctor's predicted this progressive disease would end his life by January 2002. The UCLA doctors informed him that any technology for preventing the growth of the CO<sub>2</sub> had not been developed yet. Fortunately patient A. found our center. We stand alone in our technology since we are able to clean his physical organs from CO<sub>2</sub>, nerve's biochemical toxic gases, radioactive radiations, etc. Medical doctors have yet to match our technology. Which is why the FDA has approved our laser medical device and given it a classification of it's own.

UCLA offered the patient an experimental drug called Rilutek. The prescribed drug would somehow subside suffocation, but the side effects would compromise his liver and kidney functions. The drug, with these side effects, could not extend the patients life beyond 6 months which matched his CO<sub>2</sub> prognosis. Fortunately the patient A declined the medication.

Patient A. suffered from ALS-Berbery type, beside the difficulty breathing and swallowing his symptoms included falling down. Patient A. came to the Biotechnological Health Center January 13, 2002. Hopeless and near death he was desperately looking for help. He had heard that I helped a patient suffering from ALS who's mobility was restored after the K-BTE treatments. With this type of ALS- Berbery - CO<sub>2</sub> levels were at 43 points which is extremely high for the lungs. As noted, this level of CO<sub>2</sub> would naturally increase and eventually cause suffocation. Within 10 days of treatments his CO<sub>2</sub> was decreased by one point bringing it to 42. The treatments were performed directly into the chest area simultaneously from front and the back. The patient released by coughing up colorless, sticky layers of compressed mucous. By releasing these elementary laser's beams of enriched bio electron's photons of the biological electricity into the skin and then into the blood vessels in the lungs we started the process of cleaning. After 1 month of sessions his CO<sub>2</sub> decreased and his muscle structure was strengthened. After 180 treatments the CO<sub>2</sub> was lowered to 28 which is normal, and it never increased again. We also treated the throat area, strengthening the nodules on the vocal

cords thus recovering speech, rejuvenating the esophagus tissues and restoring the ability to swallow. By treating the neck area his head was able to become straightened to its normal vertical position within one month. Arms and legs were restored from atrophy and restored the existing areas from paralysis. After 18 months the patient's results were notable, walking, laughing, speaking, swallowing, his entire metabolic condition improved. His life was extended 8 years. But unfortunately, Patient A did not commit to the recommended follow-ups.

#### IV. PARKINSON'S DISEASE CASE

Parkinson's disease affects the neurons that control the complex performance of body movements. Their decline causes weakness and the patient experiences tremors in the arms and legs gradually becoming paralyzed.

Patient B. is a 80 year old man with Parkinson's Disease: The patient had tremors in both arms and his right leg causing aggravated mobility. UCLA medical doctors prescribed a combination of levodopa and carbidopa which is used to treat the symptoms of Parkinson's Disease. The drugs didn't help, and the UCLA doctors didn't have any other technological healing options. The patient was not satisfied with the traditional treatment plan so he sought treatment at The Biotechnological Health Center, Inc. His active brain nerve cells were strengthened by the penetrating enriched bio electron's photons in the form of elementary needles of energetic acupuncture. The passive brain nerve cells were awakened by the elemental biochemical charges of different energetic vibrations. We successfully reversed his nerve damage and reversed the muscle damage. Patient B's arms and legs were restored from tremors thus returning to his normal mobile function. His symptoms were completely eliminated confirming our results as notable and worthy of attention from the medical community. The enriched bio electron's photons of bio-electricity also renewed Patient B's weakened and sore knee tissues, bone and soft cartilage.

Patient B's testimony which was written after his recovery can be found on my website. In addition, his testimony was filmed by Croatian National Television. Patient B. is first case in the world cured from Parkinson's diseases.

#### V. TREATMENT FOR ALZHEIMER'S

Alzheimer's disease affects the memory and intelligence. Patients become unable to recognize the closest of family members and their environment. Treatments plan is a minimum of 1 year, 6 days per week with 50 minute sessions, we think double sessions each day can speed up the recovery time.

The damaged areas of the brain caused by Alzheimer's disease are treated as I explained earlier with striking the skull with enriched bio electron's photons in the form of elementary needles of energetic acupuncture through biological agents.

As noted, the bio photon energy wirelessly penetrates through the skin directly into the sickened areas deep into the brain, targeting the sources of the illness. The biological electricity is enriched with amino acids of Virgin olive oil etc which is converted into an energetic form of enriched bio electron's photons. These enriched amino acids in the biological agents penetrate into the brain revealing the damaged brain areas, the sources of the disease which we gently yet powerfully destroy. Modern science hasn't yet discovered the causes of Alzheimer's disease as well as most neurological disorders, yet we can easily find the exact damaged areas deep into the brain, because they are painful. Directing these sheaves of enriched electrons into these painful areas we destroy and excrete these unhealthy cells from the brain. We know improvements are made when the pain level had decreased, neuronal functioning is restored and the patient reports that memory and intelligence has definitely improved.

#### VI. MS DISEASE CASE

Patient C. is a 33 years old female patient from Zagreb, Croatia. She suffered from an extremely progressive type of multiple sclerosis. Her symptoms included lose of balance and falling down. After nineteen weeks of treatments the patient was recovered to normal balance.

MS disorder is caused by inflammation of the myelin sheath which causes impairment and a decline of motor neuron functioning. Gradually the muscular system becomes paralyzed, diminishing the patient's mobility. Using the same technique of intensive therapy by the K-TBE laser medical device, releasing enriched bio electron's photons into the body, the patient's legs and arms muscle impairment was reversed and mobility was restored. In addition, the blood circulation returned to these areas and reflexes were restored and active. These improvements were accomplished by regenerating active and awakening passive/hibernating brain nerve cells with the elemental biochemical values. The damaged areas of the brain and spinal cord were struck with enriched bio electron's photons of biological electricity. The sources of the MS disease were destroyed and dispersed without any negative side effects. It is important to point out that in this case the painful spots were detected deep in the brain confirming inflammation of the myelin sheath which caused the impairment of the spinal cord fluid from reaching the brain. We completely reversed the nerve damage as well as we reversed the muscle weakness and patient C. is

now free of the disease. Testimonials from Zagreb, Croatia is written by Prof. Dr. Zlatko Drvar and can be found in preface of my book "Universe God's Jewel".

a) *The Patient C. is first case in the world cured from MS*

MS, Neuropathy and Dementia treatments take approximately 6 months with 50 minutes sessions, 5 days a week. Intervals between device use is not necessary or recommended. Regaining mobility with significant degrees of improvement and reversing muscle weakness is unheard of. After our treatments are completed if a patient has been in a wheelchair for a while then physical therapy is imperative to regain muscle strength in the atrophied muscles in order to walk without the wheelchair or a cane. Duration of the restored health condition is long lasting with advised once a year follow up treatments.

On our website we have testimonials and medical records which will validate the results with substantial scientific evidence. The K-BTE Medical Laser Device performs this bio-electric surgery and therapy providing clinically significant improvement in patients illnesses based on significant and valid scientific evidence. While at the same time, this device poses no risk of illness or injury to any healthy cells. This therapy is highly successful in the recuperation from these diseases and offers significant mitigation of symptoms. Additionally, this advanced technological discovery is an adjunct to early diagnosis of various illnesses. It is capable of detecting and revealing painful areas in the brain or any other physical organ before they even show up on MRI's or CAT SCANS. The K-BTE device keenly reveals the damaged areas affected with unhealthy cells. MRI's and other diagnostic equipment are not always able to detect the early origin of many diseases, but we are able to penetrate and with precision to locate the damaged unhealthy areas. After each treatment the pain immediately subsides. Once the cleaning process is completed, the once affected areas with unhealthy cells is no longer painful and treatments now start to feel comfortable. The duration of treatments for eliminating tumors and malignant cancers could be from 2 to 6 months, we consider this as short term use. Neurological Disorders including some of the most difficult cases are a minimum of 6 months to one year or more, we consider this long term use.

For patients with any recent surgical procedures we do not recommend having the K-BTE treatment. Although the K-BTE device is capable of performing on open wounds and does help in speeding up the recovery time, we restrict our treatment until the patient has recovered from their previous surgery.

According to official statistics, 60 million US citizens are suffering from 600 hundred different types of neurological disorders. Utilizing the K-BTE device's bio-electric surgery and therapy we are capable of

significantly improving the cognitive functioning, memory and mobility of many of these neurological disorders.

The K-BTE medical laser device is extremely capable to mitigate many symptoms associated with these 600 different neurological diseases as well as eliminating a number of these disorders.

This KBTE Device can prevent diseases from developing, including neurological diseases, cancer, stroke and heart disease as well as restore those afflicted with these diseases making their lives healthy, vital and longer lasting.

The Kostovic Health Center has 17 years of research and studies of helping incapacitated ALS, Alzheimers and MS patients regain the use of their limbs and no longer needing wheelchairs after only months of this unique therapy. Some we completely healed but most of them we absolutely improved their health, which modern science today is unable to do. Modern science attests to the fact that they might be able to slow down the progression but have never improved their symptoms nor stopped the deterioration of motor skills and declining brain functioning.



This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: A  
NEUROLOGY AND NERVOUS SYSTEM  
Volume 16 Issue 2 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Strokes in Black Africa

By Kokou Mensah Guinhouya, Nyinevi Anayo, Léhleng Agba, Mofou Belo  
& A. A. Koffi Balogou

*Universite de Lome*

**Abstract-** The study of strokes in Africa bears at the same time an epidemiological, etiological, semiological and therapeutical interest. The studies made on the black continent [11] these early thirty years show the necessity in this sector which remains unexplored, to evaluate the incidence and the prevalence of stroke in order to elaborate programmes and research protocols adapted to our realities. However, it is difficult to have a coherent interpretation of the results of these studies because of the high variability of epidemiological clues.

In black Africa, in Nigeria [1], the prevalence of strokes was 60,67/100.000 persons. These rates of prevalence observed in Africa go against the rate reported in industrialised countries 145/100.000 persons [2] and could suggest the existence of some particularities that are special to Africa continent.

*GJMR- A Classification: NLMC Code: WL 356*



*Strictly as per the compliance and regulations of:*



© 2016. Kokou Mensah Guinhouya, Nyinevi Anayo, Léhleng Agba, Mofou Belo & A. A. Koffi Balogou. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License <http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

# Strokes in Black Africa

Kokou Mensah Guinhouya <sup>α</sup>, Nyinevi Anayo <sup>σ</sup>, Léhleng Agba <sup>ρ</sup>, Mofou Belo <sup>ω</sup> & A. A. Koffi Balogou <sup>¥</sup>

## I. INTRODUCTION

The study of strokes in Africa bears at the same time an epidemiological, etiological, semiological and therapeutical interest. The studies made on the black continent [11] these early thirty years show the necessity in this sector which remains unexplored, to evaluate the incidence and the prevalence of stroke in order to elaborate programmes and research protocols adapted to our realities. However, it is difficult to have a coherent interpretation of the results of these studies because of the high variability of epidemiological clues.

In black Africa, in Nigeria [1], the prevalence of strokes was 60,67/100.000 persons. These rates of prevalence observed in Africa go against the rate reported in industrialised countries 145/100.000 persons [2] and could suggest the existence of some particularities that are special to Africa continent.

In fact, since about fifty years, the study of population pyramid in black Africa showed a population with a high fecundity, with an important mortality and life expectancy relatively short (44-54 years) people under fifteen years represent 50-60% of the population. The demographic weigh of this group of age on the epidemiologic indices had been noticed by many showed that the strokes in black Africa went under a sharp decrease of mortality going from 70% to 18% [1], the progressivity of the handicap of the survived is unchanged. The thrombolysis is non-existent. Therefore according to the previsions of World Health Organisation (WHO) [4], black Africa is an epidemiologic and demographic transition phase with, in the year 2020, the standing back of infectious transmissible pathologies and the high increasing of non-infectious, non-transmissible pathologies. It is evident to think again about how to take care of strokes, in black Africa. Besides the difficulties to make an ultraprecious diagnostic of stokes which has to deal with an important lack of paraclinic means of explorations on the black continent, the care field organisation, reveals in most of these countries that to sharp delay (time between the admission of patient and the first care) is very high over 6 hours [1]. This explains itself with the non-availability of urgent drugs in drugstores of hospital fees being encharge of the patient. In the other respects, apart from the mastering of difficulties of the

risk of classic cardio vascular factors (high blood pressure, diabetes, dyslipidemia, alcohol, tobacco ...) many affections not yet controlled, endemic on the black continent, especially HIV, tuberculosis are those which give stroke in the field of cerebral vascularity [1]. Besides the genetic factors like CADASIL or the drepanocytose sickle cell, are not yet completely controlled [1]. In addition, the addiction to some drugs especially cannabis that can generate stroke in the field of reversible cerebral vasoconstriction, is not yet studied. At last the caring of ischemic stroke in sharp phase in the field of thrombolysis alerts allows to reduce even cancel the handicap for the patient. The cost of this therapeutic protocol remains high, 4000 to 5000 US dollars in 1996 [5]. It is understood that with the potential disengagement of African states from the health system of their countries, thrombolysis in case of ischemic stroke, especially in Togo where 57,4% of the population lives in extreme poverty [5] is an illusion.

## BIBLIOGRAPHIC REFERENCES

1. Okon M, Adebobola NI, Julius S, Adebimpe O, Taiwo AO, Akinyemi A, Thomas NI. Stroke incidence and case fatality rate in an urban population. *J Stroke Cerebrovasc Dis.* 2015 Apr; 24(4): 771-7.
2. Giroud M<sup>1</sup>, Beuriat P, Gisselmann A, Dusserre L, Dumas R. Epidemiology of cerebrovascular accidents. According to Dijon's registry (1985-1988). *Presse Med.* 1989 Jun 3; 18(22): 1103-6.
3. Wein TH, Hickenbottom SL, Alexandrov AV. Thrombolysis, stroke units and other strategies for reducing acute stroke costs. *Pharmacoeconomics.* 1998 Dec; 14(6): 603-11.
4. OMS. Rapport sur l'état de santé dans le monde 2002 : réduire les risques et promouvoir une vie saine. OMS 2002, Genève, 261 pages
5. Adjoh KM. Actualisation de l'approximation quantitative de la pauvreté au Togo. Ministère

Author <sup>α σ ρ ω</sup>: Service de neurologie du CHU Sylvanus OLYMPIO; BP: 57, Lomé- Togo. e-mail: herve\_guinhouya@yahoo.fr

Author <sup>¥</sup>: Service de neurologie du CHU du Campus; BP: 30284, Lomé- Togo.



This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: A  
NEUROLOGY AND NERVOUS SYSTEM  
Volume 16 Issue 2 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Pilot Study Revealed Association of DRD4 Promoter Variants with ADHD Associated Functional Deficit in Indian Proband

By Subhamita Maitra, Kaushik Mukherjee, Mahasweta Chatterjee, Arijit Karmakar,  
Swagata Sinha & Kanchan Mukhopadhyay

*Manovikas Kendra*

**Abstract- Background:** Attention Deficit Hyperactivity Disorder (ADHD) is often associated with cognitive deficit. Since brain regions regulating cognition has higher expression of Dopamine receptor 4 (DRD4), we explored association between functional DRD4 promoter variants and cognition of ADHD probands.

**Methods:** Subjects recruited following DSM-IV-TR were assessed for Short Attention Span (SAS) and Erratic Organization Capability (EOC), based on scores obtained through Conner's Parent Rating Scale and DSM-IV-TR as well as computerized games. Functional variants were analyzed in ADHD probands, their parents and age-matched controls.

**Results:** Proband exhibited significant impairment in SAS and EOC. rs10902180, rs747303, rs936462, showed association with cognitive deficit. Proband with co-morbid learning disability showed higher cognitive impairment. Significant interactive effects were evident between the markers.

**Keywords:** ADHD; molecular genetics; cognitive impairment; learning difficulties.

**GJMR- A Classification:** NLMC Code: WL 348



P I L O T S T U D Y R E V E A L E D A S S O C I A T I O N F O R D R D 4 P R O M O T E R V A R I A N T S W I T H A D H D A S S O C I A T E D F U N C T I O N A L D E F I C I T I N I N D I A N P R O B A N D S

*Strictly as per the compliance and regulations of:*



© 2016. Subhamita Maitra, Kaushik Mukherjee, Mahasweta Chatterjee, Arijit Karmakar, Swagata Sinha & Kanchan Mukhopadhyay. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.



# Pilot Study Revealed Association of DRD4 Promoter Variants with ADHD Associated Functional Deficit in Indian Probands

Subhamita Maitra <sup>α</sup>, Kaushik Mukherjee <sup>σ</sup>, Mahasweta Chatterjee <sup>ρ</sup>, Arijit Karmakar <sup>ω</sup>, Swagata Sinha <sup>¥</sup>  
& Kanchan Mukhopadhyay <sup>§</sup>

**Abstract- Background:** Attention Deficit Hyperactivity Disorder (ADHD) is often associated with cognitive deficit. Since brain regions regulating cognition has higher expression of Dopamine receptor 4 (DRD4), we explored association between functional DRD4 promoter variants and cognition of ADHD probands.

**Methods:** Subjects recruited following DSM-IV-TR were assessed for Short Attention Span (SAS) and Erratic Organization Capability (EOC), based on scores obtained through Conner's Parent Rating Scale and DSM-IV-TR as well as computerized games. Functional variants were analyzed in ADHD probands, their parents and age-matched controls.

**Results:** Probands exhibited significant impairment in SAS and EOC. rs10902180, rs747303, rs936462, showed association with cognitive deficit. Probands with co-morbid learning disability showed higher cognitive impairment. Significant interactive effects were evident between the markers.

**Conclusion:** Impaired in information processing and scholastic performance, strong genotype-phenotype correlations more robust in ADHD cases with learning difficulty, suggest significant contribution of DRD4 in ADHD etiology, possibly due to attenuated receptor functioning.

**Keywords:** ADHD; molecular genetics; cognitive impairment; learning difficulties.

## I. INTRODUCTION

The current theory on Attention Deficit Hyperactivity Disorder (ADHD) emphasizes on delayed maturation of brain regions involved in controlling executive function (EF),<sup>1,2</sup> thus leading to age-inappropriate impulsivity, hyperactivity and inattention.<sup>3</sup> Though deficit in inhibitory control mechanisms was earlier hypothesized as the major cause for improper EF,<sup>4</sup> recent studies revealed that this is primarily moderated by deficits in basic information processing.<sup>5</sup> Apart from the core symptoms, individuals with ADHD frequently suffer from co-morbid learning difficulty (LD), oppositional defiant disorder, and conduct disorder,<sup>3</sup> which also could be due to improper information management.

Image analysis revealed significant reduction in the prefrontal cortex (PFC) volume of ADHD probands.<sup>6</sup>

Author <sup>α</sup>: Bijali Consultancy Services, Kolkata, India.

Author <sup>§</sup>: Manovikas Biomedical Research and Diagnostic Centre, 482, Madudah, Plot I-24, Sec. J, E.M. Bypass, Kolkata, 700107, India.  
e-mail: kanchanmvk@yahoo.com

As PFC is interconnected with other brain regions like the neocortical regions, amygdala, limbic circuit and cerebellum, it was proposed to have vital role in memory encoding and retrieval as well as decision making,<sup>7</sup> emotion related arousal,<sup>8</sup> and motor movements.<sup>9</sup> PFC microcircuits are supposed to play key roles in perception of action cycle while dealing with different types of environmental and social stimuli thereby executing a particular behavioral response.<sup>10</sup> Thus sustained attention and information processing, mediators of executive processes, may also be regulated by PFC.

As proposed by Dr. Barkley, EF involves six sets of self regulatory activities, such as self-inhibition, self-directed sensory-motor action, self-directed private speech, self-directed emotion/motivation, self-directed play, and self-monitoring which eventually affect future consequences.<sup>11</sup> He also concluded that these six functions form the Instrumental-Self-directed level of EF that is most proximal to PFC development and functioning. Self inhibition, spatial management and sustenance of self-motivation form part of these self-regulatory behaviors and injuries / or developmental anomalies of the PFC were found to disturb these functions.

Dopamine (DA) is one of the major neurotransmitter involved in movement, motivation and other executive processes<sup>12</sup> and the PFC is enriched with DA receptors, both type I and II. While bioavailability of DA in the PFC and striatum is regulated by DA receptor 2 (DRD2), receptor 4 (DRD4) and DA transporter,<sup>13</sup> PFC is preferentially enriched with DRD4.<sup>14</sup> A dual role of DRD4 on  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, hypothesized to underlie the mechanisms of evoke related response, inhibitory control and other cognitive processes, has also been documented; during the hyper-activated state of the PFC, DRD4 was found to reduce glutamatergic transmission while at the hypoactive state PFC was reported to trigger AMPA response via the same pathway.<sup>15</sup>

Genetic polymorphisms in the DRD4 have been explored widely. The most frequently investigated site is a variable number of tandem repeat in the exon3 and

meta-analysis revealed association of higher repeats (>6R) with ADHD in the Caucasoid<sup>16</sup> as well as Indo-Caucasoid probands.<sup>17</sup> Individuals homozygous for the common 4R variant showed reduction in the PFC gray matter volume<sup>18</sup> while being less efficient in a measure of executive attention.<sup>19</sup> Based on these findings, we speculated that DRD4 may have a contributory role in the EF of ADHD probands and for the first time investigated association of functional DRD4 promoter variants with Erratic Organizational Capability (EOC) and Short Attention sustainability (SAS), as part of self-regulatory trajectories under EF, in eastern Indian probands with or without co-morbid LD.

## II. METHODS

### a) *Participants and study design*

Nuclear families with ADHD probands (N=200; mean age 7.7 yrs; sex ratio M:F 9.5:1) were enrolled based on the Diagnostic and Statistical Manual for Mental Disorders-IV-text revised (DSM-IV-TR) criteria.<sup>3</sup> ADHD index, hyperactivity level and cognitive attributes/inattentiveness of probands were measured by the Conners' Parent Rating Scale-Revised (CPRS).<sup>20</sup> Intelligence/developmental quotient were assessed by the Wechsler's Intelligence Scale for children<sup>21</sup> for proband above five years and Developmental Screening Test for children below 5 years.<sup>22</sup> Out of 200 probands, 160 were complete parent-proband trios, 22 had only one parent while 18 were affected probands only. Majority of the probands belonged to the combined subtype (72.5%) while hyperactive/impulsive (12.5%) and inattentive (15%) subtypes were only few. 60% probands showed cognitive deficit while 63% exhibited hyperactivity. Co-morbid conditions assessed using the DSM-IV-TR criteria<sup>3</sup> showed LD in 29% of probands. Subjects with only psychiatric problems including pervasive developmental disorders, any form of mental retardation (IQ ≤ 70) and fragile-X syndrome, were excluded.

Ethnically matched control subjects were evaluated for the DSM-IV-TR criteria for ADHD<sup>3</sup>, hypothyroidism, intelligence/developmental quotient (>80) as well as for any psychiatric disorder running in the family and those without any abnormality (N=200; Mean age 13.45 yrs; sex ratio 1.4:1) were recruited. Informed written consent was obtained for participation in the study and the protocol was approved by the Institutional Human Ethics Committee.

### b) *Assessment of traits*

SAS and EOC were measured through questions selected from the DSM-IV-TR and CPRS scale (Table 1), scores (0-3) were given based on the responses received, and the total score was converted to percentage. CPRS score percentage for each trait was cross validated with the DSM-IV-TR score and an individual exhibiting more than 5% deviation was

excluded. Based on the CPRS score percentage, individuals having less than 30% were considered to have low deficit (1), whereas those with 30-60% were identified as having medium deficit (2) and more than 60% were coined as having maximum deficit (3).

Computerized games were used to measure the cognitive function of ADHD probands (N=25, 6-12 yrs, 23 male / 2 female) and controls (N=10, 7-12 yrs, 6 male / 4 female). Participants were tested for working memory (Game 1), speed (Game 2) and spatial (Game 3) information processing, and dual N back test (Game 4) for 5 minutes. For each game, there were 3 levels with increasing complexity followed by automatic recording of score. Wrong entry in any round iterated the same level and thus score increased with delay/error in response.

Probands (N=80; mean age 12.67 ± 3.95 years) were reassessed after 3 years using the same questionnaire (Table 1) to follow their performance.

### c) *Genetic analysis*

Online programs F-SNP (compbio.cs.queensu.ca/F-SNP/), Brain-array (<http://brainarray.mbni.med.umich.edu/brainarray/database/searchsnp/snpfunc.aspx>), and SNPinfo (<http://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.cgi>) were used to analyze functional roles of seven upstream variants. Peripheral blood leukocytes were processed for extraction of genomic DNA.<sup>23</sup> Oligonucleotides designed using the Primer3 ([www.bioinformatics.nl/primer3plus/](http://www.bioinformatics.nl/primer3plus/)) program were used for PCR amplification in ABI Gene Amplifier #9700 PCR system. rs 916455 was genotyped by restriction fragment length polymorphism analysis of PCR amplicon using RsaI restriction enzyme (New England Biolab); in presence of the "T" allele, two fragments of 58 and 163 bp were generated. The other SNPs were analyzed by sequencing of the PCR amplicon in Applied Biosystems 3130 Genetic analyzer using Big Dye v 3.1 chemistry and Sequencing Analysis Software, v 5.2.

### d) *Data analysis*

#### i. *Association analysis*

Unphased version 3.1.7<sup>24</sup> was used for population- and family-based analysis. Hardy-Weinberg equilibrium (HWE) was analyzed using the online software (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl-hwe>) and Piface version 1.72<sup>25</sup> was used to quantify the strength of statistically significant results (P<=0.05). The Odds ratio (OR) was calculated by online program (<http://www.hutchon.net/ConfidOR.htm>).

#### ii. *Analysis of interaction between the sites*

Interaction between haplotypes was analyzed by the Cocophase program. Linkage Disequilibrium was calculated using the Haploview program.<sup>26</sup> SNP-SNP interaction was analyzed by the Multifactor dimensionality reduction (MDR) program.<sup>27</sup>

iii. *Genotype-phenotype correlation analysis*

Association between each phenotypic trait and the gene variants were analyzed by Mann-Whitney test (<http://elegans.som.vcu.edu/~leon/stats/utest.html>).

Association between genotypes and co-morbid LD was analyzed using the Cocophase program.

ADHD probands were grouped into three categories, all cases, ADHD with co-morbid LD (ADHD+LD) and without LD (ADHD-LD) for analyzing the level of SAS and EOC. Frequency of probands having various levels of SAS and EOC, calculated through CPRS, were analyzed using the excel work book. Correlation between pair of traits was obtained through online Pearson's calculator (<http://www.socscistatistics.com/tests/pearson/>) and regression analysis software (<http://www.alcula.com/calculators/statistics/linear-regression/>) was used for calculating the interdependence of these traits.

iv. *Measurement of cognitive function*

Mean scores obtained for ADHD probands and controls through computerized assessment were analyzed by the 1 tailed unpaired T test using online software (<http://studentsttest.com/>).

### III. RESULTS

a) *Analysis of variants*

Sequence analysis showed presence of a novel G>T substitution (Table 2, NSNP) 45 bases before rs747302. All the seven SNPs are binding sites for transcription factors and four revealed moderate regulatory potential (Suppl Table S1). rs916455 is located in the CpG island (ratio=0.99).

Genotypes of rs747303 deviated from the HWE in the probands (P=0.0009). rs10902180 genotypes deviated for the proband (P=0.0001) as well their parents. Genotypes of all other variants followed the HWE. Population based analysis showed significant bias for rs10902180 "C" allele (Suppl Table S1; P=0.01, Power=71, OR=1.57) with a trend of association (P=0.08) for the "CC" genotype (Table 2). rs916455 "CC" and rs936462 "AA" genotypes showed significantly higher frequencies in the ADHD+LD probands as compared to control as well as ADHD-LD (Table 2, P<0.04). rs10902180 showed higher frequency of the "GG" genotype in the ADHD+LD compared to ADHD-LD individuals (P=0.001).

Family-based analysis revealed biased transmission of rs936462 "A", rs747303 "T", rs1800955 "T" and NSNP "G" alleles (Table 3). For rs1800955 "T", a paternal bias was noticed ( $\chi^2=6.32$ , P=0.01). Analysis of haplotypes failed to show any significant difference.

Linkage Disequilibrium pattern was different in the control individuals, probands and their parents, but coefficient of correlation was insignificant (Suppl Fig. 1).

b) *Analysis of phenotypic traits*

EOC and SAS showed linear correlation in both ADHD-LD (R=0.73) and ADHD+LD (R=0.88). Regression analysis validated EOC score as a function of SAS for these subgroups ( $Y=2.31+0.86X$  &  $y=1.08X-10.30$  respectively). Analysis between different subgroups exhibited higher number of ADHD+LD probands with high SAS score ( $\chi^2=21$ ;  $p>0.0001$ ) as compared to ADHD-LD group (Suppl Fig. 2). No significant difference was noticed for the EOC score (Suppl Fig. 2). rs747303 "TT" showed association with higher EOC score (Suppl Table S2, P=0.05), while the NSNP "GG" showed association with both high EOC and SAS scores (P=0.02 & 0.04 respectively).

Performance of ADHD probands was poor, more strikingly for Game 1 and 2, as compared to age-matched control children (Fig. 1).

Association of higher scores for Game 1 and 2 with rs916455 "CC" was observed. rs936462 "AA" and rs747303 "TT" revealed nominal differences, while rs10902180 "GC" showed distinct difference in Game 2 score with a mild difference for Game 1 (Suppl Fig. 3). Higher mean score was also noticed for rs1800955 "CC" in case of Game4. No difference could be observed for rs747302 and data for NSNP could not be shown due to the presence of only one heterozygote (Suppl Fig. 3).

Interaction analysis revealed major independent effects of both SAS and EOC (Fig. 2 A & B respectively) in ADHD individuals exhibiting higher scores (score>1) against those having low score (score=1). With EOC as a phenotypic co-variate, interaction between rs916455-rs747302 and rs1800955-NSNP was also noticed (Fig. 2B). Stratification based on the presence of co-morbid LD revealed major independent effects of phenotypic traits and gene variants in ADHD-LD probands as compared to the control individuals (Fig. 2C), while in ADHD+LD individuals, strong interactive effect was observed between SAS-rs1800955 and EOC-rs747303 in absence of any major independent effect (Fig. 2 D), as compared to ADHD-LD individuals. Mild positive interaction was also noticed between SAS-rs747302, SAS-rs747303, and EOC-rs1800955 (Fig. 2D).

Follow up after three years showed that while the number of probands with high EOC gradually reduced with time (Suppl Fig. 4, Low T0/T3=2/24, High T0/T3=44/15,  $\chi^2=32.5$ , P=0.0001), SAS score improved in a number of probands (Suppl Fig. 4, Low T0/T3=0/11, High T0/T3=56/48,  $\chi^2=11.5$ , P=0.003). ADHD subjects harboring rs916455CC, rs747303TT and NSNPGG genotypes had higher EOC scores after three years, while NSNP also showed association with high EOC score (Suppl Table S3). Follow up study also revealed strikingly low scholastic improvement in ADHD+LD (58%) probands as compared to ADHD-LD (79%).

#### IV. DISCUSSION

Earlier investigators reported delayed maturation of brain regions controlling EF, affecting self regulation, attention and working memory.<sup>2</sup> Since these regions are enriched with DRD4 receptor, we investigated association between DRD4 promoter variants and EF of ADHD probands. LD is a major comorbid condition and may result from low attention sustainability, memory retrieval, working memory, and poor comprehension. We compared the genotypic pattern of ADHD+LD individuals with that of ADHD-LD individuals as well as controls to find out if any particular genotype is affecting the trait.

Based on the data obtained, we for the first time report significant association of DRD4 promoter variants with EF deficit of Indo-Caucasoid ADHD probands. F-SNP analysis revealed that rs9164555, an upstream variant, may regulate binding of transcription factor, though the mechanism is yet to be understood. The rs916455 "C" allele showed association with persistence of symptoms in Chinese ADHD subjects.<sup>28</sup> Follow up of ADHD probands during the present study also revealed association of "CC" with high EOC score. Higher occurrence of the "CC" genotype was earlier reported in ADHD+LD probands<sup>29</sup> and further analysis in extended samples also revealed association of the "CC" genotype with ADHD+LD as compared to controls (P=0.05) as well as ADHD-LD (P=0.04). MDR analysis exhibited additive effect of rs916455 and rs747302 on EOC. In ADHD+LD individuals, this site showed strong independent effect. "CC" was also associated with Game 1 and 2, depicting its role in working memory impairment as well as poor cognitive flexibility while follow up revealed link between the "CC" genotype and poor attention.

rs747302, presented as a trimorphic variant (C/A/G) in the dbSNP database (build 86/142), showed only two alleles (C/G) in the present study as well as previous investigations.<sup>30, 31</sup> F-SNP analysis suggested that the C allele affects binding of transcription factor E2F. Comparative analysis failed to show any significant association of rs747302 with ADHD in the Indo-Caucasoid population and further investigation in other ethnic population is warranted to understand the actual role.

Frequency of rs936462 "A" allele was 50% less in the studied Indo-Caucasoid population as compared to the Hungarian population.<sup>31</sup> We have noticed preferential transmission of the "A" allele by family-based analysis (Odds ratio 4.73). Individuals harboring "AA" showed higher score for Game 1, 3 and 4. While Game 1 is a test for working memory, Game 3 and 4 requires sustained attention and organizational efficiency. Therefore, the "A" allele may be considered as a risk allele in this population. A previous report showed that absence of the "G" allele caused a

significant difference in the genotype of -521 C/T, i.e. rs1800955,<sup>31</sup> though in the studied Indian population no such difference was noticed. On the basis of the present study, rs936462 merits further analysis to understand the role of the site in the disease etiology.

rs747303 was rarely investigated in ADHD patients and the present study revealed biased transmission of the "T" allele (OR 2.81). F-SNP analyses suggested regulation of transcriptional activity; the GC box disappears in presence of the T allele thus affecting transcription initiation. ADHD probands with the "TT" genotype had poorer information processing capability as compared to probands harboring the "GG" genotype. This is also indicated by scores for Game 3 & 4. MDR analysis showed positive effect of this site on poor attention span in ADHD+LD subjects. On the basis of these findings, rs747303 "T" allele could be considered as a risk variant for ADHD which merits further in depth analysis.

This first association analysis on rs10902180 identified the site as a transcriptional regulator. Marginally higher frequency of the "C" allele and "CC" genotype was noticed in the ADHD probands as compared to control. Individuals with the "CC" genotype obtained higher scores for Game 1 and 2. On the other hand, analysis among the subgroups showed significantly higher frequency of the "GG" genotype in ADHD+LD. This contradictory finding may suggest a different mechanism of DRD4 expression in the ADHD+LD subgroup since the gene not only interferes with NMDA receptor or other D2 type receptors, but also interacts with D1 type D5 receptors which work by upstream regulation of gene (analyzed by KEGG pathway). MDR analysis showed strong independent effect of this site on the phenotypic traits. Since our study involves only limited number of ADHD+LD probands, we conclude that this site may have a role in the learning problem of ADHD probands which merits further analysis in higher number of subjects.

rs1800955 is a transcriptional regulator widely investigated in ADHD as well as other psychiatric disorders.<sup>32</sup> Transcription factor CAP is functional in presence of the "T" allele; transcriptional activity was reduced by 40% in presence of the "T" allele<sup>33</sup> though the finding could not be reproduced.<sup>34</sup> Earlier studies on the Indo-Caucasoid population revealed biased parental transmission of haplotype 7R-T of DRD4 Exon3 VNTR and rs1800955.<sup>35</sup> The present study also revealed parental over transmission of "T" to the probands, which is basically paternal in nature. "CC" was associated with higher scores for SAS and EOC measured through CRS as well as Game 2 and 4 suggesting its role in cognitive impairment as a whole. MDR showed strong independent effect of rs1800955 in ADHD. In ADHD+LD both attention sustainability and information processing was found to be affected in presence of this variant

thereby suggesting a role of this site in ADHD associated cognitive deficit.

The novel substitution NSNP detected in the 5' upstream region showed a parental bias in transmission of the wild type allele and interaction with rs1800955. The heterozygous form showed association with both SAS and EOC. However the site failed to show any significant functional contribution thus making it difficult to interpret its role.

Linkage Disequilibrium between rs747302–rs1800955 and rs916455–rs1800955 in the Indo-Caucasoid control population was similar to that observed in the Japanese population.<sup>36</sup> However, in the Hungarian population, a strong bond was noticed between rs936462–rs1800955<sup>30</sup> which was absent in the Indian population. Further, in families with ADHD probands, the pattern was totally different as compared to the ethnically matched control population. From the observed pattern, we may interpret that the DRD4 promoter region harbors recombination hotspots which culminates in a break in the Indo-Caucasoid population.

ADHD associated EF deficit was hypothesized to occur from poor flexibility, self motivation and working memory, ultimately giving rise to altered behavioral response.<sup>11,37</sup> Uncontrolled inhibition with triggered impulsivity and error prone behavior was also noticed.<sup>37</sup> Further investigation showed improper information processing as the major reason for ADHD associated symptoms.<sup>5</sup> These domains are supposed to be affected in children with LD too. As In the present study, we have noticed aberrant information processing along with short attention sustainability. Higher scores for Game 1 and 2 in ADHD probands indicate poor working memory and cognitive flexibility as a result of improper information processing. Scores for Game 3 and 4 were moderately high in the ADHD probands as well as healthy individuals which may indicate that these traits involve a more complicated network of information processing which develops during adolescence. MDR analysis also revealed strong major effects of these two phenotypic traits in addition to independent effect of the studied sites and an additive effect of rs916455–rs747302 on EOC. Comparative analysis between subgroups showed that phenotypic traits of ADHD+LD subjects are affected more severely by interactive effect of the markers; while in ADHD-LD both SAS and EOC showed strong independent effects, interactive affects were pronounced in ADHD+LD. Follow up revealed a constant deficit in attention sustainability with a gradual improvement in EOC and academic achievement was worse for ADHD+LD patients. rs916455 “CC”, rs747302CC, rs936462 “AA”, rs747303 “TT”, rs1800955 “CT/TT” and NSNP “GG” were found to be more frequent in subjects with high and medium score for SAS and EOC indicating significant impact of these genotypes in the cognitive function. Follow up study

also confirmed role of rs747303 “TT”, rs1800955 “TT” and NSNP “GG” in ADHD.

Since ADHD probands are believed to have an altered function of the frontal lobe<sup>38</sup> and DRD4 density is high in this region, we speculated that the promoter variants may alter transcriptional activity leading to a reduction in DRD4 receptor density, thereby causing altered behavioral and cognitive outcome. The data obtained indicate that failure in information processing, leading to reduction in attention span, may lead to the symptoms of ADHD which is more evident in subjects with co-morbid LD. Further analysis involving additional functional variants is warranted in large cohort of subjects to validate our observation.

## ACKNOWLEDGEMENT

This work was sponsored by the Department of Science & Technology, Govt. of India (SR/CSI/17/2009), SM was a DST project fellow. Authors are thankful to the study volunteers for participation.

### Authors' contribution

Subhamita Maitra performed genotyping and statistical analysis, participated in examination of cognitive function and prepared the manuscript draft. Kaushik Mukherjee helped in the assessment of cognitive function. Mahasweta Chatteree and Arijit Karmakar performed genotyping. Swagata Sinha recruited the study subjects and helped in functional assessment. Kanchan Mukhopadhyay designed the study, assessed cognitive function, monitored the development, and edited the manuscript draft. All the authors approved the final version of the Manuscript.

### Declaration of conflicting interests

Authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Abbreviations:** ADHD- Attention deficit hyperactivity disorder; AMPA-  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CRS- Conners' rating scale; DA- Dopamine; DRD2-Dopamine D2 receptor; DRD4-Dopamine D4 receptor; DSM-IV-TR-Diagnostic and Statistical Manual for Mental Disorders-4<sup>th</sup> edition-text revised; EOC-Erratic organization capability; HWE-Hardy-Weinberg equilibrium; LD-Learning disability; MDR-Multifactor dimension reduction test; NMDA-N methyl D aspartate; OR-Odds ratio; PFC-Prefrontal cortex; SAS-Short attention sustainability; SNP-Single nucleotide polymorphism.

## REFERENCES RÉFÉRENCES REFERENCIAS

1. Nakao T, Radua J, Rubia K, et al. (2011) Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication, *Am J Psychiatr*, vol. 168, no. 11, November, pp. 1154-1163.

2. Proal E, Reiss PT, Klein RG, et al. (2011) Brain gray matter deficits at 33-year follow-up in adults with attention-deficit/hyperactivity disorder established in childhood, *Arch Gen Psychiatr*, vol. 68, no.11, November, pp. 1122-1134.
3. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, 2000. 4th ed.-text revised. Washington, DC.
4. Pliszka SR, Glahn DC, Semrud-Clikeman M, et al. (2006) Neuroimaging of inhibitory control areas in children with attention deficit hyperactivity disorder who were treatment naive or in long-term treatment, *Am J Psychiatr*, vol. 163, no.6, June, pp.1052-1060.
5. Salum GA, Sergeant J, Sonuga-Barke E, et.al.(2014) Specificity of basic information processing and inhibitory control in attention deficit hyperactivity disorder, *Psychol Med*, vol. 44, no. 3, February, pp. 617-631.
6. Young De CG, Hirsh JB, Shane MS, et al. (2010) Testing predictions from personality neuroscience, *Psychol Sci*, vol. 21, no. 6, June, pp. 820-828.
7. Yu JY, Frank LM. (2015) Hippocampal-cortical interaction in decision making. *Neurobiol Learn Memory*, vol.117, January, pp. 34-41.
8. Price JL. (1999) Prefrontal cortical networks related to visceral function and mood. *Ann N Y Acad Sci*, vol. 877, June, pp. 383-396.
9. Watanabe J, Sugiura M, Sato K, et al. (2002) The human prefrontal and parietal association cortices are involved in NO-GO performances: an event-related fMRI study. *Neuroimage*, vol. 17, no. 3, November, pp. 1207-1216.
10. Opris I, Casanova MF. (2014) Prefrontal cortical minicolumn: from executive control to disrupted cognitive processing. *Brain*, vol.137, July, pp. 1863-1875.
11. Barkley RA. (2012) Executive functions: What are they, how they work, and why they evolved. New York, Guilford Press.
12. Redgrave P, Vautrelle N, Reynolds JN. (2011) Functional properties of the basal ganglia's reentrant loop architecture: selection and reinforcement, *Neurosci*, vol. 198, no. 3, November, pp. 138-151.
13. Fusar-Poli P, Rubia K, Rossi G, et.al. (2012) Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis, *Am J Psychiatr*, vol. 169, no. 3, March, pp. 264-272.
14. Mrzljak L, Bergson C, Pappy M, et al. (1996) Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. *Nature*, vol. 381, no. 6579, pp. 245-248.
15. Yuen EY, Yan Z. (2011) Cellular mechanisms for dopamine D4 receptor-induced homeostatic regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. *J Biol Chem*, vol. 286, no. 28, July, pp. 57-65.
16. Nikolidas A, Gray JR. (2010) ADHD and the DRD4 exon III 7-repeat polymorphism: an international meta-analysis. *Soc Cogn Affect Neurosci*, vol. 5, no. 2-3, June, pp. 188-93.
17. Das M, Das Bhowmik A, Bhaduri N, et al. (2011) Role of gene-gene/gene-environment interaction in the etiology of eastern Indian ADHD probands, *Prog Neuro-Psychopharmacol Biol Psychiatr*, vol. 35, no. 2, March, pp. 577-587.
18. Durston S, Fossella JA, Casey BJ, et al. (2005) Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their unaffected siblings, and controls. *Mol Psychiatr*, vol. 10, no.7, July, pp. 678-685.
19. Fossella J, Sommer T, Fan J, et al. (2002) Assessing the molecular genetics of attention networks. *BMC Neurosci*; vol. 3, pp. 14.
20. Conners CK, Parker JDA, Sitarenios G, et al. (1998) The Revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. *J Abnormal Child Psychol*, vol.26, no. 4, August, pp. 257-268.
21. Wechsler D. Wechsler Intelligence Scale for Children-Third Edition: Manual. The Psychological Corporation. San Antonio 1991.
22. Bharat Raj J. (1971) AIISH norms on SFB with Indian children. *J All Ind Inst Speech Hear*, vol. 2, pp. 34-39.
23. Miller SA, Dykes DD, Polesky HF. (1998) A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*, vol.16, no. 3, February, pp. 1215.
24. Dudbridge F. (2003) Pedigree disequilibrium tests for multilocus haplotypes. *Genet Epidemiol*, vol. 25, no. 2, September, pp. 115-121.
25. Lenth RV. (2007) Statistical power calculations. *J Anim Sci*, vol. 85, no.13, March, pp.24-29.
26. Barrett JC, Fry B, Maller J, et al. (2005) Haploview: analysis and visualization of LD and haplotype maps. *Bioinform*, vol. 21, no. 2, January, pp. 263-265.
27. Moore JH, White BC. (2007) Tuning relief for genome-wide genetic analysis. *Lect Notes Comp Sci*, vol. 4447, pp. 166-175.
28. Li Y, Baker-Ericzen M, Ji N, et.al. (2013) Do SNPs of DRD4 gene predict adult persistence of ADHD in a Chinese sample? *Psychiatr Res*, vol. 205, no. 1-2, January, pp. 143-50.
29. Maitra S, Sarkar K, Ghosh, P, et.al. (2014) Potential contribution of dopaminergic gene variants in ADHD core traits and co-morbidity: A study on eastern Indian probands. *Cell Mol Neurobiol*, vol. 34, no. 4, May, pp. 549-64.

30. Nemoda Z, Lyons-Ruth K, Szekely A, et al. (2010) Association between dopaminergic polymorphisms and borderline personality traits among at-risk young adults and psychiatric inpatients, *Behav Brain Func*, vol. 6, January, pp. 4.
31. Vereczkei A, Demetrovics Z, Szekely A, et.al. (2013) Multivariate Analysis of Dopaminergic Gene Variants as Risk Factors of Heroin Dependence. *Plos One*, vol. 8, no. 6:e66592, June.
32. Lowe N, Kirley A, Mullins C, et al. (2004) Multiple marker analysis at the promoter region of the DRD4 gene and ADHD: evidence of linkage and association with SNP -616. *Am J Med Genet (NeuropsychiatrGenet)*, vol. 131(B), no. 1, November pp. 33-37.
33. Okuyama Y, Ishiguro H, Toru M, et al. (1999) A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. *Biochem Biophys Res Commun*, vol. 258, no. 2, May, pp. 292-295.
34. Kereszturi E, Király O, Csapó Z, et al.(2007) Analysis of the dopamine D4 receptor gene variants in attention deficit hyperactivity disorder. *Neuropsychopharmacol Hungary*, vol. 9, no. 1, March, pp. 11-18.
35. Das Bhowmik A, Sarkar K, Ghosh P, et al. (2013) Significance of dopaminergic gene variants in the male biasness of Attention Deficit Hyperactivity Disorder. *Journal of Attention Disorders*. DOI: 10.1177/1087054713494004. 2013
36. Nakajima M, Hattori E, Yamada K, et.al. (2007) Association and synergistic interaction between promoter variants of the DRD4 gene in Japanese schizophrenics. *J Human Genet*, vol.52, no. 1, pp. 86-91.
37. Narbona-Garcia J, Sanchez-Carpintero R. (1999) Neurobiology of attention deficit-hyperactivity disorder. *Rev Neurol*, Supplementary 2, S160-4.
38. Lazar JW, Frank Y. (1998) Frontal systems dysfunction in children with Attention-Deficit/Hyperactivity Disorder and Learning Disabilities. *J Neuropsychiatr Clin Neurosci*; vol.10, no.2, pp.160-167.

LEGEND TO FIGURES




Figure 1: Comparative analysis between control individuals and ADHD probands for mean scores obtained through computerized games.




Figure 2: MDR analysis performed using case-control data: (A) EOC & (B) SAS as phenotypic co-variates; (C) ADHD-LD and (D) ADHD+LD subgroups. P1-SAS, P2-EOC, A-rs916455, B-rs747302, C-rs936462, D-rs747303, E-rs10902180, F-1800955, G-NSNP.

Table 1 : Assessment of SAS and EOC from questions selected from DSM-IV and CRS.

Scales used for analysis	SAS	EOC
DSM IV-TR	Make careless mistakes in school/work/other activities Has difficulty in sustained attention Lacks attention during one/one conversation Is often easily distracted by extraneous stimuli Reluctant to perform tasks requiring mental effort	Does not follow instruction/fails to finish school work Has difficulty in organizing task Often loses things necessary for tasks and activities Is often forgetful in daily activities Reluctant to perform tasks that require mental effort
CRS	Inattentive, easily distracted Short attention span Distractibility or attention span a problem Gets distracted when given instruction to do something Has trouble concentrating in class Easily frustrated in efforts Avoids or expresses reluctance in tasks that require sustained mental effort	Has difficulty doing or completing home work Messy or disorganized at home or school Needs close supervision to get through assignments Avoids or expresses reluctance in tasks requiring sustained mental effort Does not follow through instructions and fails to finish school works.

Table 2 : Comparative analysis on genotypic frequencies of DRD4 promoter variants.

\*Compared to controls; ! Compared to ADHD-LD.

ID	Genotype	Control (N=200)	All (N=200)	$\chi^2(P)$	Probands		$\chi^2 (P)^*$	$\chi^2 (P)!$
					ADHD-LD (N=146)	ADHD+LD (N=54)		
rs916455	CC	0.88	0.89	1.53	0.85	0.94	6.34	6.34
	CT	0.12	0.10	(0.47)	0.14	0.04	(0.05)	(0.04)
	TT	0.0	0.01		0.01	0.02		
rs747302	CC	0.34	0.39	0.95	0.37	0.41	1.22	1.82
	GC	0.46	0.43	(0.62)	0.46	0.37	(0.54)	(0.40)
	GG	0.20	0.18		0.17	0.22		
rs936462	AA	0.90	0.93	3.22	0.91	1.0	7.43	9.42
	GA	0.09	0.07	(0.20)	0.09	0.0	(0.02)	(0.002)
	GG	0.01	0.0		0.0	0.0		
rs747303	GG	0.09	0.10	3.97	0.10	0.12	4.44	1.79
	GT	0.36	0.26	(0.14)	0.28	0.20	(0.10)	(0.41)
	TT	0.55	0.64		0.62	0.68		
rs10902180	GG	0.77	0.66	5.02	0.61	0.83	1.06	13.2
	GC	0.17	0.24	(0.08)	0.26	0.14	(0.59)	(0.001)
	CC	0.06	0.10		0.13	0.03		
rs1800955	CC	0.19	0.16	0.93	0.16	0.15	2.08	0.78
	CT	0.51	0.50	(0.62)	0.49	0.44	(0.35)	(0.68)
	TT	0.30	0.34		0.35	0.41		
NSNP	GG	0.82	0.80	0.10	0.81	0.77	0.47	0.48
	GT	0.18	0.20	(0.74)	0.19	0.23	(0.49)	(0.49)
	TT	0.0	0.0		0.00	0.00		



**Table 3 :** Analysis of familial allelic transmission by Haplotype-based Haplotype Relative Risk test.

SNP	Allele	Transmitted	Not transmitted	$\chi^2(P)$	Power (%)	Odds Ratio
rs916455	C	0.96	0.94	1.47 (0.23)	---	---
	T	0.04	0.06			
rs747302	C	0.63	0.59	0.64 (0.42)	---	---
	G	0.37	0.41			
rs936462	A	0.99	0.93	9.01 (0.003)	85	4.73 (1.15- 19.41)
	G	0.01	0.07			
rs747303	G	0.10	0.25	17.7 (2.59e-005)	99	2.81 (1.36-5.82)
	T	0.90	0.75			
rs10902180	G	0.83	0.82	0.07 (0.79)	---	---
	C	0.17	0.18			
rs1800955	C	0.37	0.48	5.54 (0.02)	65	1.52 (0.89-2.74)
	T	0.63	0.52			
NSNP	G	0.97	0.82	27.15 (1.89e-007)	99	4.89 ( 1.94 -12.06)
	T	0.03	0.18			

N.B. Statistically significant differences are presented in bold.

**Supplementary Table S1 :** Details on studied DRD4 promoter variants.


ID	Predicted functional score		Allele	Frequency		$\chi^2(P)$
	F-SNP	SNPinfo		Control	Probands	
rs916455	0.109	0.148029	C	0.942	0.941	0.0002 (0.96)
			T	0.057	0.058	
rs747302	0.208	0.086621	C	0.58	0.61	0.78 (0.37)
			G	0.42	0.39	
rs936462	0	0.086409	A	0.95	0.97	1.62 (0.20)
			G	0.05	0.03	
rs747303	0.208	0.172765	G	0.27	0.23	1.67 (0.20)
			T	0.73	0.77	
rs10902180	0.05	0.163562	G	0.86	0.78	6.39 (0.01)
			C	0.14	0.20	
rs1800955	0.176	0.181188	C	0.45	0.41	0.91 (0.34)
			T	0.55	0.59	
NSNP	None detected	--	G	0.91	0.90	1.00 (0.75)
			T	0.09	0.10	

**Supplementary Table S2 :** Analysis of association between genotypes and phenotypic attributes of ADHD probands


ID	Genotype	EOC		SAS	
		Mean± SE	P value	Mean± SE	P value
rs916455	CC	65.38 2.06	--	70.51, 1.66	--
	CT	65.19 5.34		71.82, 3.96	
rs747302	CC	66.72 3.13	--	74.37, 2.24	--
	GC	66.41 2.77		68.04, 2.61	
rs936462	GG	60.99 5.08	--	71.05, 3.79	--
	AA	65.17 2.02		71.17, 1.66	
rs747303	GA	69.67 6.96	--	67.60, 6.31	---
	GG	58.78±4.43		71.71±4.44	
rs10902180	GT	64.90±3.90	0.05	70.06, 3.35	--
	TT	67.10±2.53		71.59±1.99	
	GG	67.21±2.20		70.21, 1.89	
rs1800955	GC	61.91± 4.83	0.09	73.68, 3.91	--
	CC	61.46±6.51		72.67, 4.39	
	TT	68.40±3.11		72.7±2.75	
NSNP	CT	62.51±2.73	0.02	69.31±2.19	0.04
	CC	69.30±5.21		74.68, 4.13	
	GG	67.48±2.15		72.37±1.81	
	GT	56.92±4.78		64.67±4.01	

Supplementary Table S3 : Genotype-phenotype association of probands obtained after follow up.


Score for phenotypic traits							
ID	Genotypes	SAS			EOC		
		Low	Medium	High	Low	Medium	High
rs916455	CC	100	100	92	90	93	100
	CT	0	0	8	10	7	0
	CC	13	64	46	32	52	64
rs747302	GC	62	29	36	50	28	36
	GG	25	7	18	18	20	0
rs936462	AA	89	100	93	91	96	93
	GA	11	0	7	9	4	7
	GG	22	0	7	14	4	7
rs747303	GT	22	8	28	36	17	14
	TT	56	92	65	50	79	79
	GG	78	50	77	73	74	79
rs10902180	GC	22	29	14	23	10	7
	CC	0	21	9	4	16	14
	CC	12	7	12	10	16	7
rs1800955	CT	44	57	49	45	26	57
	TT	44	36	39	45	26	57
NSNP	GG	63	83	74	63	82	77
	GT	37	17	26	37	18	23




Supplementary Figure 1 : LD analysis for all ADHD probands (A), Father of the probands (B), Mother of the probands (C), ethnically matched healthy individuals (D).



Supplementary Figure 2 : Comparative analysis subgroups of ADHD individuals having different levels of EOC & SAS scores obtained from CPRS.



Supplementary Figure 3 : Analysis of performance of ADHD probands based on their genotypic constitution.



Supplementary Figure 4 : Frequency of probands with different levels of trait score at the time of recruitment (T0) and after three years (T3).





GLOBAL JOURNAL OF MEDICAL RESEARCH: A  
NEUROLOGY AND NERVOUS SYSTEM  
Volume 16 Issue 2 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Recurring Ischemic Infarcts Showing Biermer's Disease Associated with Protein S Deficiency

By Kokou Mensah Guinhouya, Léhleng Agba, Nyinévi Anayo & Mofou Belo

*Universite de Lome*

**Observation-** Mrs ASS....AKOU, 36 married and right handed household was at her second episode of stroke in six months.

Concerning her history; six months ago, during her first episode of stroke she was discovered and known to have a high blood pressure in the left anterior cerebral artery, responsible of an after effects right crural hemiparesis at 4/5.

She was not using hormonal contraception and there was not a sign of alcoholic or tobacco intoxication. Since six months she has been under second prevention with acetylsalicylic under 100 mg per day and sartan 150 mg per day.

The current episode was marked by a brutal installation of a left hemi body deficit predominant to inferior member in the morning of 26th December 2014 at her home. When she was admitted the exam allowed to note a blood pressure of 160/80 Hg in the left hand and 160/90 mmHg in the right, a beat of 78 pulsations per minute, a temperature at 37°C talking of a neurology she was conscious without trouble of superior functions.

*GJMR- A Classification: NLMC Code: WL 348*



*Strictly as per the compliance and regulations of:*



© 2016. Kokou Mensah Guinhouya, Léhleng Agba, Nyinévi Anayo & Mofou Belo. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License <http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

# Recurring Ischemic Infarcts Showing Biermer's Disease Associated with Protein S Deficiency

Kokou Mensah Guinhouya <sup>α</sup>, Léhleng Agba <sup>σ</sup>, Nyinévi Anayo <sup>ρ</sup> & Mofou Belo <sup>ω</sup>

**Observation-** Mrs ASS...AKOU, 36 married and right handed household was at her second episode of stroke in six months

Concerning her history; six months ago, during her first episode of stroke she was discovered and known to have a high blood pressure in the left anterior cerebral artery, responsible of an after effects right crural hemiparesis at 4/5.

She was not using hormonal contraception and there was not a sign of alcoholic or tobacco intoxication. Since six months she has been under second prevention with acetylsalicylic under 100 mg per day and sartin 150 mg per day.

The current episode was marked by a brutal installation of a left hemi body deficit predominant to inferior member in the morning of 26<sup>th</sup> December 2014 at her home. When she was admitted the exam allowed to note a blood pressure of 160/80 Hg in the left hand and 160/90 mmHg in the right, a beat of 78 pulsations per minute, a temperature at 37°4C talking of a neurology she was conscious without trouble of superior functions. She was presenting a paraplegia with no sensitive level nor trouble of sphincter with a left predominance and mortice forces at 4/5 in the right inferior member and 1/5 in the left inferior member. There was signs of spasticity in the right inferior member. The cerebral scan CT which was urgently made allowed to objective post ischemic after effect in the left anterior cerebral artery and a sharp phase of ischemic in the right anterior cerebral artery (fig 1). The injected tomography from supra aortic artery trunks was normal. The electrocardiogram was at a sinusal rhythm and so was the transthoracic and the trans oesophagus echography. The hemogram showed a slight anaemia (haemoglobin = 11,5 g/dl) macrocytic (MCV = 115 fl). The mixture protein S and C showed a deficit in protein S. the renal and hepatic functions was normal.

## REFERENCES BIBLIOGRAPHIQUES

1. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and

subarachnoid haemorrhage. *J Neurol Neurosurg Psychiatry* 1990; 53: 16-22.

2. Bevan H, Sharma K, Braley W. Stroke in young adults. *Stroke* 1990; 21:382-6.
3. Tairou A., Stadler A., Ahawo A. K. M. Création d'un système d'approvisionnement en médicaments essentiels et de recouvrement des coûts dans la région centrale du Togo. *Echos de santé* 1996; 34: 56-57.
4. A. Bougteba, A. Basir, N. Kissani. Infarctus cérébral récidivant révélant une maladie de Biermer. *Rev Neurol (Paris)*. 2009 Dec; 165 (12): 1099-102.
5. Rodeghiero F, Tosetto A. The epidemiology of inherited thrombophilia: the VITA Project. Vicenza Thrombophilia and Atherosclerosis Project. *Thromb Haemost* 1997; 78: 636-40.




Figure 1 : Infarcts in both left and right anterior cerebral arteries

Author <sup>α σ ρ ω</sup>: Service de neurologie du CHU Sylvanus OLYMPIO; BP 57 ; 30284, Lomé- Togo. e-mail: herve\_guinhouya@yahoo.fr

This page is intentionally left blank





GLOBAL JOURNAL OF MEDICAL RESEARCH: A  
NEUROLOGY AND NERVOUS SYSTEM  
Volume 16 Issue 2 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Size of Hemorrhage on CT Scan and GC Scale use to Determine the Outcome of Hemorrhagic Stroke in Hypertensive Patients

By Milisha Lal, Nisha Gaur, Sumit Kamble, Harsh Chapadia, Sindhu Avula,  
Karthik Gangu, Kimmyben Patel & Abhishek Vadher

*North Shore University hospital, United States*

**Abstract- Introduction:** This study was to identify hypertensive Intracranial Hemorrhage with hematoma as well as the relation to various factors and outcomes.

**Objective:** To find the correlation between the site and size of hemorrhage, GCS score, and the outcome.

**Methods:** This is a prospective observational trial. The study consists of 65 patients with Intracranial hemorrhage, presenting with the criteria and symptoms in order to correlate with the GCS score and GC scale. This study was conducted at Shree Sayaji General Hospital, Baroda during December 2013 to November 2014. The GC scale was used to assess the outcome. The GC score was used for distribution of the patients with presenting symptoms. CT scan of the head was also used to identify the site of the hemorrhage and the size of the hemorrhage.

**Results:** The increase in hematoma volume in the study shows the high percentage of mortality. This shows that the lower the GC score is worse for prognosis than a higher GC score of >14.

**Conclusion:** Our results show that a low GC score and high size of the bleed can significantly affect the prognosis.

**GJMR- A Classification:** NLMC Code: WG 106, WH 312



SIZE OF HEMORRHAGE ON CT SCAN AND GC SCALE USE TO DETERMINE THE OUTCOME OF HEMORRHAGIC STROKE IN HYPERTENSIVE PATIENTS

*Strictly as per the compliance and regulations of:*



© 2016. Milisha Lal, Nisha Gaur, Sumit Kamble, Harsh Chapadia, Sindhu Avula, Karthik Gangu, Kimmyben Patel & Abhishek Vadher. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.



# Size of Hemorrhage on CT Scan and GC Scale use to Determine the Outcome of Hemorrhagic Stroke in Hypertensive Patients

Milisha Lal <sup>α</sup>, Nisha Gaur <sup>σ</sup>, Sumit Kamble <sup>ρ</sup>, Harsh Chapadia <sup>ω</sup>, Sindhu Avula <sup>¥</sup>, Karthik Gangu <sup>§</sup>,  
Kimmyben Patel <sup>χ</sup> & Abhishek Vadher <sup>ν</sup>

**Abstract- Introduction:** This study was to identify hypertensive Intracranial Hemorrhage with hematoma as well as the relation to various factors and outcomes.

**Objective:** To find the correlation between the site and size of hemorrhage, GCS score, and the outcome.

**Methods:** This is a prospective observational trial. The study consists of 65 patients with Intracranial hemorrhage, presenting with the criteria and symptoms in order to correlate with the GCS score and GC scale. This study was conducted at Shree Sayaji General Hospital, Baroda during December 2013 to November 2014. The GC scale was used to assess the outcome. The GC score was used for distribution of the patients with presenting symptoms. CT scan of the head was also used to identify the site of the hemorrhage and the size of the hemorrhage.

**Results:** The increase in hematoma volume in the study shows the high percentage of mortality. This shows that the lower the GC score is worse for prognosis than a higher GC score of >14.

**Conclusion:** Our results show that a low GC score and high size of the bleed can significantly affect the prognosis.

## I. INTRODUCTION

Cerebrovascular accident or stroke is defined as an acute loss of focal and at times global (applied to patient in deep coma and those with subarachnoid hemorrhage) cerebral function, the symptoms lasting more than 24 hours or leading to death with no apparent cause other than that of vascular origin(WHO). Stroke can be ischemic or hemorrhagic and this is due to lack of blood flow to the brain and bleeding in the brain tissue respectively. Stroke can manifest with symptoms like loss of sensory or motor functions on one side of the body. It can also manifest as loss of vision, inability to speak or understand<sup>1,2</sup>. Cerebrovascular accidents represent third commonest cause of death worldwide. In United States, every year around 795000 people suffer from stroke and 130000

people die from stroke which is equal to 1 in every 20 deaths<sup>3</sup>. 87% of the stroke are due to ischemia and the rest 13% are due to hemorrhage<sup>4</sup>. The death due to stroke annually in United States is 130000 which is equal to 1 in every 20. Hypertension is the most important risk factor for stroke<sup>5</sup>. Hemorrhagic stroke has higher morbidity and mortality when compared to ischemic stroke. Hemorrhagic stroke is due to bleeding either in the brain or in the subarachnoid space<sup>6</sup>. Identifying high risk patients for development of Intracerebral Hemorrhage and to institute vigorous treatment in these patients is vital for prevention of Intracerebral Hemorrhage. Factors such as age, the score on Glasgow coma scale, the size of hematoma, rupture of hemorrhage in ventricle, midline shift and pulse pressure have been identified as determinant of outcome. The clinical and the CT correlates may contribute to the ultimate prognosis of these patients. By studying prognostic parameters of hypertensive Intracerebral Hemorrhage we can identify high risk patients, who are prone to develop Intracerebral Hemorrhage. Therefore, we can offer prompt and right treatment to patients with Intracerebral Hemorrhage.

## II. OBJECTIVES

1. To study the prognosis of patients with hypertensive intracerebral hemorrhage clinically.
2. To study prognosis of patients of hypertensive intracerebral hemorrhage with help of CT scan brain.

## III. MATERIALS AND METHODS

This is a prospective observational study with 65 patients. Follow up was done after one month of the patients included in the study. All CT proven hypertensive intracerebral haemorrhage patients admitted included in study with systolic BP >140mm of Hg and diastolic BP >90 mm of Hg. Patients having haemorrhage as a result of head injury, bleed in primary or secondary brain tumours, haemorrhage within a cerebral infarct, bleeding secondary to arteriovenous malformation and aneurysms were excluded. A thorough General examination was undertaken in particular for Glasgow coma scale, Vital examination

Author <sup>α</sup>: Physician, Bharati Vidyapeeth hospital.

Author <sup>σ</sup>: Physician, Baroda Medical College.

Author <sup>ρ</sup>: Neurology Resident, MBS Hospital & Medical College, Kota.

Author <sup>ω</sup>: Physician, Chapadia Medical Center.

Author <sup>¥</sup>: Resident physician, Saint Joseph Mercy, Ann Arbor.

Author <sup>§</sup>: Resident physician, Steward Carney hospital.

Author <sup>χ</sup>: Observer, North Penn Cardiovascular Institute.

Author <sup>ν</sup>: Research Assistant, North Shore University hospital.

e-mail: abhibvadher@gmail.com

including temperature, pulse, respiratory rate, and blood pressure was noted, Peripheral signs of atherosclerosis like arcus senillis, locomotor, brachialis, thickened vessel wall, vascular bruit, xanthomas and xanthelemas. Detailed Nervous System examination was done including fundoscopy. After history and examination investigations like Complete blood count, Urine albumin, sugar, urine microscopy, Random blood sugar on admission, Serum urea, creatinine levels as renal function test, Lipid Profile: total cholesterol, Triglyceride, LDL level, HDL Level, VLDL, total cholesterol/HDL ratio, LDL/HDL ratio were done. ECG to find out if signs of ischemia, arrhythmia, hypertrophy are present or not. In CT scan a preliminary lateral topogram of the cranium was obtained. Serial transaxial scans were then performed with OM line as reference and employing 10mm and 5 mm sections. 5/5 mm sections were performed through posterior fossa. CT Head was carried out to know the site, size, volume, mass effect, ventricular extension, cerebral edema of intracerebral hemorrhage. All data was analysed using appropriate statistical tests. A p value of <.05 will be considered significant. Data was entered in excel sheet and analyzed by EPI INFO software.


#### IV. RESULT AND ANALYSIS

Table -1 : Age Distribution of Hypertensive Intracerebral Hemorrhage In Study

Age group (yrs)	Survived	Expired	Total
30-39	2	0	2
40-49	5	2	7
50-59	5	6	11
60-69	6	15	21
70-79	4	9	13
80-89	2	6	8
>90	0	3	3
Total	24	41	65

Table-3 : Distribution of Patients With Gc Score and Correlation with Outcome

GC Score	Total Cases	Survived (%)	Expired (%)	P value
3-4	15(23.1%)	-	15 (100%)	0.002
5-8	22(33.8%)	2(9.1%)	20 (90.90%)	
9-13	4(6.1%)	-	4 (100%)	
14-15	24(36.9%)	22(91.7%)	2 (8.3%)	
TOTAL	65	24(36.9%)	41 (63.1%)	



Two thirds of the stroke are in patients with age greater than 65<sup>7</sup>. In our study, there were 45 patients with age > 60 which is 69.23%.

Table-2 : Distribution According To Presenting Symptoms

Symptoms	No.of cases	Percentage
Weakness of limb		
- Hemiplegia	41	46.15%
- single limb	2	3.0%
Altered sensorium	40	61.5%
Headache	31	47.69%
Vomiting	31	47.69%
Convulsion	7	10.76%
Sensory symptoms	-	-
Vertigo	2	3.0%
Aphasia	1	1.5%

Maximum patients presented with altered sensorium (61.5%). Headache was present in 47.69% patients and vomiting was present in 47.69%. Hemiplegia was present in 46.1% patients.


In our study 40 (61.5%) patients were known case of hypertension, in which 22 (55%) patients expired. Our study is showing higher mortality (76%) in first time diagnosed hypertensive patients than in patients who were known case of hypertension.

In our study 14 (21.5%) patients were known case of Diabetes in which 12 (85.7%) patients expired. So higher mortality was seen in patients with Diabetes Mellitus (85.7%) than in patients without Diabetes (56.8%). In our study 37(56.9%) were smokers and higher mortality (70.2%) was seen amongst smokers than nonsmokers(53.6%).

In our study maximum patients were in GC score 14-15 (53.3%). GC Score 3-4, 5-8, 9-13 had 100%, 90.9%, 100% mortality respectively, but GC Score 14-15 had only 8.5% mortality. This shows that prognosis (mortality) is worse with lower GC Score (p value = 0.002). This is statistically significant.

Table-4: Correlation between Site of Hemorrhage, Gcs Score and Outcome

Site of Hemorrhage	NO. of PT	GCS Score				Expired
		3-4	5-8	9-13	14-15	
<b>Single site of hemorrhage:</b>						
• Cerebral cortex	5	-	2	-	3	2(40%)
• Thalamus	2	-	1	-	1	1(50%)
• Internal capsule	-	-	-	-	-	
• Putamen	-	-	-	-	-	
• Basal ganglion	2	-	-	-	2	1(50%)
• Cerebellum	4	1	2	-	1	2(50%)
<b>Total patients</b>	13(20%)	1(7.7%)	5(38.4)	-	7(53.8%)	6(46.2%)
<b>Two site of hemorrhage:</b>						
• Fronto-temporal	5		2		1	2(40%)
• Temporo-parietal	2		2			2(100%)
• Frontal-parietal	3	2	1			3(100%)
• Thalamus+internal capsule	15		2	1	12	3
• Basal ganglia+internal capsule	5	1				1
• Pons+mid brain	1	1	1		3	1
<b>Total</b>	31(47.7%)	4(12.9%)	8(25.8%)	1(3.2%)	16(51.6%)	13(18.46%)
<b>Three site of hemorrhage:</b>						
• Thalamus-basal ganglia-internal capsule	3	1	2			3
• Frontal-parieto-temporal	6	4	1	1		5
• Frontal+thalamus+internal capsule	1	1				1
• Basal ganglia+thalamus+midbrain	3	3				3
<b>Total</b>	13(20%)	9(69.2%)	3(23%)	1(7.6%)		12(92.3%)
<b>&gt;3 sites of hemorrhage</b>	10(15.4%)	3(30%)	6(60%)	1(10%)		10(100%)




In our study patients with single site hemorrhage were 13(20%) with 46.2% mortality, 46.6% with GC score of 14-15 at the time of presentation. With three sites of hemorrhage 69.2 % patients were in GC score 3-4 and 92.3 % patients expired. With > 3 sites there was 100% mortality. So in our study with increasing sites of hemorrhage there is decreasing GC

score at presentation with increasing mortality trend (p value= 0.07). Here, as p value is >0.05, this is not statistically significant. But as per some studies, brain stem hematoma, intraventricular extension of bleed and ventricular compression along and with midline shift are associated with early mortality in intracranial hemorrhage<sup>8</sup>.

Table-5: Size of Hemorrhage Versus Outcome

Volume of Hemorrhage(mm3)	NO. Of Cases	NO. Of Patients Expired(%)	P value
<2500	21(32.3%)	1(4.1%)	0.0001
2501-5000	6(9.2%)	3(50%)	
5001-7500	5(7.6%)	4(80%)	
7501-10000	3(4.6%)	3(100%)	
>10000	30(46.15%)	30(100%)	



In our study maximum no. of patients had hematoma volume > 10,000 mm<sup>3</sup> - 30(46.15%) followed by 21 (32.3%) patients with volume <2500 mm<sup>3</sup>. Mortality is rising with increasing volume of hemorrhage in the study. There was 100% mortality with hematoma volume >7500mm<sup>3</sup>. P value was 0.0001 and this shows that the result was statistically significant. As per some studies, when the size of hematoma is >30 cm<sup>3</sup>, the morbidity and mortality increases significantly<sup>8</sup>.

### V. DISCUSSION

As per age distribution, in our study, 100% mortality was noted in age group 70-79 yrs., 80-89 yrs. and >90 yrs. In our study for sex distribution, out of 65 patients, 55.3 % were males and 44.6% were females. Thus the ratio of male to female was 1.2:1. There was no significant association was found in male and female sex and poor outcome. (p value=0.497). For history of hypertension, in our study 61.5% were known case of hypertension, out of them 55% patients expired. Rest 38.4% patients were freshly detected cases of hypertension. Our hospital gets patients from lower socioeconomic strata with poor education. Our history for Diabetes Mellitus shows out of 65 patients, 21.5% patients had H/O diabetes, out of which 85.7 % expired. The GC score established significant correlation between the Glasgow coma scale on admission and poor outcome. (p=0.002). In our study for site of

hematoma, high mortality was not significantly associated with No. of sites of hemorrhage (p=0.07). However, the increasing No. of hemorrhages is associated with increasing mortality. Most patients had multiple sites of hemorrhage at the time of presentation. Therefore, prognosis on the basis of site (basal ganglia, thalamus, lobar, brain stem, cerebellar) was not possible. The volume of hemorrhage study shows the volume of intracerebral hemorrhage >10,000 mm<sup>3</sup> is considered a severe stroke and proven as poor prognostic parameter for 30 days' mortality outcome. (p value =0.0001).

### VI. CONCLUSION

Glasgow coma scale on admission is significant for poor prognosis. Number of sites of hemorrhage in a CT scan is not significant with poor outcome. The volume of the hemorrhage is significant for poor outcome of stroke.

### REFERENCES RÉFÉRENCES REFERENCIAS

1. Donnan GA, Fisher M, Macleod M, Davis SM (May 2008). "Stroke". *Lancet*. 371 (9624): 1612–23. doi: 10.1016/S0140-6736(08)60694-7
2. "What Are the Signs and Symptoms of a Stroke?". <http://www.nhlbi.nih.gov>. March 26, 2014. Retrieved 27 February 2015.

3. CDC, NCHS. Underlying Cause of Death 1999-2013 on CDC WONDER Online Database, released 2015. Data are from the Multiple Cause of Death Files, 1999-2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed Feb. 3, 2015.
4. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation*. 2015 ;e29-322.
5. "Who Is at Risk for a Stroke?". [www.nhlbi.nih.gov](http://www.nhlbi.nih.gov). *March 26, 2014*. Retrieved 27 February 2015.
6. Feigin VL, Rinkel GJ, Lawes CM, Algra A, Bennett DA, van Gijn J, Anderson CS (2005). "Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies". *Stroke*. 36(12): 2773–80. doi:10.1161/01.STR.0000190838.02954.e8
7. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C (2014). "Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010". *Lancet*. 383 (9913): 245–54. doi:10.1016/S0140-6736(13)61953-4
8. Chiranjib Nag, Kamalesh Das,<sup>1</sup> Mrinalkanti Ghosh,<sup>2</sup> and M R Khandakar Prediction of Clinical Outcome in Acute Hemorrhagic Stroke from a Single CT Scan on Admission
9. *N Am J Med Sci*. 2012 Oct; 4(10): 463–467. doi: 10.4103/1947-2714.101986



This page is intentionally left blank





GLOBAL JOURNAL OF MEDICAL RESEARCH: A  
NEUROLOGY AND NERVOUS SYSTEM  
Volume 16 Issue 2 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Impact of Gender on Dementia in Elderly Urban Population

By Dr. Mrs. Gayatri Godbole, Shrirang Godbole & Dr. Mrs. Savita Vaidya

*Bharati Vidyapeeth Medical College*

**Abstract-** Dementia is characterized by progressive deterioration in intellectual, cognitive and judgmental functions of the brain. It is associated with high levels of dependency and morbidity. Therefore early detection and prevention is more important.

**Material and Methods:** 300 subjects aged 60 years and above were screened with MMSE. MMSE scores above 23 indicate normal cognitive function and score of < 23 indicates both the likelihood of cognitive impairment.

**Results:** Amongst the study population, 66 subjects had a MMSE score less than 23. Out of the total male subjects 11.47% had cognitive impairment. Out of the total female subjects 29.21% of females had cognitive impairment.

**Conclusion:** In a given sample, cognitive impairment is more prevalent in females than males.

**Keywords:** elderly population, cognitive impairment, MMSE, gender.

**GJMR- A Classification:** NLMC Code: WM 220



*Strictly as per the compliance and regulations of:*



© 2016. Dr. Mrs. Gayatri Godbole, Shrirang Godbole & Dr. Mrs. Savita Vaidya. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

# Impact of Gender on Dementia in Elderly Urban Population

Dr. Mrs. Gayatri Godbole <sup>α</sup>, Shirang Godbole <sup>σ</sup> & Dr. Mrs. Savita Vaidya <sup>ρ</sup>

**Abstract-** Dementia is characterized by progressive deterioration in intellectual, cognitive and judgmental functions of the brain. It is associated with high levels of dependency and morbidity. Therefore early detection and prevention is more important.

**Material and Methods:** 300 subjects aged 60 years and above were screened with MMSE. MMSE scores above 23 indicate normal cognitive function and score of < 23 indicates both the likelihood of cognitive impairment.

**Results:** Amongst the study population, 66 subjects had a MMSE score less than 23. Out of the total male subjects 11.47% had cognitive impairment. Out of the total female subjects 29.21% of females had cognitive impairment.

**Conclusion:** in a given sample, cognitive impairment is more prevalent in females than males.

**Keywords:** elderly population, cognitive impairment, MMSE, gender.

## I. INTRODUCTION

The percentage of elderly populace across the globe is increasing day by day and dementia is emerging as an important health problem in them.<sup>1</sup> Dementia is characterized by progressive deterioration in intellectual, cognitive and judgmental functions of the brain. Dementia is an irreversible clinical syndrome. It is associated with high levels of dependency and morbidity.

As the patient is increasingly dependent on other people, it becomes a great burden for him as well as his family<sup>2</sup>. Additionally, associated co-morbid conditions may complicate their status. Dementia even reduces the lifespan of the affected person.

The disease is insidious in onset and progress gradually. The patient slowly moves from bad to worse. People don't take the symptoms seriously and think of it as a natural, normal process associated with advanced age. This we owe to the fact that there is less awareness about this condition in the population at large. It remains a reality that most of these cases are undetected for long or remain undiagnosed. The patients present to the clinician at a very late stage, where treatment may not have the expected benefits. As the incidence of dementia grows, the pinch of this reality is being acutely felt.

Dementia is increasing in tandem with the increasing life expectancies worldwide. This increase is resulting in huge socio-economical consequences on patients, caregivers and even communities everywhere. After taking into consideration various etiologies of dementia, age and gender remain important non-modifiable risk factors. Some researchers state that women are at higher risk of developing Alzheimer's disease. They show a higher prevalence and increased rate of cognitive decline.<sup>3</sup> While a survey conducted by Sunil Kumar Raina in residents aged 60 years and above concludes that there is no significant difference in cognitive scores between males and females.<sup>4</sup>

Of the other causes of dementia, some can be treated partially but others cannot. Hence, early detection, in order to prevent further deterioration, has gained much significance.<sup>5</sup> This will help in instituting symptomatic treatment early and thus help to delay the progression of the disease.

The Mini Mental State Examination (MMSE) is a tool used for early identification and assessment of dementia.<sup>6</sup> It assesses cognitive function in depth, through a series of questions which have their respective scores. People are then categorized based on their scores. It is comparatively an easy tool to use and analyze. Also it is well understood by the patients. This makes it a near perfect screening tool. Comprehensive neuropsychiatric and medical examinations are necessary to diagnose dementia. They are too expensive and time consuming to be used in such studies done in primary settings. Hence, a screening tool like the MMSE is valuable for early detection of dementia.

Therefore this study was planned to screen people for dementia using MMSE and to correlate it with their gender.

**Aim:** To screen for dementia in the elderly and to the study the impact of gender on it.

## II. OBJECTIVES

1. To screen elderly people for dementia using Mini Mental State Examination (MMSE) Questionnaire.
2. To evaluate effect of gender on dementia.

## III. METHODOLOGY

It was a cross sectional community based study in urban area. People above 60 years of age were

**Author <sup>α σ ρ</sup>:** Assistant professor, Bharati Vidyapeeth Medical College, Pune. e-mails: ggodbole@gmail.com, sgodbole4@gmail.com, drsavitavaidya@gmail.com



included in the study. Known cases of dementia or depression and subjects with severe hearing impairment were excluded.

300 Residents (males and females) aged 60 years and above were identified randomly. Detailed interview of the subject and informant was taken and clinical examination of the subject was conducted. Demographic variable were noted down.

Subjects were administered Mini Mental State Examination (MMSE) which is known as the gold standard for cognitive screening.<sup>7</sup> It assesses cognitive function in relation to orientation, memory, attention and calculation, language and visual construction. It has 11 questions and the maximum score is 30. MMSE scores above 23 indicate normal cognitive function and score of < 23 indicates both the likelihood of cognitive impairment and the need for further evaluation.

Subjects with MMSE score <23 in both sexes were compared.

#### IV. RESULTS

A total of 300 subjects were interviewed. The study population consisted of 122 males and 178 females. Amongst them, 66 subjects had a MMSE score less than 23 (Table no.1). Out of the total male subjects 11.47% had cognitive impairment. Out of the total female subjects 29.21% of females had cognitive impairment (Table no.2).

#### V. DISCUSSION

Dementia is a major contributor towards disability amongst the elderly population. In this study total 300 people were assessed using the MMSE. Amongst the study population, 66 subjects had a MMSE score less than 23 (Table no.1). This group comprised of 52 females & 14 males. Out of 122 males in study population, 11.47% had cognitive impairment. In females, out of 178 total females 29.21% were cognitively impaired subjects (Table no.2). We can thus conclude that, it is more prevalent in females. Therefore gender is a non-modifiable risk factor for dementia.

The American Alzheimer Association also postulates that at an age above 60 years the risk of an average female getting dementia is 1 in 6 compared to an average male, who has a risk of 1 in 116.8 Other researches carried out in this field had similar results.

Luine et al. and Goodman et al. quote that estrogen plays a major role in this phenomenon. Estrogen has been reported to have beneficial effects on the brain, possibly acting as a protective factor in AD via its ability to promote the growth, survival and activity of cholinergic neurons.<sup>9, 10</sup> The hypothesis that sex hormones affect the response of the patient to acetylcholinesterase inhibitors is the basis of this important (which are an important treatment modality) has also garnered substantial evidence.

Scerri et al. quote that an emerging risk factor in dementia is depression.<sup>11</sup> The greater the frequency and severity of depressive symptoms, the greater are the risks. On an average, women have higher rates of depression than men and that is related to more prevalence of cognitive impairment in females.

The variable survival rates between men and women might affect the outcome here. Hence it is prudent to extend due caution before coming to any conclusion. On the contrary Prencipe and coworkers had concluded that prevalence rates did not differ in both sexes in Alzheimer and vascular dementia.<sup>12</sup>

A multitude of factors interact to give rise to the difference in dementia prevalence among men and women. Influence of genetic factors which predispose some to dementia is important. The neuroprotective effect of estrogen cannot be understated. Lastly, cultural and psychosocial factors have a lasting impact as far as gender prevalence is concerned. It is interesting to note that Indian women are more actively engaged in artistic and group activities; they are adept at socializing.

On the other hand an overall lower level of education & poor nutritional status of women put them on back foot. The interplay of these factors is an important aspect of the etiology here. But in the case of women, their advantages are often undermined by their shortcomings. This goes hand in hand with the findings of this study. After taking cognizance of the results, we can reasonably conclude that in a given sample, cognitive impairment is more prevalent in females than males.

#### REFERENCES RÉFÉRENCES REFERENCIAS

1. W M van der Flier and P Scheltens Epidemiology and risk factors of dementia J Neurol Neurosurg Psychiatry 2005; 76(Suppl V):v2-v7.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington D.C.: American Psychiatric Association; 1994.
3. Carlo Gabelli, Alessandra Codemo Gender differences in cognitive decline and Alzheimer's disease Ital J Gender-Specific Med 2015; 1: 21-28.
4. Raina SK, Raina S, Chander V, Grover A, Singh S, Bhardwaj A, Identifying risk for dementia across populations: A study on the prevalence of dementia in tribal elderly population of Himalayan region in Northern India. Ann Indian Acad Neurol 2013; 16: 640-4.
5. Shaji KS, Jotheeswaran AT, Girish N, Srikala Bharath, Amit Dias, Meera Pattabiraman and Mathew Varghese. Alzheimer's & Related Disorders Society of India (2010). The Dementia India Report: prevalence, impact, costs and services for Dementia. (Eds) ARDSI, New Delhi.
6. Bart Sheehan, Assessment scales in dementia. Ther Adv Neurol Disord (2012) 5(6) 349- 358.

7. Shilpa Gaidhane, Abhay M Gaidhane, Quazi Syed Zahiruddin, Nazli Khatib, Essential hypertension and cognitive function in elderly. *Global Journal of Medicine and Public Health* 2014; 3:1-12.
8. [http://www.alz.org/documents\\_custom/2014\\_facts\\_figures\\_fact\\_sheet\\_women.pdf](http://www.alz.org/documents_custom/2014_facts_figures_fact_sheet_women.pdf)
9. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury and amyloid betapeptide toxicity in hippocampal neurons. *Journal of Neurochemistry* 1996; 66(5): 1836–44.
10. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. *Experimental Neurology* 1985; 89(2); 484–90.
11. Charles Scerri The curvy side of dementia: The impact of gender on prevalence and care giving *Journal of the Malta College of Pharmacy Practice* Issue 2014; 20: 37-39.
12. Prencipe, Casini, Ferretti, Lattanzio, Fiorlli, Culasso Prevalence of dementia in an elderly rural population: effect of age, sex and education *J Neurol Neurosurg Psychiatry* 1996; 60: 628-633.

*Table no. 1:* Sex distribution in study group

Parameter (Sex)	Frequency	Percentage (%)
Males	122	40.66 %
Females	178	59.34%
Total	300	100%

Table no. 1 shows that out of total 300 subjects 40.66 % were males and 59.34% were females.

*Table no. 2:* MMSE score in male and female subjects

Sex	MMSE score	Frequency	Percentage
Males	> 23	108	88.52
	< 23	14	11.47
	Total	122	100
Females	> 23	126	70.78
	< 23	52	29.21
	Total	178	100

Table no. 2 shows that in the total study population, subjects with scores below 23 were 22%. It constituted 11.47% of the total male subjects and females constituted 29.21% of total females in the study group.



This page is intentionally left blank





GLOBAL JOURNAL OF MEDICAL RESEARCH: A  
NEUROLOGY AND NERVOUS SYSTEM  
Volume 16 Issue 2 Version 1.0 Year 2016  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Early Diagnosis of Neuron Mitochondrial Dysfunction May Reverse Global Metabolic and Neurodegenerative Disease

By Martins IJ

*University of Western Australia*

*Editorial-* The rise in obesity and diabetes in various countries have reached epidemic proportions [1] with the inability of the brain to regulate body weight and energy balance in the early part of life and related to neurodegenerative disease in these countries. Neurons in the brain become sensitive to Western diets with alterations in neurons that lead to brain circuitry disorders or feeding signals [2]. In insulin resistance and neurodegenerative diseases the astrocyte-neuron interaction is defective in the brain [3] and consumption of a Western diet does not allow neurons to metabolize glucose and fatty acids but instead leads to mitochondrial apoptosis and programmed neuron death. In the periphery in global communities liver steatosis can be reversible with hepatocyte mitochondria still able to metabolize fatty acids and glucose after consumption of a healthy low calorie diet but in the brain neuron mitochondria may not continue with mitochondrial biogenesis but continue to undergo apoptosis with neuron death.

*GJMR- A Classification: NLMC Code: WL 358.5*



*Strictly as per the compliance and regulations of:*



# EDITORIAL

## Early Diagnosis of Neuron Mitochondrial Dysfunction May Reverse Global Metabolic and Neurodegenerative Disease

Martins IJ

### EDITORIAL


The rise in obesity and diabetes in various countries have reached epidemic proportions [1] with the inability of the brain to regulate body weight and energy balance in the early part of life and related to neurodegenerative disease in these countries. Neurons in the brain become sensitive to Western diets with alterations in neurons that lead to brain circuitry disorders or feeding signals [2]. In insulin resistance and neurodegenerative diseases the astrocyte-neuron interaction is defective in the brain [3] and consumption of a Western diet does not allow neurons to metabolize glucose and fatty acids but instead leads to mitochondrial apoptosis and programmed neuron death. In the periphery in global communities liver steatosis can be reversible with hepatocyte mitochondria still able to metabolize fatty acids and glucose after consumption of a healthy low calorie diet but in the brain neuron mitochondria may not continue with mitochondrial biogenesis but continue to undergo apoptosis with neuron death.

Networks between various brain cells involve membrane and nuclear lipid signals with diets involved in the regulation, transmission and communication between various brain cells. The three main types of glial cells are the astrocytes, oligodendrocytes and microglia with astrocytes involved with the maintenance of endothelial cells in brain capillaries and the blood brain barrier (BBB) to prevent toxic substances and their entry into the brain with the prevention of mitochondrial apoptosis in neurons. Astrocytes have been shown to be important to neuron lifespan and survival [4,5] with diets and lifestyle involved with epigenetic modification that disrupt astrocyte signalling [3] involved in the maintenance of neurons in individuals in global populations. Nutritional diets that prevent epigenetic alterations include DNA methylation, covalent histone modification and non-coding RNAs that are involved in

gene activation and repression with chromatin structure modifications associated with intact circadian regulation critical for the increased survival of astrocytes and neurons. Atherogenic diets that stimulate bacterial lipopolysaccharides (LPS), mycotoxin and xenobiotics into the central nervous system may induce various cellular stresses with the induction of mitochondrial apoptosis induced neurodegenerative diseases.

The increased global susceptibility to insulin resistance associated with brain aging and neurodegenerative diseases now indicate neuron vulnerability to senescence or apoptosis [6] and require early plasma biomarker diagnosis that may assist with reversal of neuron senescence to healthy neurons that may be interpreted from lipidomic tests, genomic tests and proteomic tests [7]. The information provided from these tests now are relevant to the early diagnosis of neuron senescence and linked to mitochondrial biogenesis versus mitochondrial apoptosis that determine the lifespan of neurons. The tests may further assist in novel and important Alzheimer's disease therapeutics that reverse amyloid beta oligomers damage to neurons in diabetes related neurodegenerative disease and Alzheimer's disease [8].

*Author: School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia 6027, Australia.  
e-mail: i.martins@ecu.edu.au*



**Figure 1:** Downregulation of the calorie sensitive gene Sirtuin 1 is important to mitochondrial biogenesis with Sirt 1/p53 regulation of other anti-aging genes such as Klotho, p66shc, Foxo3a and the anti-aging transcription factor PGC1-alpha involved in mitochondrial function. Plasma protein analysis for the diagnosis of neuron mitochondrial function has become important with neurodegeneration closely linked to the global diabetic epidemic, NAFLD and various chronic diseases. Proteins such as apelin, angiotensin II, gelsolin, heat shock proteins, thrombospondin 1, transforming growth factor beta, tumour necrosis factor alpha, insulin like growth factor 1, fibroblast growth factor 21, adiponectin, GDF11 and hepatocyte growth factor are involved with mitochondrial survival and may involve p53 regulation of mitochondrial function in metabolic and neurodegenerative diseases.

Genomic analysis now indicate that the anti-aging gene Sirtuin 1 (Sirt 1) regulates other anti-aging genes that are now critical to mitochondrial biogenesis and neuron proliferation [8]. Sirt 1's regulation of mitochondria involve p53 regulation and include other anti-aging genes (Figure 1) that synthesize the Klotho anti-aging protein, p66shc longevity protein and transcription factors such as Forkhead box O3(FOXO3a) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1 apha) that are essential for the maintenance of mitochondrial function in cells [9-11]. In Figure 1 the plasma proteome analysis of various proteins may now indicate the diagnosis of neuron apoptosis versus neuron survival from the determination of plasma proteins that are relevant to mitochondrial biogenesis versus mitochondrial apoptosis. The plasma proteome analysis for neuron survival that involve mitochondrial health include proteins such as apelin, angiotensin II, gelsolin, heat shock proteins (HSP 70, HSP 60), thrombospondin 1 (TSP-1), Transforming growth factor beta (TGF beta), Tumour necrosis factor alpha (TNF alpha), Insulin like growth factor 1 (IGF-1), Fibroblast growth factor 21 (FGF21), adiponectin, GDF11 and hepatocyte growth factor (HGF). Dysregulated crosstalk between the adipose tissue and the liver [10] alter the release of these proteins with low and defective transport of these proteins to neurons in

the brain relevant to increased mitochondrial senescence versus mitochondrial biogenesis.

The gene-environment interaction identifies Sirt 1 in many global populations as the defective gene involved in the defective nuclear-mitochondria interactions in the adipose tissue and the liver relevant to the mitochondrial theory of aging [12-14]. Sirt 1 (nicotinamide adenine dinucleotide dependent class III histone deacetylase) targets transcription factors such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC 1-<alpha>), p53, pregnane X receptor (PXR), peroxisome proliferator-activated receptor (PPAR) to adapt gene expression to mitochondrial function with relevance to metabolic activity, insulin resistance and inflammation. Sirt 1 is involved in chromatin remodelling with effects on the nuclear and mitochondria interactions that determine neuron proliferation via mitochondrial biogenesis by deacetylation of PGC 1 alpha and p53 transcription factors that are important to mitochondrial DNA homeostasis [15-19]. Sirt 1's regulation of circadian clocks regulate mitochondrial function that determine neuron synaptic plasticity in various neurological diseases [10, 20-34]. Major commercial interests in simple proteome tests that can be conducted in any routine laboratory may now indicate from plasma proteome analysis the proliferation of mitochondria with relevance to neuron survival and prevention of

programmed cell death. In the current global non alcoholic fatty liver disease (NAFLD) epidemic the various proteins are important to neuron mitochondrial biogenesis and alterations in these proteins in the blood plasma may be involved in mitochondrial apoptosis and determine early neuron cell death. Sirt 1 and Sirt 3 are both involved with neuron mitochondria function with Sirt 1's important role in circadian regulation of Sirt 3's regulation of mitochondrial function [35,36]. However with the aging process various plasma proteins are now relevant to mitochondrial health by the regulation of Sirt 1/p53 expression (**Figure 1**) that may involve astrocyte regulation of mitochondrial biogenesis versus apoptosis that determine synaptic dysfunction and neurodegeneration [37-39].

HGF has also been shown to be important to neuron and axon survival with relevance to HGF in p53 transcriptional regulation and mitochondrial biogenesis [40-49]. FGF 21 is regulated by Sirt 1 and is a biomarker for mitochondrial disease with relevance to neuronal mitochondrial apoptosis [50-53]. Apelin and Angiotensin II [54-56] regulate mitochondrial function via Sirt 1 [57] with both peptides involved with mitochondrial function and apoptosis. HSP 60 and 70 regulate mitochondrial function with Sirt 1 involved in the metabolism of HSP 60 and 70 [58-60]. Gelsolin and its involvement in mitochondrial survival involves p53 transcriptional regulation to maintain mitochondrial health in metabolic disease and aging [61-63]. NGF regulates the circadian clock with effects on p53 regulation of neuron mitochondrial function [64-75]. IGF-1 and GDF11 are now important to maintain mitochondrial function [76,77] with its connections to Sirt 1/IGF-1/GH regulation by diet and nutrition [78]. TNF alpha [79] is particularly sensitive to mitochondrial induced neuronal apoptosis and with TGF beta [80] override Sirt 1's control of circadian regulation with relevance to mitochondrial related neuron apoptosis [81,82].

Adiponectin levels are closely connected to mitochondrial biogenesis with Sirt 1 regulation important to adiponectin gene expression [83-87]. Plasma TSP1 levels have become important to mitochondrial apoptosis with levels of LPS involved in TSP1 regulation and Sirt 1 repression [7]. TSP1 effects on CD47 receptor to prevent mitochondrial biogenesis and TSP-1 effects on p53 expression override Sirt 1/p53 transcriptional regulation of neuron synapticity and survival [88-93]. Sirt 1 regulation of brain derived neurotrophic factor (BDNF) is now important to BDNF induced mitochondrial function and synaptic plasticity [9]. Early analysis of plasma proteins (**Figure 1**) that determine mitochondrial survival by p53 transcriptional regulation may now be important to Sirt 1 metabolism of toxic oligomers such as amyloid beta and alpha synuclein in neurodegenerative diseases [9,10].

Furthermore plasma lipidomic analysis allow interpretation that in insulin resistance and

neurodegenerative diseases the increased plasma ceramides and sphingosine 1 phosphate are associated with increased liver/neuron mitochondrial apoptosis with programmed cell death of neurons associated with Sirt 1 repression. Lipids such as ceramides have been shown to inhibit Sirt 1/p53 transcriptional regulation and induce cell death in neurons or hepatocytes [94,95]. In contrast sphingosine 1 phosphate may act as a Sirt 1 activator by actions on increased PGC1alpha levels with increased mitochondrial biogenesis [96]. Ceramides supersede the effects of various plasma proteins (**Figure 1**) that have been shown to regulate p53 transcriptional activity to prevent mitochondrial apoptosis with relevance to neuron differentiation with plasma ceramide levels important to mitochondrial related defects in synaptic plasticity and neurodegeneration [3,7].

Nutritional therapy is required to promote the nuclear-mitochondria interaction and prevent mitochondrial apoptosis with improvement in the astrocyte-neuron crosstalk that determines the lifespan of neurons [97]. Diet and nutrition is particularly relevant to neuron Sirt 1 regulation of the circadian rhythm with relevance to mitochondrial biogenesis and the prevention of high glucose induced mitochondrial dysfunction in neurons [98]. The effects of high fat diets that contain palmitic acid induce liver steatosis and steatosis may be reversible but accelerated mitochondrial disease in neurons [99-103] by palmitic acid as a Sirt 1 inhibitor may induce irreversible neurodegenerative disease [53]. Nutriproteomic diets [7] have become important by the release from the adipose tissue and liver of proteins essential for the maintenance of the nuclear-mitochondria crosstalk in neurons. In the developing world nutritional therapy may be superseded with relevance to xenobiotic induced mitochondrial apoptosis [104] with accelerated synaptic plasticity defects and neurodegeneration. Activators of Sirt 1 such as leucine may be essential for mitochondrial biogenesis [105,106] and with stress disorders the apelinergic system defects [57] may lead to accelerated mitochondrial apoptosis with neuroendocrine disease. Interests in nutritional therapy include Sirt 1 activators such as pyrroloquinoline quinone, resveratrol and rutin [107-110] that specifically stimulate mitochondria biogenesis in the liver and brain compared with ochratoxin A [111] that interferes with mitochondrial respiration.

## CONCLUSION

Interests in the early diagnosis of neuron senescence has become a major concern for many global communities with accelerated neurodegeneration involved with the metabolic syndrome and various chronic diseases. The mitochondria in neurons are sensitive to dysregulation with irreversible defects in these mitochondria that result in neuron apoptosis early

in life. The plasma proteins such as Apelin, Angiotensin II, Gelsolin, Heat shock proteins (HSP 70, HSP 60), Thrombospondin 1 (TSP-1), Transforming growth factor beta (TGF beta), Tumour necrosis factor alpha (TNF alpha), Insulin like growth factor 1 (IGF-1), Fibroblast growth factor 21 (FGF21), GDF11, Adiponectin and Hepatocyte growth factor (HGF) should be measured early in life to determine mitochondrial damage in brain cells. The importance of the plasma profile is now relevant to assessment by nutritional therapy to reverse and halt neuron loss that is irreversible with relevance to the accelerated neurodegeneration and early nutritional regulation has become critical to the reversal of the global NAFLD, metabolic syndrome and chronic diseases.

### ACKNOWLEDGEMENTS

This work was supported by grants from Edith Cowan University, the McCusker Alzheimer's Research Foundation and the National Health and Medical Research Council.

### REFERENCES RÉFÉRENCES REFERENCIAS

- Eisenberg D.M. and Burgess J.D., (2015): Nutrition Education in an Era of Global Obesity and Diabetes: Thinking Outside the Box. *Acad. Med*; 90(7): 854-60.
- Martins I.J., (2016) Appetite Control with Relevance to Mitochondrial Biogenesis and Activation of Post-Prandial Lipid Metabolism in Obesity Linked Diabetes. *Ann. Obes. Disord*; 1(3): 1-3.
- Martins I.J. and Creegan R., (2014): Links between Insulin Resistance, Lipoprotein Metabolism and Amyloidosis in Alzheimer's Disease. *Health*; 6(12): 1549-1579.
- Ricci G., Volpi L., Pasquali L., Petrozzi L. and Siciliano G., (2009): Astrocyte-neuron interactions in neurological disorders. *J Biol Phys*; 2009; 35(4): 317-336.
- Vernadakis A., (1996): Glia-neuron intercommunications and synaptic plasticity. *Prog Neurobiol*; 49(3): 185-214.
- Mattson M.P. and Magnus T., (2006): Ageing and neuronal vulnerability. *Nat Rev Neurosci*; 7(4): 278-94.
- Martins I.J., (2016): The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease. *Proteomes*; 4(2): 1-19.
- Lane R.F., Shineman D.W., Steele J.W., Lee L.B. and Fillit H.M., (2012); Beyond amyloid: the future of therapeutics for Alzheimer's disease. *Adv Pharmacol*; 64: 213-71.
- Martins I.J., (2016): Anti-Aging Genes Improve Appetite Regulation and Reverse Cell Senescence and Apoptosis in Global Populations. *Adv Aging Res*; 5: 9-26.
- Martins I.J., (2015): Unhealthy Nutrigenomic Diets Accelerate NAFLD and Adiposity in Global communities. *J Mol Genet Med*; 9(1): 1-11.
- [https://www.researchgate.net/profile/Ian\\_Martins2/Article/Appetite\\_Control\\_with\\_Relevance\\_to\\_Mitochondrial\\_Biogenesis\\_and.../presentation/antagonizing-genes-regulate-post-prandial-lipid-metabolism-with-relevance-to-appetite-chronic-disease-and-neurodegeneration-2nd-international-conference-and-expo-on-lipids-metabolism-nutrition-and-health-october-03-05-2016](https://www.researchgate.net/profile/Ian_Martins2/Article/Appetite_Control_with_Relevance_to_Mitochondrial_Biogenesis_and.../presentation/antagonizing-genes-regulate-post-prandial-lipid-metabolism-with-relevance-to-appetite-chronic-disease-and-neurodegeneration-2nd-international-conference-and-expo-on-lipids-metabolism-nutrition-and-health-october-03-05-2016).
- Gulbins E., Dreschers S. and Bock J., (2003): Role of mitochondria in apoptosis. *Exp Physiol*; 88(1): 85-90.
- Lee H.C. and Wei Y.H. (2012): Mitochondria and aging. *Adv Exp Med Biol*; 942:311-27.
- Voloboueva L.A., Suh S.W., Swanson R.A. and Giffard R.G., (2007): Inhibition of mitochondrial function in astrocytes: implications for neuroprotection. *J Neurochem*; 102(4):1383-94.
- Koczor C.A., White R.C., Zhao P., Zhu L., Fields E., et al. (2012): p53 and Mitochondrial DNA, Their Role in Mitochondrial Homeostasis and Toxicity of Antiretrovirals. *Am J Pathol*; 180(6): 2276-2283.
- Park J-H, Zhuang J., Li J., and Hwang P.M. (2016): p53 as guardian of the mitochondrial genome. *FEBS Letters*; 590(7): 924-934.
- Safdar A., Little J.P., Stokl A.J., Hettinga B.P., Akhtar M., et al. (2011): Exercise increases mitochondrial PGC-1 $\alpha$  content and promotes nuclear-mitochondrial cross-talk to coordinate mitochondrial biogenesis. *J Biol Chem*; 286(12): 10605-17.
- Sen N., Satija Y.K. and Das S., (2011): PGC-1 $\alpha$ , a key modulator of p53, promotes cell survival upon metabolic stress. *Mol Cell*; 44(4): 621-34.
- Aquilano K., Baldelli S., Pagliei B., Cannata S.M., Rotilio G. and Ciriolo M.R. (2013): p53 Orchestrates the PGC-1 $\alpha$ -Mediated Antioxidant Response Upon Mild Redox and Metabolic Imbalance. *Antioxid Redox Signal*; 18(4): 386-399.
- Neufeld-Cohen A., Robles M.S., Aviram R., Manella G., Adamovich Y., et al. (2016): Circadian control of oscillations in mitochondrial rate-limiting enzymes and nutrient utilization by PERIOD proteins. *Proc Natl Acad Sci U S A*; 113(12): E1673-82.
- Sheng Z.H. and Cai Q. (2012): Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. *Nat Rev Neurosci*; 13(2): 77-93.
- Sheng Z.H., (2014): Mitochondrial trafficking and anchoring in neurons: New insight and implications. *J Cell Biol*; 204(7): 1087-98.
- Ben-Shachar D. and Laifenfeld D. (2004): Mitochondria, synaptic plasticity, and schizophrenia. *Int Rev Neurobiol*; 59: 273-96.
- Oliva-Ramírez J<sup>1</sup>, Moreno-Altamirano MM, Pineda-Olivera B, Cauich-Sánchez P, Sánchez-García FJ.



- Crosstalk between circadian rhythmicity, mitochondrial dynamics and macrophage bactericidal activity. *Immunology*. 2014 Nov; 143(3): 490-7.
25. Langmesser S<sup>1</sup>, Albrecht U. Life time-circadian clocks, mitochondria and metabolism. *Chronobiol Int*. 2006; 23(1-2): 151-7.
  26. Hu F. and Liu F., (2011): Mitochondrial stress: a bridge between mitochondrial dysfunction and metabolic diseases? *Cell Signal*; 23(10): 1528-33.
  27. Todorova V. and Blokland A., (2016): Mitochondria and Synaptic Plasticity in the Mature and Aging Nervous System. *Curr Neuropharmacol*; 2016. [Epub ahead of print]
  28. Aguilar-Arnal L. and Sassone-Corsi P., (2015): Chromatin landscape and circadian dynamics: Spatial and temporal organization of clock transcription. *Proc Natl Acad Sci U S A*; 112(22): 6863-70.
  29. Hirschey M.D., Shimazu T., Huang J.Y. and Verdin E., (2009): Acetylation of mitochondrial proteins. *Methods Enzymol*; 457: 137-47.
  30. Tang B.L. (2016): Sirt1 and the Mitochondria. *Mol Cells*; 39(2): 87-95.
  31. Rey G. and Reddy A.B., (2013): Protein acetylation links the circadian clock to mitochondrial function. *Proc Natl Acad Sci U S A*; 110(9): 3210-1.
  32. Anderson K.A. and Hirschey M.D., (2012): Mitochondrial protein acetylation regulates metabolism. *Essays Biochem*; 52: 23-35.
  33. Sack M.N. and Finkel T., (2012) Mitochondrial metabolism, sirtuins, and aging. *Cold Spring Harb Perspect Biol*; 1:4(12).
  34. Kil I.S., Ryu K.W., Lee S.K., Kim J.Y., Chu S.Y. et al., (2015): Circadian Oscillation of Sulfiredoxin in the Mitochondria. *Mol Cell*; 59(4): 651-63.
  35. Brenmoehl J. and Hoefflich A., (2013): Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3. *Mitochondrion*. 13;6: 755-761.
  36. Hirschey M.D., Shimazu T., Capra J.A., Pollard K.S. and Verdin E. (2011): SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1, 2 and HMGCS1, 2. *Aging (Albany NY)*; 3(6): 635-42.
  37. Stephen T.L., Gupta-Agarwal S. and Kittler J.T., (2014): Mitochondrial dynamics in astrocytes. *Biochem Soc Trans*; 42(5): 1302-10.
  38. Cabezas R., El-Bachá R.S., González J. and Barreto G.E., (2012): Mitochondrial functions in astrocytes: Neuroprotective implications from oxidative damage by rotenone. *Neurosci Res*; 74 (2): 80-90.
  39. Hayakawa K., Esposito E., Wang X., Terasaki Y., Liu Y., et al., (2016): Transfer of mitochondria from astrocytes to neurons after stroke. *Nature*; 535 (7613): 551-5.
  40. Funakoshi H and Nakamura T., (2003): Hepatocyte growth factor: from diagnosis to clinical applications. *Clin Chim Acta*; 327(1-2): 1-23.
  41. Metcalfe A.M., Dixon R.M. and Radda G.K., (1997): Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter. *Nucleic Acids Res*; 25(5): 983-986.
  42. Stein Y., Jacob A., Goldfinger N., Straussman R. and Rotter V., (2016): Mutant p53 modulates the signal of hepatocyte growth factor (HGF) to endow cancer cells with drug resistance. *European Journal of Cancer*; 61(Supplement 1): S134.
  43. Xia S. and Laterra J., (2006): Hepatocyte growth factor increases mitochondrial mass in glioblastoma cells. *Biochem Biophys Res Commun*; 345(4): 1358-64.
  44. Tyndall S.J. and Walikonis R.S., (2007) Signaling by hepatocyte growth factor in neurons is induced by pharmacological stimulation of synaptic activity. *Synapse*; 61(4): 199-204.
  45. Maina F. and Klein R., (1999): Hepatocyte growth factor, a versatile signal for developing neurons. *Nat Neurosci*; 2(3): 213-7.
  46. Maina F., Hilton M.C., Andres R., Wyatt S., Klein R., et al., (1998): Multiple roles for hepatocyte growth factor in sympathetic neuron development. *Neuron*; 20(5): 835-46.
  47. Hamanoue M., Takemoto N., Matsumoto K., Nakamura T., Nakajima K. et al., (1996): Neurotrophic effect of hepatocyte growth factor on central nervous system neurons in vitro. *J Neurosci Res*; 43(5): 554-64.
  48. Wong W.K., Cheung A.W., Yu S.W., Sha O. and Cho E.Y. (2014): Hepatocyte growth factor promotes long-term survival and axonal regeneration of retinal ganglion cells after optic nerve injury: comparison with CNTF and BDNF. *CNS Neurosci Ther*; 20(10): 916-29.
  49. Watanabe T., Sakata Y., Matsubara S., Yamagishi T., Nagaie K., Kuwata T., et al., (2006): Changes in plasma levels of hepatocyte growth factor and its associated factors during pregnancy. *J Obstet Gynaecol Res*; 32(1): 10-4.
  50. Chau M.D., Gao J., Yang Q., Wu Z. and Gromada J., (2010): Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1 $\alpha$  pathway. *Proc Natl Acad Sci U S A*; 107(28): 12553-8.
  51. Suomalainen A., (2013): Fibroblast growth factor 21: a novel biomarker for human muscle-manifesting mitochondrial disorders. *Expert Opin Med Diagn*; 7(4): 313-7.
  52. Davis R.L., Liang C., Edema-Hildebrand F., Riley C., Needham M., et al., (2013): Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. *Neurology*; 81(21): 1819-26.
  53. Martins I.J., (2016): Diet and Nutrition reverse Type 3 Diabetes and Accelerated Aging linked to Global chronic diseases. *J Diab Res Ther*; 2(2): 1-6.

54. Attané C., Foussal C., Le Gonidec S., Benani A., Daviaud D., et al., (2012): Apelin treatment increases complete Fatty Acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice. *Diabetes*; 61(2): 310-20.
55. Frier B.C., Williams D.B. and Wright D.C., (2009) The effects of apelin treatment on skeletal muscle mitochondrial content. *Am J Physiol Regul Integr Comp Physiol*; 297(6): R1761-8.
56. Dikalov S.I. and Nazarewicz R.R., (2013): Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. *Antioxid Redox Signal*; 19(10): 1085-94.
57. Martins I.J., (2015): Nutritional diets accelerate amyloid beta metabolism and prevent the induction of chronic diseases and Alzheimer's disease. Photon ebooks. UBN: 015-A94510112017
58. Herrmann J.M., Stuart R.A., Craig E.A. and Neupert W., (1994): Mitochondrial heat shock protein 70, a molecular chaperone for proteins encoded by mitochondrial DNA. *J Cell Biol*; 127(4): 893-902.
59. Deocaris C.C., Kaul S.C. and Wadhwa R., (2006) On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60. *Cell Stress Chaperones*; 11(2): 116-28.
60. Martins I.J., (2016): Type 3 diabetes with links to NAFLD and Other Chronic Diseases in the Western World. *Int J Diab*; 1: 1-5.
61. Koya R.C., Fujita H., Shimizu S., Ohtsu M., Takimoto M., et al., (2000): Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. *J Biol Chem*; 275(20): 15343-9.
62. An J.H., Kim J.W., Jang S.M., Kim C.H., Kang E.J., et al., (2011):Gelsolin negatively regulates the activity of tumor suppressor p53 through their physical interaction in hepatocarcinoma HepG2 cells. *Biochem Biophys Res Commun*; 412(1): 44-9.
63. Zhou Y., Deng X., Ma X., Zang N., Li H., et al., (2015): Cellular transcriptomics: gelsolin negatively regulates the expression of apoptosis-associated genes and inhibits apoptosis in hepatocarcinoma cells. *Int J Clin Exp Pathol*;8(11):13871-85.
64. Chada S.R. and Hollenbeck P.J., (2004): Nerve growth factor signaling regulates motility and docking of axonal mitochondria. *Curr Biol*; 14(14): 1272-6.
65. Chu C., Levine E., Gear R.W., Bogen O. and Levine J.D., (2011):Mitochondrial dependence of nerve growth factor-induced mechanical hyperalgesia. *Pain*; 152(8): 1832-7.
66. Zhang J., Yan W. and Chen X., (2006): p53 is required for nerve growth factor-mediated differentiation of PC12 cells via regulation of TrkA levels. *Cell Death Differ*; 13(12): 2118-28.
67. Wong V., Glass D.J., Arriaga R, Yancopoulos G.D., Lindsay R.M., et al., (1997): Hepatocyte growth factor promotes motor neuron survival and synergizes with ciliary neurotrophic factor. *J Biol Chem*; 272(8): 5187-91.
68. Brynczka C. and Merrick B.A., (2007) Nerve growth factor potentiates p53 DNA binding but inhibits nitric oxide-induced apoptosis in neuronal PC12 cells. *Neurochem Res*; 32(9): 1573-85.
69. Zhou X., Hao Q., Liao P., Luo S., Zhang M, et al.,(2016): Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator. *Elife*; 5. pii: e15099.
70. Tedeschi A. and Di Giovanni S., (2009): The non-apoptotic role of p53 in neuronal biology: enlightening the dark side of the moon. *EMBO Rep*; 10(6): 576-83.
71. Bina, K.G. and Rusak B., (1996): Nerve growth factor phase shifts circadian activity rhythms in Syrian hamsters. *Neurosci Lett*; 206(2-3): 97-100.
72. Pizzio G.A., Hainich E.C., Plano S.A., Ralph M.R. and Golombek D.A., (2005): Nerve growth factor-induced circadian phase shifts and MAP kinase activation in the hamster suprachiasmatic nuclei *European J Neurosci*; 22(3): 665-71.
73. Jang M.U., Park J.W., Kho H.S., Chung S.C., Chung J.W., (2011): Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients. *Oral Dis*; 17(2): 187-93.
74. Emanuele E., Politi P., Bianchi M., Minoretti P., Bertona M., et al., (2006): Raised plasma nerve growth factor levels associated with early-stage romantic love. *Psychoneuroendocrinology*; 31(3): 288-94.
75. Park J-H., Zhuang J., Li J. and Hwang P.M., (2016): p53 as guardian of the mitochondrial genome. *FEBS Letters*; 590(7):924-934.
76. Sádaba M.C., Martín-Estal I., Puche J.E. and Castilla-Cortázar I., (2016): Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases. *Biochim Biophys Acta*; 1862(7): 1267-78.
77. Sinha M., Jang Y.C., Oh J., Khong D., Wu E.Y., et al., (2014): Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. *Science*; 344(6184): 649-52.
78. Yamamoto M., Iguchi G., Fukuoka H., Suda K., Bando H.,et al., (2013): SIRT1 regulates adaptive response of the growth hormone--insulin-like growth factor-I axis under fasting conditions in liver. *Proc Natl Acad Sci U S A*; 110(37): 14948-53.
79. Doll D.N., Rellick S.L., Barr T.L., Ren X. and Simpkins J.W., (2015): Rapid mitochondrial dysfunction mediates TNF-alpha-induced neurotoxicity. *J Neurochem*; 132(4): 443-51.
80. Jain M., Rivera S., Monclus E.A., Synenki L., Zirk A., et al., (2013): Mitochondrial reactive oxygen species

- regulate transforming growth factor- $\beta$  signaling. *J Biol Chem*; 288(2): 770-7.
81. Gast H., Gordic S., Petrzilka S., Lopez M., Müller A., et al., (2012): Transforming growth factor-beta inhibits the expression of clock genes. *Ann N Y Acad Sci*; 1261: 79-87.
  82. Lopez M., Meier D., Müller A., Franken P., Fujita J., et al., (2014): Tumor necrosis factor and transforming growth factor  $\beta$  regulate clock genes by controlling the expression of the cold inducible RNA-binding protein (CIRBP). *J Biol Chem*; 289(5): 2736-44.
  83. Barnea M., Chapnik N., Genzer Y. and Froy O., (2015): The circadian clock machinery controls adiponectin expression. *Mol Cell Endocrinol*; 399: 284-7.
  84. Gómez-Abellán P., Gómez-Santos C., Madrid J.A., Milagro F.I., Campion J., et al., (2010): Circadian expression of adiponectin and its receptors in human adipose tissue. *Endocrinology*; 151(1): 115-22.
  85. Nilsson C., Ståhlberg F., Thomsen C., Henriksen O., Herring M., et al., (1992): Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. *Am J Physiol*; 262(1 Pt 2): R20-4.
  86. Gan L., Yan J., Liu Z., Feng M. and Sun C., (2015): Adiponectin prevents reduction of lipid-induced mitochondrial biogenesis via AMPK/ACC2 pathway in chicken adipocyte. *J Cell Biochem*; 116(6): 1090-100.
  87. Qiao L., Kinney B., Yoo H.S., Lee B., Schaack J., et al., (2012): Adiponectin increases skeletal muscle mitochondrial biogenesis by suppressing mitogen-activated protein kinase phosphatase-1. *Diabetes*; 61(6): 1463-70.
  88. Roué G., Bitton N., Yuste V.J., Montange T., Rubio M., et al., (2003): Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release. *Biochimie*; 85(8): 741-6.
  89. Frazier, E.P., Isenberg J.S., Shiva S., Zhao L., Schlesinger P., et al., (2011): Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. *Matrix Biol*; 30(2): 154-61.
  90. Grossfeld G.D., Ginsberg D.A., Stein J.P., Bochner B.H., Esrig D., et al., (1997): Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. *J Natl Cancer Inst*; 89(3): 219-27.
  91. Alvarez A.A., Axelrod J.R., Whitaker R.S., Isner P.D., Bentley R.C., et al., (2001): Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. *Gynecol Oncol*; 82(2): 273-8.
  92. Kaur S., Soto-Pantoja D.R., Stein E.V., Liu C., Elkahloun, A.G., et al., (2013): Thrombospondin-1 Signaling through CD47 Inhibits Self-renewal by Regulating c-Myc and Other Stem Cell Transcription Factors *Scientific Reports*; 3(1673): 1-12.
  93. Baek K.H., Bhang D., Zaslavsky A., Wang L.C., Vachani A., et al., (2013): Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. *J Clin Invest*; 123(10): 4375-89.
  94. Hage-Sleiman R., Esmerian M.O., Kobeissy H., and Dbaibo G., (2013): p53 and Ceramide as Collaborators in the Stress Response. *Int J Mol Sci*; 14(3): 4982-5012.
  95. Dbaibo G.S., Pushkareva M.Y., Rachid R.A., Alter N., Smyth M.J., et al., (1998). p53-dependent ceramide response to genotoxic stress. *J Clin Invest*; 102(2): 329-39.
  96. Shen Z., Liu C., Liu P., Zhao J. and Xu W., (2014): Sphingosine 1-phosphate (S1P) promotes mitochondrial biogenesis in Hep G2 cells by activating Peroxisome proliferator-activated receptor  $\gamma$  coactivator 1 $\alpha$  (PGC-1 $\alpha$ ). *Cell Stress Chaperones*; 19(4): 541-8.
  97. Sikora E., Bielak-Zmijewska A. and Mosieniak G., (2014): Cellular senescence in ageing, age-related disease and longevity. *Curr Vasc Pharmacol*; 12(5): 698-706.
  98. Russell J.W., Golovoy D., Vincent A.M., Mahendru P., Olzmann J.A., et al., (2002): High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. *FASEB J*; 16(13): 1738-48.
  99. Yuzefovych L., Wilson G. and Rachek L., (2010): Different effects of oleate vs. palmitate on mitochondrial function, apoptosis, and insulin signaling in L6 skeletal muscle cells: role of oxidative stress. *Am J Physiol Endocrinol Metab*; 299(6): E1096-105.
  100. Mironova G.D., Gritsenko E, Gateau-Roesch O, Levrat C, Agafonov A, et al., (2004): Formation of palmitic acid/Ca<sup>2+</sup> complexes in the mitochondrial membrane: a possible role in the cyclosporin-insensitive permeability transition. *J Bioenerg Biomembr*; 36(2): 171-8.
  101. Kwon B. and Querfurth H.W., (2014): Opposite effects of saturated and unsaturated free fatty acids on intracellular signaling and metabolism in neuronal cells. *Inflamm Cell Signal*; 1: e200.
  102. Penzo D., Tagliapietra C., Colonna R., Petronilli V. and Bernardi P., (2002): Effects of fatty acids on mitochondria: implications for cell death. *Biochim Biophys Acta*; 1555(1-3): 160-5.
  103. Hsiao Y.H., Lin C.I., Liao H., Chen Y.H. and Lin S.H., (2014): Palmitic acid-induced neuron cell cycle G2/M arrest and endoplasmic reticular stress through protein palmitoylation in SH-SY5Y human

neuroblastoma cells. *Int J Mol Sci*; 15(11): 20876-99.

104. Martins I.J., (2013): Increased Risk for Obesity and Diabetes with Neurodegeneration in Developing Countries. *J Mol Genet Med*; S1(001): 1-12.
105. Liang C., Curry B.J., Brown P.L., and Zemel M.B., (2014): Leucine Modulates Mitochondrial Biogenesis and SIRT1-AMPK Signaling in C2C12 Myotubes. *J Nutrit Metab*; 2014: Article ID 239750, 11 pages.
106. Sun X, and Zemel M.B., (2009): Leucine modulation of mitochondrial mass and oxygen consumption in skeletal muscle cells and adipocytes. *Nutr Metab (Lond)*; 6: 26.
107. Zhang J., Meruvu S., Bedi Y.S., Chau J., Arguelles A., et al., (2015): Pyrroloquinoline quinone increases the expression and activity of Sirt1 and -3 genes in HepG2 cells. *Nutr Res*; 35(9): 844-9.
108. Higashida K., Kim S.H., Jung S.R., Asaka M., Holloszy J.O. et al., (2013): Effects of resveratrol and SIRT1 on PGC-1 $\alpha$  activity and mitochondrial biogenesis: a reevaluation. *PLoS Biol*; 11(7): e1001603.
109. Seo S., Lee M.S., Chang E., Shin Y., Oh S., et al., (2015): Rutin Increases Muscle Mitochondrial Biogenesis with AMPK Activation in High-Fat Diet-Induced Obese Rats. *Nutrients*; 7(9): 8152-69.
110. Su K.Y., Yu C.Y., Chen Y.W., Huang Y.T., Chen C.T., et al., (2014): Rutin, a flavonoid and principal component of saussurea involucreta, attenuates physical fatigue in a forced swimming mouse model. *Int J Med Sci*; 11(5): 528-37.
111. Martins I.J., et al., (2015): Overnutrition Determines LPS Regulation of Mycotoxin Induced Neurotoxicity in Neurodegenerative Diseases. *Int J Mol Sci*; 16(12): 29554–29573.

# GLOBAL JOURNALS INC. (US) GUIDELINES HANDBOOK 2016

---

[WWW.GLOBALJOURNALS.ORG](http://WWW.GLOBALJOURNALS.ORG)

# FELLOWS

## FELLOW OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (FARSM)

Global Journals Incorporate (USA) is accredited by Open Association of Research Society (OARS), U.S.A and in turn, awards "FARSM" title to individuals. The 'FARSM' title is accorded to a selected professional after the approval of the Editor-in-Chief/Editorial Board Members/Dean.



- The "FARSM" is a dignified title which is accorded to a person's name viz. Dr. John E. Hall, Ph.D., FARSS or William Walldroff, M.S., FARSM.

FARSM accrediting is an honor. It authenticates your research activities. After recognition as FARSM, you can add 'FARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and reputation to your name. You may use it on your professional Counseling Materials such as CV, Resume, and Visiting Card etc.

*The following benefits can be availed by you only for next three years from the date of certification:*



FARSM designated members are entitled to avail a 40% discount while publishing their research papers (of a single author) with Global Journals Incorporation (USA), if the same is accepted by Editorial Board/Peer Reviewers. If you are a main author or co-author in case of multiple authors, you will be entitled to avail discount of 10%.

Once FARSM title is accorded, the Fellow is authorized to organize a symposium/seminar/conference on behalf of Global Journal Incorporation (USA). The Fellow can also participate in conference/seminar/symposium organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent.



You may join as member of the Editorial Board of Global Journals Incorporation (USA) after successful completion of three years as Fellow and as Peer Reviewer. In addition, it is also desirable that you should organize seminar/symposium/conference at least once.

We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.





The FARSM can go through standards of OARS. You can also play vital role if you have any suggestions so that proper amendment can take place to improve the same for the benefit of entire research community.

As FARSM, you will be given a renowned, secure and free professional email address with 100 GB of space e.g. [johnhall@globaljournals.org](mailto:johnhall@globaljournals.org). This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.



The FARSM will be eligible for a free application of standardization of their researches. Standardization of research will be subject to acceptability within stipulated norms as the next step after publishing in a journal. We shall depute a team of specialized research professionals who will render their services for elevating your researches to next higher level, which is worldwide open standardization.

The FARSM member can apply for grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A. Once you are designated as FARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria. After certification of all your credentials by OARS, they will be published on your Fellow Profile link on website <https://associationofresearch.org> which will be helpful to upgrade the dignity.



The FARSM members can avail the benefits of free research podcasting in Global Research Radio with their research documents. After publishing the work, (including published elsewhere worldwide with proper authorization) you can upload your research paper with your recorded voice or you can utilize chargeable services of our professional RJs to record your paper in their voice on request.



The FARSM member also entitled to get the benefits of free research podcasting of their research documents through video clips. We can also streamline your conference videos and display your slides/ online slides and online research video clips at reasonable charges, on request.





The FARSM is eligible to earn from sales proceeds of his/her researches/reference/review Books or literature, while publishing with Global Journals. The FARSS can decide whether he/she would like to publish his/her research in a closed manner. In this case, whenever readers purchase that individual research paper for reading, maximum 60% of its profit earned as royalty by Global Journals, will be credited to his/her bank account. The entire entitled amount will be credited to his/her bank account exceeding limit of minimum fixed balance. There is no minimum time limit for collection. The FARSM member can decide its price and we can help in making the right decision.

The FARSM member is eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get remuneration of 15% of author fees, taken from the author of a respective paper. After reviewing 5 or more papers you can request to transfer the amount to your bank account.



## MEMBER OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (MARSM)

The ' MARSM ' title is accorded to a selected professional after the approval of the Editor-in-Chief / Editorial Board Members/Dean.

The “MARSM” is a dignified ornament which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., MARSM or William Walldroff, M.S., MARSM.



MARSM accrediting is an honor. It authenticates your research activities. After becoming MARSM, you can add 'MARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and repute to your name. You may use it on your professional Counseling Materials such as CV, Resume, Visiting Card and Name Plate etc.

*The following benefits can be availed by you only for next three years from the date of certification.*



MARSM designated members are entitled to avail a 25% discount while publishing their research papers (of a single author) in Global Journals Inc., if the same is accepted by our Editorial Board and Peer Reviewers. If you are a main author or co-author of a group of authors, you will get discount of 10%.

As MARSM, you will be given a renowned, secure and free professional email address with 30 GB of space e.g. [johnhall@globaljournals.org](mailto:johnhall@globaljournals.org). This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.







We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.



The MARSM member can apply for approval, grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A.



Once you are designated as MARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria.

It is mandatory to read all terms and conditions carefully.



## AUXILIARY MEMBERSHIPS

### Institutional Fellow of Open Association of Research Society (USA) - OARS (USA)

Global Journals Incorporation (USA) is accredited by Open Association of Research Society, U.S.A (OARS) and in turn, affiliates research institutions as “Institutional Fellow of Open Association of Research Society” (IFOARS).

The “FARSC” is a dignified title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FARSC or William Walldroff, M.S., FARSC.



The IFOARS institution is entitled to form a Board comprised of one Chairperson and three to five board members preferably from different streams. The Board will be recognized as “Institutional Board of Open Association of Research Society”-(IBOARS).

*The Institute will be entitled to following benefits:*



The IBOARS can initially review research papers of their institute and recommend them to publish with respective journal of Global Journals. It can also review the papers of other institutions after obtaining our consent. The second review will be done by peer reviewer of Global Journals Incorporation (USA) The Board is at liberty to appoint a peer reviewer with the approval of chairperson after consulting us.

The author fees of such paper may be waived off up to 40%.

The Global Journals Incorporation (USA) at its discretion can also refer double blind peer reviewed paper at their end to the board for the verification and to get recommendation for final stage of acceptance of publication.



The IBOARS can organize symposium/seminar/conference in their country on behalf of Global Journals Incorporation (USA)-OARS (USA). The terms and conditions can be discussed separately.

The Board can also play vital role by exploring and giving valuable suggestions regarding the Standards of “Open Association of Research Society, U.S.A (OARS)” so that proper amendment can take place for the benefit of entire research community. We shall provide details of particular standard only on receipt of request from the Board.



Journals Research  
inducing researches

The board members can also join us as Individual Fellow with 40% discount on total fees applicable to Individual Fellow. They will be entitled to avail all the benefits as declared. Please visit Individual Fellow-sub menu of GlobalJournals.org to have more relevant details.



We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.



After nomination of your institution as “Institutional Fellow” and constantly functioning successfully for one year, we can consider giving recognition to your institute to function as Regional/Zonal office on our behalf. The board can also take up the additional allied activities for betterment after our consultation.

**The following entitlements are applicable to individual Fellows:**

Open Association of Research Society, U.S.A (OARS) By-laws states that an individual Fellow may use the designations as applicable, or the corresponding initials. The Credentials of individual Fellow and Associate designations signify that the individual has gained knowledge of the fundamental concepts. One is magnanimous and proficient in an expertise course covering the professional code of conduct, and follows recognized standards of practice.



Open Association of Research Society (US)/ Global Journals Incorporation (USA), as described in Corporate Statements, are educational, research publishing and professional membership organizations. Achieving our individual Fellow or Associate status is based mainly on meeting stated educational research requirements.

Disbursement of 40% Royalty earned through Global Journals : Researcher = 50%, Peer Reviewer = 37.50%, Institution = 12.50% E.g. Out of 40%, the 20% benefit should be passed on to researcher, 15 % benefit towards remuneration should be given to a reviewer and remaining 5% is to be retained by the institution.



We shall provide print version of 12 issues of any three journals [as per your requirement] out of our 38 journals worth \$ 2376 USD.

**Other:**

**The individual Fellow and Associate designations accredited by Open Association of Research Society (US) credentials signify guarantees following achievements:**

- The professional accredited with Fellow honor, is entitled to various benefits viz. name, fame, honor, regular flow of income, secured bright future, social status etc.



- In addition to above, if one is single author, then entitled to 40% discount on publishing research paper and can get 10% discount if one is co-author or main author among group of authors.
- The Fellow can organize symposium/seminar/conference on behalf of Global Journals Incorporation (USA) and he/she can also attend the same organized by other institutes on behalf of Global Journals.
- The Fellow can become member of Editorial Board Member after completing 3yrs.
- The Fellow can earn 60% of sales proceeds from the sale of reference/review books/literature/publishing of research paper.
- Fellow can also join as paid peer reviewer and earn 15% remuneration of author charges and can also get an opportunity to join as member of the Editorial Board of Global Journals Incorporation (USA)
- • This individual has learned the basic methods of applying those concepts and techniques to common challenging situations. This individual has further demonstrated an in-depth understanding of the application of suitable techniques to a particular area of research practice.

**Note :**

//

- In future, if the board feels the necessity to change any board member, the same can be done with the consent of the chairperson along with anyone board member without our approval.
- In case, the chairperson needs to be replaced then consent of 2/3rd board members are required and they are also required to jointly pass the resolution copy of which should be sent to us. In such case, it will be compulsory to obtain our approval before replacement.
- In case of “Difference of Opinion [if any]” among the Board members, our decision will be final and binding to everyone.

//



## PROCESS OF SUBMISSION OF RESEARCH PAPER

---

The Area or field of specialization may or may not be of any category as mentioned in 'Scope of Journal' menu of the GlobalJournals.org website. There are 37 Research Journal categorized with Six parental Journals GJCST, GJMR, GJRE, GJMBR, GJSFR, GJHSS. For Authors should prefer the mentioned categories. There are three widely used systems UDC, DDC and LCC. The details are available as 'Knowledge Abstract' at Home page. The major advantage of this coding is that, the research work will be exposed to and shared with all over the world as we are being abstracted and indexed worldwide.

The paper should be in proper format. The format can be downloaded from first page of 'Author Guideline' Menu. The Author is expected to follow the general rules as mentioned in this menu. The paper should be written in MS-Word Format (\*.DOC, \*.DOCX).

The Author can submit the paper either online or offline. The authors should prefer online submission. Online Submission: There are three ways to submit your paper:

**(A) (I) First, register yourself using top right corner of Home page then Login. If you are already registered, then login using your username and password.**

**(II) Choose corresponding Journal.**

**(III) Click 'Submit Manuscript'. Fill required information and Upload the paper.**

**(B) If you are using Internet Explorer, then Direct Submission through Homepage is also available.**

**(C) If these two are not convenient, and then email the paper directly to dean@globaljournals.org.**

Offline Submission: Author can send the typed form of paper by Post. However, online submission should be preferred.



# PREFERRED AUTHOR GUIDELINES

## MANUSCRIPT STYLE INSTRUCTION (Must be strictly followed)

Page Size: 8.27" X 11"

- Left Margin: 0.65
- Right Margin: 0.65
- Top Margin: 0.75
- Bottom Margin: 0.75
- Font type of all text should be Swis 721 Lt BT.
- Paper Title should be of Font Size 24 with one Column section.
- Author Name in Font Size of 11 with one column as of Title.
- Abstract Font size of 9 Bold, "Abstract" word in Italic Bold.
- Main Text: Font size 10 with justified two columns section
- Two Column with Equal Column with of 3.38 and Gaping of .2
- First Character must be three lines Drop capped.
- Paragraph before Spacing of 1 pt and After of 0 pt.
- Line Spacing of 1 pt
- Large Images must be in One Column
- Numbering of First Main Headings (Heading 1) must be in Roman Letters, Capital Letter, and Font Size of 10.
- Numbering of Second Main Headings (Heading 2) must be in Alphabets, Italic, and Font Size of 10.

**You can use your own standard format also.**

### Author Guidelines:

1. General,
2. Ethical Guidelines,
3. Submission of Manuscripts,
4. Manuscript's Category,
5. Structure and Format of Manuscript,
6. After Acceptance.

### 1. GENERAL

Before submitting your research paper, one is advised to go through the details as mentioned in following heads. It will be beneficial, while peer reviewer justify your paper for publication.

### Scope

The Global Journals Inc. (US) welcome the submission of original paper, review paper, survey article relevant to the all the streams of Philosophy and knowledge. The Global Journals Inc. (US) is parental platform for Global Journal of Computer Science and Technology, Researches in Engineering, Medical Research, Science Frontier Research, Human Social Science, Management, and Business organization. The choice of specific field can be done otherwise as following in Abstracting and Indexing Page on this Website. As the all Global

Journals Inc. (US) are being abstracted and indexed (in process) by most of the reputed organizations. Topics of only narrow interest will not be accepted unless they have wider potential or consequences.

## 2. ETHICAL GUIDELINES

Authors should follow the ethical guidelines as mentioned below for publication of research paper and research activities.

Papers are accepted on strict understanding that the material in whole or in part has not been, nor is being, considered for publication elsewhere. If the paper once accepted by Global Journals Inc. (US) and Editorial Board, will become the copyright of the Global Journals Inc. (US).

**Authorship: The authors and coauthors should have active contribution to conception design, analysis and interpretation of findings. They should critically review the contents and drafting of the paper. All should approve the final version of the paper before submission**

The Global Journals Inc. (US) follows the definition of authorship set up by the Global Academy of Research and Development. According to the Global Academy of R&D authorship, criteria must be based on:

- 1) Substantial contributions to conception and acquisition of data, analysis and interpretation of the findings.
- 2) Drafting the paper and revising it critically regarding important academic content.
- 3) Final approval of the version of the paper to be published.

All authors should have been credited according to their appropriate contribution in research activity and preparing paper. Contributors who do not match the criteria as authors may be mentioned under Acknowledgement.

Acknowledgements: Contributors to the research other than authors credited should be mentioned under acknowledgement. The specifications of the source of funding for the research if appropriate can be included. Suppliers of resources may be mentioned along with address.

**Appeal of Decision: The Editorial Board's decision on publication of the paper is final and cannot be appealed elsewhere.**

**Permissions: It is the author's responsibility to have prior permission if all or parts of earlier published illustrations are used in this paper.**

Please mention proper reference and appropriate acknowledgements wherever expected.

If all or parts of previously published illustrations are used, permission must be taken from the copyright holder concerned. It is the author's responsibility to take these in writing.

Approval for reproduction/modification of any information (including figures and tables) published elsewhere must be obtained by the authors/copyright holders before submission of the manuscript. Contributors (Authors) are responsible for any copyright fee involved.

## 3. SUBMISSION OF MANUSCRIPTS

Manuscripts should be uploaded via this online submission page. The online submission is most efficient method for submission of papers, as it enables rapid distribution of manuscripts and consequently speeds up the review procedure. It also enables authors to know the status of their own manuscripts by emailing us. Complete instructions for submitting a paper is available below.

Manuscript submission is a systematic procedure and little preparation is required beyond having all parts of your manuscript in a given format and a computer with an Internet connection and a Web browser. Full help and instructions are provided on-screen. As an author, you will be prompted for login and manuscript details as Field of Paper and then to upload your manuscript file(s) according to the instructions.



To avoid postal delays, all transaction is preferred by e-mail. A finished manuscript submission is confirmed by e-mail immediately and your paper enters the editorial process with no postal delays. When a conclusion is made about the publication of your paper by our Editorial Board, revisions can be submitted online with the same procedure, with an occasion to view and respond to all comments.

Complete support for both authors and co-author is provided.

#### 4. MANUSCRIPT'S CATEGORY

Based on potential and nature, the manuscript can be categorized under the following heads:

Original research paper: Such papers are reports of high-level significant original research work.

Review papers: These are concise, significant but helpful and decisive topics for young researchers.

Research articles: These are handled with small investigation and applications

Research letters: The letters are small and concise comments on previously published matters.

#### 5. STRUCTURE AND FORMAT OF MANUSCRIPT

The recommended size of original research paper is less than seven thousand words, review papers fewer than seven thousands words also. Preparation of research paper or how to write research paper, are major hurdle, while writing manuscript. The research articles and research letters should be fewer than three thousand words, the structure original research paper; sometime review paper should be as follows:

**Papers:** These are reports of significant research (typically less than 7000 words equivalent, including tables, figures, references), and comprise:

(a) Title should be relevant and commensurate with the theme of the paper.

(b) A brief Summary, "Abstract" (less than 150 words) containing the major results and conclusions.

(c) Up to ten keywords, that precisely identifies the paper's subject, purpose, and focus.

(d) An Introduction, giving necessary background excluding subheadings; objectives must be clearly declared.

(e) Resources and techniques with sufficient complete experimental details (wherever possible by reference) to permit repetition; sources of information must be given and numerical methods must be specified by reference, unless non-standard.

(f) Results should be presented concisely, by well-designed tables and/or figures; the same data may not be used in both; suitable statistical data should be given. All data must be obtained with attention to numerical detail in the planning stage. As reproduced design has been recognized to be important to experiments for a considerable time, the Editor has decided that any paper that appears not to have adequate numerical treatments of the data will be returned un-refereed;

(g) Discussion should cover the implications and consequences, not just recapitulating the results; conclusions should be summarizing.

(h) Brief Acknowledgements.

(i) References in the proper form.

Authors should very cautiously consider the preparation of papers to ensure that they communicate efficiently. Papers are much more likely to be accepted, if they are cautiously designed and laid out, contain few or no errors, are summarizing, and be conventional to the approach and instructions. They will in addition, be published with much less delays than those that require much technical and editorial correction.





The Editorial Board reserves the right to make literary corrections and to make suggestions to improve brevity.

It is vital, that authors take care in submitting a manuscript that is written in simple language and adheres to published guidelines.

## Format

*Language: The language of publication is UK English. Authors, for whom English is a second language, must have their manuscript efficiently edited by an English-speaking person before submission to make sure that, the English is of high excellence. It is preferable, that manuscripts should be professionally edited.*

Standard Usage, Abbreviations, and Units: Spelling and hyphenation should be conventional to The Concise Oxford English Dictionary. Statistics and measurements should at all times be given in figures, e.g. 16 min, except for when the number begins a sentence. When the number does not refer to a unit of measurement it should be spelt in full unless, it is 160 or greater.

Abbreviations supposed to be used carefully. The abbreviated name or expression is supposed to be cited in full at first usage, followed by the conventional abbreviation in parentheses.

Metric SI units are supposed to generally be used excluding where they conflict with current practice or are confusing. For illustration, 1.4 l rather than  $1.4 \times 10^{-3} \text{ m}^3$ , or 4 mm somewhat than  $4 \times 10^{-3} \text{ m}$ . Chemical formula and solutions must identify the form used, e.g. anhydrous or hydrated, and the concentration must be in clearly defined units. Common species names should be followed by underlines at the first mention. For following use the generic name should be constricted to a single letter, if it is clear.

## Structure

All manuscripts submitted to Global Journals Inc. (US), ought to include:

Title: The title page must carry an instructive title that reflects the content, a running title (less than 45 characters together with spaces), names of the authors and co-authors, and the place(s) wherever the work was carried out. The full postal address in addition with the e-mail address of related author must be given. Up to eleven keywords or very brief phrases have to be given to help data retrieval, mining and indexing.

*Abstract, used in Original Papers and Reviews:*

### Optimizing Abstract for Search Engines

Many researchers searching for information online will use search engines such as Google, Yahoo or similar. By optimizing your paper for search engines, you will amplify the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in a further work. Global Journals Inc. (US) have compiled these guidelines to facilitate you to maximize the web-friendliness of the most public part of your paper.

### Key Words

A major linchpin in research work for the writing research paper is the keyword search, which one will employ to find both library and Internet resources.

One must be persistent and creative in using keywords. An effective keyword search requires a strategy and planning a list of possible keywords and phrases to try.

Search engines for most searches, use Boolean searching, which is somewhat different from Internet searches. The Boolean search uses "operators," words (and, or, not, and near) that enable you to expand or narrow your affords. Tips for research paper while preparing research paper are very helpful guideline of research paper.

Choice of key words is first tool of tips to write research paper. Research paper writing is an art. A few tips for deciding as strategically as possible about keyword search:



- One should start brainstorming lists of possible keywords before even begin searching. Think about the most important concepts related to research work. Ask, "What words would a source have to include to be truly valuable in research paper?" Then consider synonyms for the important words.
- It may take the discovery of only one relevant paper to let steer in the right keyword direction because in most databases, the keywords under which a research paper is abstracted are listed with the paper.
- One should avoid outdated words.

Keywords are the key that opens a door to research work sources. Keyword searching is an art in which researcher's skills are bound to improve with experience and time.

Numerical Methods: Numerical methods used should be clear and, where appropriate, supported by references.

*Acknowledgements: Please make these as concise as possible.*

#### References

References follow the Harvard scheme of referencing. References in the text should cite the authors' names followed by the time of their publication, unless there are three or more authors when simply the first author's name is quoted followed by et al. unpublished work has to only be cited where necessary, and only in the text. Copies of references in press in other journals have to be supplied with submitted typescripts. It is necessary that all citations and references be carefully checked before submission, as mistakes or omissions will cause delays.

References to information on the World Wide Web can be given, but only if the information is available without charge to readers on an official site. Wikipedia and Similar websites are not allowed where anyone can change the information. Authors will be asked to make available electronic copies of the cited information for inclusion on the Global Journals Inc. (US) homepage at the judgment of the Editorial Board.

The Editorial Board and Global Journals Inc. (US) recommend that, citation of online-published papers and other material should be done via a DOI (digital object identifier). If an author cites anything, which does not have a DOI, they run the risk of the cited material not being noticeable.

The Editorial Board and Global Journals Inc. (US) recommend the use of a tool such as Reference Manager for reference management and formatting.

#### Tables, Figures and Figure Legends

*Tables: Tables should be few in number, cautiously designed, uncrowned, and include only essential data. Each must have an Arabic number, e.g. Table 4, a self-explanatory caption and be on a separate sheet. Vertical lines should not be used.*

*Figures: Figures are supposed to be submitted as separate files. Always take in a citation in the text for each figure using Arabic numbers, e.g. Fig. 4. Artwork must be submitted online in electronic form by e-mailing them.*

#### Preparation of Electronic Figures for Publication

Even though low quality images are sufficient for review purposes, print publication requires high quality images to prevent the final product being blurred or fuzzy. Submit (or e-mail) EPS (line art) or TIFF (halftone/photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Do not use pixel-oriented software. Scans (TIFF only) should have a resolution of at least 350 dpi (halftone) or 700 to 1100 dpi (line drawings) in relation to the imitation size. Please give the data for figures in black and white or submit a Color Work Agreement Form. EPS files must be saved with fonts embedded (and with a TIFF preview, if possible).

For scanned images, the scanning resolution (at final image size) ought to be as follows to ensure good reproduction: line art: >650 dpi; halftones (including gel photographs) : >350 dpi; figures containing both halftone and line images: >650 dpi.



Color Charges: It is the rule of the Global Journals Inc. (US) for authors to pay the full cost for the reproduction of their color artwork. Hence, please note that, if there is color artwork in your manuscript when it is accepted for publication, we would require you to complete and return a color work agreement form before your paper can be published.

*Figure Legends: Self-explanatory legends of all figures should be incorporated separately under the heading 'Legends to Figures'. In the full-text online edition of the journal, figure legends may possibly be truncated in abbreviated links to the full screen version. Therefore, the first 100 characters of any legend should notify the reader, about the key aspects of the figure.*

## **6. AFTER ACCEPTANCE**

Upon approval of a paper for publication, the manuscript will be forwarded to the dean, who is responsible for the publication of the Global Journals Inc. (US).

### **6.1 Proof Corrections**

The corresponding author will receive an e-mail alert containing a link to a website or will be attached. A working e-mail address must therefore be provided for the related author.

Acrobat Reader will be required in order to read this file. This software can be downloaded

(Free of charge) from the following website:

[www.adobe.com/products/acrobat/readstep2.html](http://www.adobe.com/products/acrobat/readstep2.html). This will facilitate the file to be opened, read on screen, and printed out in order for any corrections to be added. Further instructions will be sent with the proof.

Proofs must be returned to the dean at [dean@globaljournals.org](mailto:dean@globaljournals.org) within three days of receipt.

As changes to proofs are costly, we inquire that you only correct typesetting errors. All illustrations are retained by the publisher. Please note that the authors are responsible for all statements made in their work, including changes made by the copy editor.

### **6.2 Early View of Global Journals Inc. (US) (Publication Prior to Print)**

The Global Journals Inc. (US) are enclosed by our publishing's Early View service. Early View articles are complete full-text articles sent in advance of their publication. Early View articles are absolute and final. They have been completely reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after sending them. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the conventional way.

### **6.3 Author Services**

Online production tracking is available for your article through Author Services. Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The authors will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript.

### **6.4 Author Material Archive Policy**

Please note that if not specifically requested, publisher will dispose off hardcopy & electronic information submitted, after the two months of publication. If you require the return of any information submitted, please inform the Editorial Board or dean as soon as possible.

### **6.5 Offprint and Extra Copies**

A PDF offprint of the online-published article will be provided free of charge to the related author, and may be distributed according to the Publisher's terms and conditions. Additional paper offprint may be ordered by emailing us at: [editor@globaljournals.org](mailto:editor@globaljournals.org) .



Before start writing a good quality Computer Science Research Paper, let us first understand what is Computer Science Research Paper? So, Computer Science Research Paper is the paper which is written by professionals or scientists who are associated to Computer Science and Information Technology, or doing research study in these areas. If you are novel to this field then you can consult about this field from your supervisor or guide.

#### TECHNIQUES FOR WRITING A GOOD QUALITY RESEARCH PAPER:

**1. Choosing the topic:** In most cases, the topic is searched by the interest of author but it can be also suggested by the guides. You can have several topics and then you can judge that in which topic or subject you are finding yourself most comfortable. This can be done by asking several questions to yourself, like Will I be able to carry our search in this area? Will I find all necessary recourses to accomplish the search? Will I be able to find all information in this field area? If the answer of these types of questions will be "Yes" then you can choose that topic. In most of the cases, you may have to conduct the surveys and have to visit several places because this field is related to Computer Science and Information Technology. Also, you may have to do a lot of work to find all rise and falls regarding the various data of that subject. Sometimes, detailed information plays a vital role, instead of short information.

**2. Evaluators are human:** First thing to remember that evaluators are also human being. They are not only meant for rejecting a paper. They are here to evaluate your paper. So, present your Best.

**3. Think Like Evaluators:** If you are in a confusion or getting demotivated that your paper will be accepted by evaluators or not, then think and try to evaluate your paper like an Evaluator. Try to understand that what an evaluator wants in your research paper and automatically you will have your answer.

**4. Make blueprints of paper:** The outline is the plan or framework that will help you to arrange your thoughts. It will make your paper logical. But remember that all points of your outline must be related to the topic you have chosen.

**5. Ask your Guides:** If you are having any difficulty in your research, then do not hesitate to share your difficulty to your guide (if you have any). They will surely help you out and resolve your doubts. If you can't clarify what exactly you require for your work then ask the supervisor to help you with the alternative. He might also provide you the list of essential readings.

**6. Use of computer is recommended:** As you are doing research in the field of Computer Science, then this point is quite obvious.

**7. Use right software:** Always use good quality software packages. If you are not capable to judge good software then you can lose quality of your paper unknowingly. There are various software programs available to help you, which you can get through Internet.

**8. Use the Internet for help:** An excellent start for your paper can be by using the Google. It is an excellent search engine, where you can have your doubts resolved. You may also read some answers for the frequent question how to write my research paper or find model research paper. From the internet library you can download books. If you have all required books make important reading selecting and analyzing the specified information. Then put together research paper sketch out.

**9. Use and get big pictures:** Always use encyclopedias, Wikipedia to get pictures so that you can go into the depth.

**10. Bookmarks are useful:** When you read any book or magazine, you generally use bookmarks, right! It is a good habit, which helps to not to lose your continuity. You should always use bookmarks while searching on Internet also, which will make your search easier.

**11. Revise what you wrote:** When you write anything, always read it, summarize it and then finalize it.



**12. Make all efforts:** Make all efforts to mention what you are going to write in your paper. That means always have a good start. Try to mention everything in introduction, that what is the need of a particular research paper. Polish your work by good skill of writing and always give an evaluator, what he wants.

**13. Have backups:** When you are going to do any important thing like making research paper, you should always have backup copies of it either in your computer or in paper. This will help you to not to lose any of your important.

**14. Produce good diagrams of your own:** Always try to include good charts or diagrams in your paper to improve quality. Using several and unnecessary diagrams will degrade the quality of your paper by creating "hotchpotch." So always, try to make and include those diagrams, which are made by your own to improve readability and understandability of your paper.

**15. Use of direct quotes:** When you do research relevant to literature, history or current affairs then use of quotes become essential but if study is relevant to science then use of quotes is not preferable.

**16. Use proper verb tense:** Use proper verb tenses in your paper. Use past tense, to present those events that happened. Use present tense to indicate events that are going on. Use future tense to indicate future happening events. Use of improper and wrong tenses will confuse the evaluator. Avoid the sentences that are incomplete.

**17. Never use online paper:** If you are getting any paper on Internet, then never use it as your research paper because it might be possible that evaluator has already seen it or maybe it is outdated version.

**18. Pick a good study spot:** To do your research studies always try to pick a spot, which is quiet. Every spot is not for studies. Spot that suits you choose it and proceed further.

**19. Know what you know:** Always try to know, what you know by making objectives. Else, you will be confused and cannot achieve your target.

**20. Use good quality grammar:** Always use a good quality grammar and use words that will throw positive impact on evaluator. Use of good quality grammar does not mean to use tough words, that for each word the evaluator has to go through dictionary. Do not start sentence with a conjunction. Do not fragment sentences. Eliminate one-word sentences. Ignore passive voice. Do not ever use a big word when a diminutive one would suffice. Verbs have to be in agreement with their subjects. Prepositions are not expressions to finish sentences with. It is incorrect to ever divide an infinitive. Avoid clichés like the disease. Also, always shun irritating alliteration. Use language that is simple and straight forward. put together a neat summary.

**21. Arrangement of information:** Each section of the main body should start with an opening sentence and there should be a changeover at the end of the section. Give only valid and powerful arguments to your topic. You may also maintain your arguments with records.

**22. Never start in last minute:** Always start at right time and give enough time to research work. Leaving everything to the last minute will degrade your paper and spoil your work.

**23. Multitasking in research is not good:** Doing several things at the same time proves bad habit in case of research activity. Research is an area, where everything has a particular time slot. Divide your research work in parts and do particular part in particular time slot.

**24. Never copy others' work:** Never copy others' work and give it your name because if evaluator has seen it anywhere you will be in trouble.

**25. Take proper rest and food:** No matter how many hours you spend for your research activity, if you are not taking care of your health then all your efforts will be in vain. For a quality research, study is must, and this can be done by taking proper rest and food.

**26. Go for seminars:** Attend seminars if the topic is relevant to your research area. Utilize all your resources.



**27. Refresh your mind after intervals:** Try to give rest to your mind by listening to soft music or by sleeping in intervals. This will also improve your memory.

**28. Make colleagues:** Always try to make colleagues. No matter how sharper or intelligent you are, if you make colleagues you can have several ideas, which will be helpful for your research.

**29. Think technically:** Always think technically. If anything happens, then search its reasons, its benefits, and demerits.

**30. Think and then print:** When you will go to print your paper, notice that tables are not be split, headings are not detached from their descriptions, and page sequence is maintained.

**31. Adding unnecessary information:** Do not add unnecessary information, like, I have used MS Excel to draw graph. Do not add irrelevant and inappropriate material. These all will create superfluous. Foreign terminology and phrases are not apropos. One should NEVER take a broad view. Analogy in script is like feathers on a snake. Not at all use a large word when a very small one would be sufficient. Use words properly, regardless of how others use them. Remove quotations. Puns are for kids, not grunt readers. Amplification is a billion times of inferior quality than sarcasm.

**32. Never oversimplify everything:** To add material in your research paper, never go for oversimplification. This will definitely irritate the evaluator. Be more or less specific. Also too, by no means, ever use rhythmic redundancies. Contractions aren't essential and shouldn't be there used. Comparisons are as terrible as clichés. Give up ampersands and abbreviations, and so on. Remove commas, that are, not necessary. Parenthetical words however should be together with this in commas. Understatement is all the time the complete best way to put onward earth-shaking thoughts. Give a detailed literary review.

**33. Report concluded results:** Use concluded results. From raw data, filter the results and then conclude your studies based on measurements and observations taken. Significant figures and appropriate number of decimal places should be used. Parenthetical remarks are prohibitive. Proofread carefully at final stage. In the end give outline to your arguments. Spot out perspectives of further study of this subject. Justify your conclusion by at the bottom of them with sufficient justifications and examples.

**34. After conclusion:** Once you have concluded your research, the next most important step is to present your findings. Presentation is extremely important as it is the definite medium through which your research is going to be in print to the rest of the crowd. Care should be taken to categorize your thoughts well and present them in a logical and neat manner. A good quality research paper format is essential because it serves to highlight your research paper and bring to light all necessary aspects in your research.

## INFORMAL GUIDELINES OF RESEARCH PAPER WRITING

### Key points to remember:

- Submit all work in its final form.
- Write your paper in the form, which is presented in the guidelines using the template.
- Please note the criterion for grading the final paper by peer-reviewers.

### Final Points:

A purpose of organizing a research paper is to let people to interpret your effort selectively. The journal requires the following sections, submitted in the order listed, each section to start on a new page.

The introduction will be compiled from reference matter and will reflect the design processes or outline of basis that direct you to make study. As you will carry out the process of study, the method and process section will be constructed as like that. The result segment will show related statistics in nearly sequential order and will direct the reviewers next to the similar intellectual paths throughout the data that you took to carry out your study. The discussion section will provide understanding of the data and projections as to the implication of the results. The use of good quality references all through the paper will give the effort trustworthiness by representing an alertness of prior workings.



Writing a research paper is not an easy job no matter how trouble-free the actual research or concept. Practice, excellent preparation, and controlled record keeping are the only means to make straightforward the progression.

### **General style:**

Specific editorial column necessities for compliance of a manuscript will always take over from directions in these general guidelines.

To make a paper clear

- Adhere to recommended page limits

Mistakes to evade

- Insertion a title at the foot of a page with the subsequent text on the next page
- Separating a table/chart or figure - impound each figure/table to a single page
- Submitting a manuscript with pages out of sequence

In every sections of your document

- Use standard writing style including articles ("a", "the," etc.)
- Keep on paying attention on the research topic of the paper
- Use paragraphs to split each significant point (excluding for the abstract)
- Align the primary line of each section
- Present your points in sound order
- Use present tense to report well accepted
- Use past tense to describe specific results
- Shun familiar wording, don't address the reviewer directly, and don't use slang, slang language, or superlatives
- Shun use of extra pictures - include only those figures essential to presenting results

### **Title Page:**

Choose a revealing title. It should be short. It should not have non-standard acronyms or abbreviations. It should not exceed two printed lines. It should include the name(s) and address (es) of all authors.



## Abstract:

The summary should be two hundred words or less. It should briefly and clearly explain the key findings reported in the manuscript-- must have precise statistics. It should not have abnormal acronyms or abbreviations. It should be logical in itself. Shun citing references at this point.

An abstract is a brief distinct paragraph summary of finished work or work in development. In a minute or less a reviewer can be taught the foundation behind the study, common approach to the problem, relevant results, and significant conclusions or new questions.

Write your summary when your paper is completed because how can you write the summary of anything which is not yet written? Wealth of terminology is very essential in abstract. Yet, use comprehensive sentences and do not let go readability for brevity. You can maintain it succinct by phrasing sentences so that they provide more than lone rationale. The author can at this moment go straight to shortening the outcome. Sum up the study, with the subsequent elements in any summary. Try to maintain the initial two items to no more than one ruling each.

- Reason of the study - theory, overall issue, purpose
- Fundamental goal
- To the point depiction of the research
- Consequences, including definite statistics - if the consequences are quantitative in nature, account quantitative data; results of any numerical analysis should be reported
- Significant conclusions or questions that track from the research(es)

## Approach:

- Single section, and succinct
- As an outline of job done, it is always written in past tense
- A conceptual should situate on its own, and not submit to any other part of the paper such as a form or table
- Center on shortening results - bound background information to a verdict or two, if completely necessary
- What you account in an abstract must be regular with what you reported in the manuscript
- Exact spelling, clearness of sentences and phrases, and appropriate reporting of quantities (proper units, important statistics) are just as significant in an abstract as they are anywhere else

## Introduction:

The **Introduction** should "introduce" the manuscript. The reviewer should be presented with sufficient background information to be capable to comprehend and calculate the purpose of your study without having to submit to other works. The basis for the study should be offered. Give most important references but shun difficult to make a comprehensive appraisal of the topic. In the introduction, describe the problem visibly. If the problem is not acknowledged in a logical, reasonable way, the reviewer will have no attention in your result. Speak in common terms about techniques used to explain the problem, if needed, but do not present any particulars about the protocols here. Following approach can create a valuable beginning:

- Explain the value (significance) of the study
- Shield the model - why did you employ this particular system or method? What is its compensation? You strength remark on its appropriateness from an abstract point of vision as well as point out sensible reasons for using it.
- Present a justification. Status your particular theory (es) or aim(s), and describe the logic that led you to choose them.
- Very for a short time explain the tentative propose and how it skilled the declared objectives.

## Approach:

- Use past tense except for when referring to recognized facts. After all, the manuscript will be submitted after the entire job is done.
- Sort out your thoughts; manufacture one key point with every section. If you make the four points listed above, you will need a least of four paragraphs.





- Present surroundings information only as desirable in order hold up a situation. The reviewer does not desire to read the whole thing you know about a topic.
- Shape the theory/purpose specifically - do not take a broad view.
- As always, give awareness to spelling, simplicity and correctness of sentences and phrases.

#### **Procedures (Methods and Materials):**

This part is supposed to be the easiest to carve if you have good skills. A sound written Procedures segment allows a capable scientist to replacement your results. Present precise information about your supplies. The suppliers and clarity of reagents can be helpful bits of information. Present methods in sequential order but linked methodologies can be grouped as a segment. Be concise when relating the protocols. Attempt for the least amount of information that would permit another capable scientist to spare your outcome but be cautious that vital information is integrated. The use of subheadings is suggested and ought to be synchronized with the results section. When a technique is used that has been well described in another object, mention the specific item describing a way but draw the basic principle while stating the situation. The purpose is to text all particular resources and broad procedures, so that another person may use some or all of the methods in one more study or referee the scientific value of your work. It is not to be a step by step report of the whole thing you did, nor is a methods section a set of orders.

#### **Materials:**

- Explain materials individually only if the study is so complex that it saves liberty this way.
- Embrace particular materials, and any tools or provisions that are not frequently found in laboratories.
- Do not take in frequently found.
- If use of a definite type of tools.
- Materials may be reported in a part section or else they may be recognized along with your measures.

#### **Methods:**

- Report the method (not particulars of each process that engaged the same methodology)
- Describe the method entirely
- To be succinct, present methods under headings dedicated to specific dealings or groups of measures
- Simplify - details how procedures were completed not how they were exclusively performed on a particular day.
- If well known procedures were used, account the procedure by name, possibly with reference, and that's all.

#### **Approach:**

- It is embarrassed or not possible to use vigorous voice when documenting methods with no using first person, which would focus the reviewer's interest on the researcher rather than the job. As a result when script up the methods most authors use third person passive voice.
- Use standard style in this and in every other part of the paper - avoid familiar lists, and use full sentences.

#### **What to keep away from**

- Resources and methods are not a set of information.
- Skip all descriptive information and surroundings - save it for the argument.
- Leave out information that is immaterial to a third party.

#### **Results:**

The principle of a results segment is to present and demonstrate your conclusion. Create this part a entirely objective details of the outcome, and save all understanding for the discussion.

The page length of this segment is set by the sum and types of data to be reported. Carry on to be to the point, by means of statistics and tables, if suitable, to present consequences most efficiently. You must obviously differentiate material that would usually be incorporated in a study editorial from any unprocessed data or additional appendix matter that would not be available. In fact, such matter should not be submitted at all except requested by the instructor.



## Content

- Sum up your conclusion in text and demonstrate them, if suitable, with figures and tables.
- In manuscript, explain each of your consequences, point the reader to remarks that are most appropriate.
- Present a background, such as by describing the question that was addressed by creation an exacting study.
- Explain results of control experiments and comprise remarks that are not accessible in a prescribed figure or table, if appropriate.
- Examine your data, then prepare the analyzed (transformed) data in the form of a figure (graph), table, or in manuscript form.

### What to stay away from

- Do not discuss or infer your outcome, report surroundings information, or try to explain anything.
- Not at all, take in raw data or intermediate calculations in a research manuscript.
- Do not present the similar data more than once.
- Manuscript should complement any figures or tables, not duplicate the identical information.
- Never confuse figures with tables - there is a difference.

### Approach

- As forever, use past tense when you submit to your results, and put the whole thing in a reasonable order.
- Put figures and tables, appropriately numbered, in order at the end of the report
- If you desire, you may place your figures and tables properly within the text of your results part.

### Figures and tables

- If you put figures and tables at the end of the details, make certain that they are visibly distinguished from any attach appendix materials, such as raw facts
- Despite of position, each figure must be numbered one after the other and complete with subtitle
- In spite of position, each table must be titled, numbered one after the other and complete with heading
- All figure and table must be adequately complete that it could situate on its own, divide from text

### Discussion:

The Discussion is expected the trickiest segment to write and describe. A lot of papers submitted for journal are discarded based on problems with the Discussion. There is no head of state for how long a argument should be. Position your understanding of the outcome visibly to lead the reviewer through your conclusions, and then finish the paper with a summing up of the implication of the study. The purpose here is to offer an understanding of your results and hold up for all of your conclusions, using facts from your research and generally accepted information, if suitable. The implication of result should be visibly described. Infer your data in the conversation in suitable depth. This means that when you clarify an observable fact you must explain mechanisms that may account for the observation. If your results vary from your prospect, make clear why that may have happened. If your results agree, then explain the theory that the proof supported. It is never suitable to just state that the data approved with prospect, and let it drop at that.

- Make a decision if each premise is supported, discarded, or if you cannot make a conclusion with assurance. Do not just dismiss a study or part of a study as "uncertain."
- Research papers are not acknowledged if the work is imperfect. Draw what conclusions you can based upon the results that you have, and take care of the study as a finished work
- You may propose future guidelines, such as how the experiment might be personalized to accomplish a new idea.
- Give details all of your remarks as much as possible, focus on mechanisms.
- Make a decision if the tentative design sufficiently addressed the theory, and whether or not it was correctly restricted.
- Try to present substitute explanations if sensible alternatives be present.
- One research will not counter an overall question, so maintain the large picture in mind, where do you go next? The best studies unlock new avenues of study. What questions remain?
- Recommendations for detailed papers will offer supplementary suggestions.

### Approach:

- When you refer to information, differentiate data generated by your own studies from available information
- Submit to work done by specific persons (including you) in past tense.
- Submit to generally acknowledged facts and main beliefs in present tense.



## THE ADMINISTRATION RULES

Please carefully note down following rules and regulation before submitting your Research Paper to Global Journals Inc. (US):

**Segment Draft and Final Research Paper:** You have to strictly follow the template of research paper. If it is not done your paper may get rejected.

- The **major constraint** is that you must independently make all content, tables, graphs, and facts that are offered in the paper. You must write each part of the paper wholly on your own. The Peer-reviewers need to identify your own perceptives of the concepts in your own terms. NEVER extract straight from any foundation, and never rephrase someone else's analysis.
- Do not give permission to anyone else to "PROOFREAD" your manuscript.
- **Methods to avoid Plagiarism is applied by us on every paper, if found guilty, you will be blacklisted by all of our collaborated research groups, your institution will be informed for this and strict legal actions will be taken immediately.)**
- To guard yourself and others from possible illegal use please do not permit anyone right to use to your paper and files.



CRITERION FOR GRADING A RESEARCH PAPER (COMPILATION)  
BY GLOBAL JOURNALS INC. (US)

Please note that following table is only a Grading of "Paper Compilation" and not on "Performed/Stated Research" whose grading solely depends on Individual Assigned Peer Reviewer and Editorial Board Member. These can be available only on request and after decision of Paper. This report will be the property of Global Journals Inc. (US).

Topics	Grades		
	A-B	C-D	E-F
<i>Abstract</i>	Clear and concise with appropriate content, Correct format. 200 words or below	Unclear summary and no specific data, Incorrect form  Above 200 words	No specific data with ambiguous information  Above 250 words
<i>Introduction</i>	Containing all background details with clear goal and appropriate details, flow specification, no grammar and spelling mistake, well organized sentence and paragraph, reference cited	Unclear and confusing data, appropriate format, grammar and spelling errors with unorganized matter	Out of place depth and content, hazy format
<i>Methods and Procedures</i>	Clear and to the point with well arranged paragraph, precision and accuracy of facts and figures, well organized subheads	Difficult to comprehend with embarrassed text, too much explanation but completed	Incorrect and unorganized structure with hazy meaning
<i>Result</i>	Well organized, Clear and specific, Correct units with precision, correct data, well structuring of paragraph, no grammar and spelling mistake	Complete and embarrassed text, difficult to comprehend	Irregular format with wrong facts and figures
<i>Discussion</i>	Well organized, meaningful specification, sound conclusion, logical and concise explanation, highly structured paragraph reference cited	Wordy, unclear conclusion, spurious	Conclusion is not cited, unorganized, difficult to comprehend
<i>References</i>	Complete and correct format, well organized	Beside the point, Incomplete	Wrong format and structuring



# INDEX

---

---

## **A**

Alzheimers · 5  
Aumytropic · 3

---

## **B**

Berbery · 3  
Biophoton · 2  
Brachialis · 24

---

## **C**

Calvarium · 2

---

## **D**

Drepanocytose · 6

---

## **E**

Encharge · 6

---

## **H**

Hemiplegia · 24

---

## **I**

Intracerebral · 23, 24  
Ischemic · 19

---

## **K**

Kostovic · 1, 5

---

## **L**

Levodopa · 4  
Linoleic · 2

---

## **N**

Neurological · 1, 5

---

## **P**

Polyphenol · 2

---

## **R**

Recurring · 19  
Rilutek · 3

---

## **T**

Thrombolysis · 6  
Triglyseride · 24

---

## **U**

Ultraprecious · 6

---

## **X**

Xanthomas · 24




save our planet



# Global Journal of Medical Research

Visit us on the Web at [www.GlobalJournals.org](http://www.GlobalJournals.org) | [www.MedicalResearchJournal.org](http://www.MedicalResearchJournal.org)  
or email us at [helpdesk@globaljournals.org](mailto:helpdesk@globaljournals.org)

ISSN 9755896



© Global Journals